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CHAPTER 1 
INTRODUCTION 
1.1 Rationale for the study 
At present, the treatment of human haemato1ogic malignancies consists of 
three major modalities, i.e., (l) radiotherapy, (2) chemotherapy, (3) immuno-
therapy or combinations of these. For acute leukaemia, great advances in 
terms of remission induction and survival time have been made during the past 
decade using various regimens of combination chemotherapy [Till et al., 1973; 
Beard and Hamilton Fairley, 1974; Penington and Keating, 1974; Vincent 
et al., 1974; Holland et al., 1975; Thomas et al., 1975; McCredie et al., 1976]. 
This is particularly true for acute lymphocytic leukaemia in children [Holland 
and Glidewell, 1972; Simone, 1974; Aur et al., 1974; Zippin et al, 1975; Frei 
et al., 1976]. In addition, data on the immunotherapy of acute leukaemia -
although still largely experimental- seem to be promising, especially when the 
tumour load has been reduced by preceding chemotherapy [Mathe et al., 1970; 
Hamilton Fairley et al., 1970; Baker and Taub, 1972; Powles et al., 1973; 
Vogler and Chan, 1974; Rubens, 1974; Gutterman et al., 1974; Hersh et al., 
1976]. Radiotherapy, consisting of low-dose total body irradiation [Johnson et 
al., 1967; Goswitz et al., 1973; Brace ct al., 1974; del Regato, l974;Johnson, 
1976] or local irradiation of tissues such as the central nervous system [ Aur et 
al., 1972; Willoughby, 1976; Dritschilo et al., 1976], the spleen and lymph 
nodes [Johnson, 1969; De Vita and Canellos, 1972; Peckham, 1974; Revol et 
al., 1974; Parmentier et al., 1974], has been applied in the treatment of various 
types of leukaemias and lymphoreticular neoplasms. Patients with acute 
leukaemia have also been submitted to high-dose whole body irradiation pre-
ceding bone marrow transplantation [Alvegard et al., 1975; Herzig et al., 1975; 
Gale et al., 1976; Thomas et al., 1976]. 
So far, combination chemotherapy has been proved to be the most effective 
treatment for human acute leukaemia. However, as known for many years, 
intensive treatment with cytostatic drugs has several limitations. Firstly, 
chemotherapy may have to be limited or even withdrawn due to severe toxic 
side-effects of cytostatics in leukaemic patients. The side-effects include depres-
sion of normal haemopoiesis [van Putten, 1974; Marsh, 1976] with subsequent 
bleeding and infections [Bodey, 1975] and damage to the gastrointestinal tract 
[Meyler, 1971] and the skin [Dreizen et al., 1975]. These may occur despite 
optimal supportive care provided by regular blood cell transfusions, antibiotics, 
barrier nursing, parenteral nutrition, etc. [Levine et al., 1974; McCredie et al., 
1974; Bodey et al., 1976]. Secondly, a certain number of patients may show 
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complete unresponsiveness towards various chemotherapy schedules. Thirdly, 
chemotherapy is contraindicated in pregnant women. In this, fortunately, 
small group of patients, treatment with cytostatics should be avoided in order to 
protect the foetus against irreversible damage. 
With these restrictions concerning chemotherapy in mind, extracorporeal 
irradiation of the blood (ECIB) was introduced as a possible therapeutic 
measure in the treatment of leukaemia [Lajtha et a!., 1962]. This method 
consists of establishing a blood circuit outside the body in which the con-
tinuously flowing blood is irradiated. Physical treatment of the blood flowing 
through an extracorporeal shunt was actually first published by Heymans in 
1921 (see Ch. 1.2). The rationale for this kind of treatment is twofold: (1) 
leukaemic cells (and normal lymphocytes)* are far more radiosensitive in com-
parison with the other blood cells, so that the blood can be selectively depleted 
ofleukaemic cells without substantial injury to the normal blood elements; and 
(2) the treatment takes place completely outside the body, thereby preventing 
damage to normal tissues. However, in order to reduce the total leukaemic cell 
population within the body, a certain degree of exchange of leukaemic cells 
between the various tissues (bone marrow, spleen, etc.) and the blood is 
required. To achieve this absolute reduction, it is necessary that the growth rate 
of the leukaemic cell population is lower than its mortality rate under the 
influence of ECIB. A diminished tumour load thus induced would then be a 
good starting point for the induction of a remission by further chemo- or 
immunotherapy. Factors which generally determine the efficacy of ECIB are 
listed in table 1.1. 
Table 1.1 Factors determining the effectiveness if ECIB 
1. total number of leukaemic cells in the blood 
2. total number of leukaemic cells in the tissue depots (bone marrow, spleen, lymphatic 
tissue, etc.) 
3. rate of exchange of leukaemic cells between the tissue depots and the blood 
4. radiosensitivity of leukaemic cells 
5. rate of leukaemic cell production; and 
6. life span of leukaemic cells 
Besides its theoretical therapeutical usefulness, the ECIB technique might 
make a significant contribution to the study of kinetics of proliferation and 
distribution ofleukaemic cells. 
Information on cellular kinetics of leukaemia comes from various sources 
(table 1.2). Proliferation kinetics have been studied in detail using tritiated 
thymidine (3H-TdR). This DNA precursor is specifically incorporated into 
* The radiosensitivity of normal lymphocytes has led to other applications of ECIB- namely, 
to induce immunosuppression by means of lymphocyte depletion and to study lymphocyte 
kinetics in normal subjects (see Ch. 1.4.6). 
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Table 1.2 Principal methods employed to study kinetics of proliferation and distribution in leukaemia 
1. Proliferation and differentiation kinetics 
tritiated thymidine labelling (in vivo, in vitro) 
pulse cytophotometry 
in vitro cultures of haemopoietic precursor cells in the blood and the bone marrow 
2. Distribution kinetics 
autotransfusion of isotope-labelled leukaemia cells 
thoracic duct cannulation 
cross circulation 
3. Effects of cell depletion on 1 and 2 
chemotherapy 
leukapheresis 
[ ·--~~-~~:.<:.~?_I-J:.()E.~_':':_l -~rE_a_diation of the blood 1 
cells during the DNA synthesis phase (S phase) of the cell cycle. After pulse 
labelling (in vivo and in vitro) or continuous infusion of 3H-TdR (in vivo), 
autoradiography is employed and, from estimates of the labelling index and 
the per cent labelled mitosis, various parameters of leukaemia growth can be 
determined. These include the growth fraction, the generation times of 
leukaemic cells, the duration of the separate phases of the cell cycle (G1, S, G 2, 
M), the transit time from the proliferative to the non proliferative compartment, 
etc. [Gavosto eta!., 1967; Killmann, 1968; Cronkite, 1968; Zimmerman eta!., 
1968; Clarkson eta!., 1970; Them! eta!., 1973; Mauer and Lampkin, 1974; 
Ernst, 1976). 
The recently developed fast method of pulse cytophotometry has also 
provided quantitative information on the proliferation kinetics in leukaemia. 
By staining the DNA of leukaemic cells with specific fluorescent dyes, a D:NA 
content distribution of the leukaemic cell population can be obtained. Mathe-
matical analysis gives a rough impression of the per cent of cells present in the 
various phases of the cell cycle (G0-G1 : 2n DNA, S : 2n-r4n, G, : 4n, 
M : 4n-r 2n), provided that the leukaemia is of a diploid nature [Buchner, 
1974; Quaglino eta!., 1974; Hillen eta!., 1975]. 
Furthermore, in vitro culture of precursor cells from blood and bone marrow 
of patients or animals with leukaemia has yielded important information on the 
proliferation and differentiation capacities ofleukaemic (stem) cells and normal 
haemopoietic (stem) cells at various stages of the leukaemic growth process 
[Robinson eta!., 1971; Tanaka eta!., 1973; Metcalf, 1973; Golde eta!., 1974; 
Moore, 1974; Hoelzer et a!., 1974a; van Bekkum eta!., 1976a; Dicke eta!., 
1976; Spitzer et a!., 1976). 
Dynamics of leukaemia cell traffic between the tissues and the blood have 
been studied by means of autotransfusion of isotope-labelled leukaemia cells 
and studying their disappearance from the circulating blood and their distribu-
tion within the body. These studies have been performed with various isotopes 
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in acute leukaemia [Killmann eta!., 1971; Hoelzer eta!., 1972; Boranic eta!., 
1974], chronic myelocytic leukaemia [Athens eta!., 1965; Galbraith, 1966; 
Chikkappa and Galbraith, 1967; Duvall and Perry, 1968] and chronic lym-
phocytic leukaemia [Pfisterer et a!., 1967; Schiffer, 1968; Strijckmans et a!., 
1968; Spivak and Perry, 1970; Bremer eta!., 1973a; Manaster eta!., 1973; 
Neumann eta!., 1974]. 
Studies involving measurement of leukaemia cell output from the thoracic 
duct after cannulation of this lymphatic vessel [Binet et a!., 1967; Sinha and 
Goldenberg, 1970; Bremer et a!., 1973] and cross-circulation experiments 
between normal and leukaemic subjects [Bierman ct a!., 1951; Hollingsworth 
and Finch, 1957; Eschbach eta!., 1965] have also contributed significantly to 
the knowledge of the kinetics of distribution ofleukaemic cells. 
Another approach to the study of the kinetics and dynamics of leukaemia 
(using the parameters mentioned above) is that of inducing a decrease in the 
number of leukaemic cells present in the organism. Principally, two methods 
have been employed: general depletion by chemotherapy [Ernst and Kill-
mann, 1969; Klein and Lennartz, 1974; Killmann, 1974] and specific deple-
tion of the blood compartment of leukaemic cells by either cell removal 
[leukapheresis; Curtis eta!., 1972; Vallejos eta!., 1973; Hoelzer eta!., 1974b; 
Hadlock eta!., 1975] or by cell destruction such as with ECIB (see Ch. 1.4.7). 
These studies have yielded some valuable inforn1ation on the presence of 
feedback mechanisms which operate to compensate for the cell loss. This might 
be expressed in terms of altering the degree of exchange of leukaemia cells 
between the tissues and the blood or changing their proliferation characteristics 
(recruitment of cells into cycle), thereby influencing the population size. 
Studies on these parameters will widen our knowledge of the leukaemic 
growth process and they are therefore of utmost ilnportance for the develop-
ment of new, more effective therapeutic regimens. VVhere the parameters 
mentioned above have been investigated in this study, they will be discussed in 
more detail. 
The effects of ECIB in acute leukaemia from both a kinetic and a therapeutic 
point of view will be discussed in this thesis. Apart from its radiobiological 
importance, this study seemed to be justified because of the lack of com-
prehensive studies in the literature, although several authors have reported on 
ECIB in various types of human acute (and chronic) leukaemia during the past 
15 years (see Ch. 1.4.7). Because of its poorer prognosis in comparison with 
other types of leukaemia, it was thought to be most profitable to apply this 
technique in acute myelocytic leukaemia (AML). This view was also strength-
ened by the facts that: (I) so far, only a limited amount of kinetic information 
has become available from the rather few ECIB studies in human AML; and 
(2) there is a complete absence of experimental data on ECIB in AML in the 
literature. Therefore, the investigations were performed in an animal model 
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for AML as background support for the clinical situation. Such a model 
requires the availability of a reproducibly growing, transplantable leukaemia 
and the feasibility of creating an extracorporeal blood circuit. The easily 
manageable rat meets both of these prerequisites; it was therefore the animal of 
choice. 
Another important factor in determining the nature of the present study was 
the availability of so-called "Leukocyte Mobilizing Agents" (LMA). These 
recently developed synthetic polyanions induce a rapid absolute increase in 
the number of lymphocytes and leukaemia cells in the peripheral blood after 
parenteral administration (see Ch. 3). Studies on this cell mobilization phe-
nomenon were considered to be of utmost importance as regards its potential 
usefulness if combined with ECIB. 
The phases of the present study will be outlined in more detail in paragraph 
1.5. However, as a background for the present investigations, a short historical 
review on the development of ECIB will first be given. This will be followed by 
a description of the various techniques and parameters which are generally 
used. Subsequently, data on both experimental and clinical ECIB from studies 
which have appeared in the literature during the past 15 years will be reviewed. 
1.2 Historical review on ECIB 
As mentioned above, the idea to treat the circulating blood outside the body 
by physical means was developed by Heymans as early as 1921 [Heymans, 
1921]. The main emphasis of his experiments in rabbits was to study the general 
effects of heating and cooling of blood flowing extracorporeally through a shunt 
between the carotid artery and the jugular vein. However, he also reported on 
X-ray and radium treatment of the blood in normal rabbits. After an irradia-
tion period of 2 to 3 hours, no significant haematologic changes were noted. The 
radiation dose to the blood was not mentioned. He suggested then that ECIB 
might be a valuable treatment modality for leukaemia. 
In view of the technical difficulties involved, only once per decade were 
data on ECIB published. In 1930, Dall'Acqua and Zopellari [Dall'Acqua and 
Zopellari, 1930] and, in 1939, Ducuing eta!. [Ducuing eta!., 1939] reported on 
ECIB with X-rays in normal experimental animals. They also did not obtain 
significant biological changes, possibly because of a combination of a limited 
irradiation time with a consecutive low irradiation dose. In 1957 and 1959, 
two preliminary reports of O'Brien and co-workers on X-irradiation of 
circulating blood in dogs and rabbits appeared [O'Brien eta!., 1957; O'Brien, 
1959]. Here again, no remarkable effects were observed. Arnauld et a!., 
applying ECIB with X-rays to anaesthetized rats with carotid-jugular shunts, 
found a transitory leukopenia and anaemia after 3 hours of ECIB [Arnauld 
et a!., 1958]. When this phenomenon was investigated in more detail usmg 
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high doses of y-rays, it was found that the leukopenia was due mainly to the 
depression of the number oflymphocytes in the peripheral blood [Pellerin eta!., 
1960]. This initial rapidly induced decrease was soon followed by an increase of 
up to 2 times the pre-ECIB level within the first 5 days after irradiation. 
Thereafter, a quick return to normal levels was observed. The rapidly induced 
anaemia disappeared within I to 2 months, depending on the radiation dose. 
The early workers in the area of ECIB had to contend with serious methodo-
logical difficulties. These prevented them from applying sufficiently high radia-
tion doses to the circulating blood. A systematic approach to the effects of 
ECIB was initiated by Cronkite and his co-workers, using modern, more 
effective radiation facilities [Cronkite eta!., 1962a; 1962b]. 
Before discussing the recent developments in experimental and clinical 
ECIB, it is useful to first summarize the various techniques and parameters 
used in ECIB. 
1.3 Methods and parameters used in ECIB 
The main methods and parameters playing a significant role in experimental 
and clinical ECIB will be summarized in this section; these are: 
1. the extracorporeal blood circulation; 
2. dosimetry; 
3. irradiators; and 
4. treatment schedules in ECIB. 
1.3.1 The extracorporeal blood circulation 
An arteriovenous shunt (carotid artery- jugular vein; femoral artery- femoral 
vein; radial artery - cephalic vein) is most commonly employed for the creation 
of an extracorporeal blood circuit. With such an arrangement, ECIB studies 
have been undertaken in various large animal species such as calves, cows and 
pigs [Cronkite eta!., 1962a; 1962b; Chanana and Cronkite, 1966; Joel eta!., 
1967a], goats [Binet eta!., 1968; Chanana eta!., 1971], baboons [Storb eta!., 
1969], dogs [Wolf and Hume, 1965; Wolfet a!., 1966; Pichlmaier and Trepel, 
1966; Maginn and Bullimore, 1968; Kriek, 1973] as well as in rabbits [Hey-
mans, 1921, Abramoff eta!., 1961; Pompidou eta!., 1975] and rats [Cauchi 
and Field, 1966; Pichlmaier and Trepel, 1966; Pellerin and Remy, 1968]. In 
calves, the arteriovenous teflon-shunts have been reported to function for up to 
50 days [Chanana and Cronkite, 1966]. In clinical ECIB, exteriorized arterio-
venous shunts as are used in haemodialysis have been employed [Quinton eta!., 
1962]. This type of shunt has led to considerable complications in terms of 
haemorrhages and local inflammation, especially in patients with leukaemia 
showing disturbances in the blood coagulation and decreased resistance to 
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infections [Chanana et al., 1968]. However, these risks have been greatly 
reduced by preparing subcutaneous arteriovenous fistulas (radial artery -
cephalic vein). The venous part of the fistula hypertrophies under the influence 
of the arterial blood pressure and can be punctured repeatedly in order to 
create an extracorporeal blood circuit [Brescia et al., 1966]. These fistulas can 
function for several years [Zerbino et al., 1974]. 
The main factor which may limit the time during which a session of ECIB 
can be performed is the clotting of the blood within the extracorporeal circuit. 
To prevent this, regional or systemic heparinization is mostly indicated. 
However, the risk of blood clotting was greatly diminished when modern 
siliconized shunt material such as is used for chronic haemodialysis was intro-
duced [Quinton et al., 1962]. Since then, teflon cannulas and silastic rubber 
coils have been mainly used. An additional advantage of silastic rubber is its 
high degree of radioresistance. Only after radiation doses in excess of 40 to 
60 X 106 rad does the material become brittle and break easily [Cronkite et al., 
1968]. 
Particularly with large extracorporeal volumes, heating of the external blood 
circuit to 37 oc was found to be necessary. Furthermore, several authors have 
used specially designed pumps in order to obtain a constant flow rate of the 
blood through the irradiation field; this is important from a dosimetric point of 
VlCW. 
Besides ECIB, extracorporeal irradiation of the lymph has also been carried 
out. Lymph flowing from the cannulated thoracic duct is led to a reservoir 
from which it is pumped through the irradiator back into a vein [Chanana and 
Cronkite, 1966;Joel et al., 1967b). 
Several authors have developed alternative methods to irradiate the circu-
lating blood. Instead of irradiating the blood extra-corporeally, small radia-
tion sources were implanted inside the body close to the blood circulation. In 
dogs, shields or pellets containing the beta-emitter 90Y were implanted into the 
abdominal aorta [Oidendorf et al., 1964; Wolf and Hume, 1965]; the insertion 
of a 90Sr-90Y source into the right atrium of the heart has also been reported 
[Barnes et al., 1965]. 
1.3.2 Dosimetry 
For a better understanding of the specific dosimetric problems in ECIB, a 
schematic representation of the method is given in fig. 1.1. This simplified 
picture shows 3 major compartments which are interacting. The extracorporeal 
blood circuit contains only a fraction of the total blood volume circulating 
within the body. A certain fraction of the total number of leukaemic cells 
present in the circulating blood will be submitted to irradiation per unit time. 
At the same time, there will be a continuous exchange ofleukaemic cells among 
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Fig. 1.1 A schematic representation of extracorporeal irradiation of the blood. 
the various organs affected by leukaemia (e.g. the bone marrow, spleen, lymph 
nodes, etc.), and the blood, as will be discussed later (see Ch. 2.6.5). 
The radiation dose delivered to the total leukaemic cell population during an 
ECIB session is dependent on 2 main factors: (I) the number of leukaemic 
cells passing through the irradiation field; and (2) the degree and rate of 
exchange of leukaemic cells among the various organs and the blood during 
ECIB. 
The most accurate dosimetric unit is the transit dose, which is defined as the 
radiation dose received by a cell when passing once through the extracorporeal 
circuit. The transit dose is directly proportional to the volume of the coil which 
is submitted to irradiation and the dose rate of the radiator and inversely 
proportional to the flow rate of the blood in the external circuit, i.e.: 
TD = VxR 
F 
where TD = the transit dose (rad); 
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V = the volume of the irradiated coil (ml); 
R = the dose rate of the radiator in the shunt tubing (radjmin); 
F =the flow rate of the blood in the external circuit (ml/min). 
(I) 
Another useful parameter is the time needed for one blood volume to pass 
through the shunt: T" (min.). This can be determined according to: 
T" = v" (2) 
F 
where V" =the blood volume of the subject (ml). 
As regards the amount and distribution of the radiation dose delivered to the 
total blood volume throughout the ECIB session, several mathematical 
approaches have been proposed by various authors. Irradiated cells returning 
from the small irradiated volume to the body will be distributed throughout the 
total blood compartment. The subsequent sample of blood flowing through the 
irradiator will therefore consist of both irradiated and nonirradiated cells. 
Obviously, the distribution of the radiation dose received by the cells present in 
the blood will change during an ECIB session, as can be calculated by methods 
of probability theory. Lajtha et al. (1962) discussed the simple exponential 
character of the process. From the Poisson distribution, it can be calculated 
that, when one blood volume (Vb) has passed through the radiation field, only 
63% of the cells present in the blood volume will have been irradiated one or 
more times. If the irradiation time is prolonged, this percentage will increase: 
after 5 blood volumes have passed, 99% of the cells have received at least one 
transit dose and, after 7 blood volumes, 99.9%. After 14 blood volumes, only a 
fraction of l0-6 has not been irradiated and this is reduced to J0-12 after 
28 blood volumes. 
Extensive mathematical studies on the interrelationship between the volume 
of the extracorporeal circuit, the flow rate of the blood, the total irradiation 
time, the dose rate of the irradiator and the dose distribution in the total blood 
volume have been published. Slatkin et al. developed a computer program 
which enabled them to calculate the fraction of blood which is irradiated n 
times in each of several total number of passages [Slatkin et al., 1963]. Oliver 
and Shepstone, using Laplace transforms [Oliver and Shepstone, 1964], and 
Marsaglia and Thomas, tackling the probability problem with the renewal 
theory [Marsaglia and Thomas, 1965], also developed mathematical formulae 
to solve the problem of dosimetry. The "differential equation" model of 
Slatkin et al. and the "exact probability" model of Marsaglia and Thomas 
were found to give identical predictions [Karlsson, 1969]. 
When the irradiation time is sufficiently long (e.g., when more than 7 blood 
volumes have passed through the irradiator), the distribution of dose becomes 
symmetrical and a third significant parameter can be easily calculated: the 
mean dose to the total circulating blood (Dx in rad). This average is dependent 
on the volume of the irradiated coil (V in milliliters), the total irradiation time 
(Tt in min.), the dose rate in the shunt tubing (R in radjmin) and the total 
blood volume (Vb in milliliters): 
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v Dx = xT,xR 
V"+V 
(3) 
It is clear that the calculation methods mentioned above are valid only for 
cells which remain within the circulating blood during the whole period of 
ECIB, i.e., erythrocytes. Although these cells are rather radioresistant (see 
Ch. 1.4.2), they still represent the main limiting factor as regards the total 
irradiation time. Dosimetric calculations concerning lymphocytes and leukae-
mic cells are considerably more complex, since these cell types are known to 
exchange continuously between the blood and the various organs (fig. 1.1). 
With respect to leukaemia, little is now known in quantitative terms about the 
parameters of this exchange process. Another important factor is the number of 
newly produced cells during the irradiation period. Information here is also 
lacking. However, various authors have attempted to simulate the problem 
mathematically based on speculative assumptions [Lajtha et al., 1962; Oliver 
and Shepstone, 1964]. Obviously, there is a great need to quantify the rate of 
exchange of cells between the tissues and the blood, to determine the average 
time a cell spends in the tissues and in the circulating blood compartment and 
to obtain information on the change in the number of leukaemic cells due to 
proliferation during ECIB. Studying these cellular kinetics of leukaemia was 
one of the major objectives of the investigations to be presented. 
The parameters required to determine the radiation dose delivered to the 
leukaemic cell population during ECIB are summarized in table 1.3. 
Table 1.3 Parameters determining the radiation dose to the leukaemic cell population during ECIB 
1. transit dose 
2. dose distribution in the total blood volume 
3. mean dose to the blood 
4. cellular kinetics of leukaemia 
1.3.3 Irradiators 
In general, irradiators used in ECIB must allow accurate dosimetry and should 
deliver a uniform radiation dose along the whole extracorporeal blood circuit. 
Different types of radiation (~, y, X-rays, UV) have been used by various 
authors. The choice of a certain type of radiator depends on the demands of the 
investigator. The qualities of the different radiation modalities with respect to 
ECIB will now be briefly discussed. 
A. Small ~-emitters give only a very low amount of external scattered radia-
tion (Bremsstrahlung). They therefore need very little shielding, which implies 
reasonable portability of the source because of its rather light weight. A special 
problem is presented by the fact that the ~-radiation is remarkably attenuated 
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when traversing the shunt material. Furthermore, as a result of the short range 
of ~-particles, there will be an uneven distribution of radiation to cells in 
different parts of the shunt cross-section. This problem can be overcome for the 
most part by a special shape of the radiator (e.g. cylindrical) and by winding 
the extracorporeal shunt to cause maximal turbulence of the flowing blood [for 
dosimetry: Slatkin and Robertson, 1970]. The most commonly used ~-radia­
tion source has been the radionuclide 90Sr-90Y, for which various radiation 
facilities have been developed [Gilbert and Lajtha, 1966; Libby et a!., 1966; 
Pichlmaier et a!., 1967; Holmer et a!., 1973]. The applicability of other 
y-emitting isotopes such as 204Tl, 147Pm, 125 !, and 170Tm is presently being 
investigated [Griffin and Cross, 1973; Hungate eta!., 1974]. Transit doses, as 
measured by the ferrous sulphate method, are in the range of 1-100 rad for the 
small portable sources described. If a greater TD is required, one can of course 
use ~-units containing more curies. Heavy metals will then be necessary for 
adequate shielding, which will make the unit too heavy to be portable. In that 
case, it is from a dosimetric point of view more advantageous to change to 
y- or X-ray sources. 
B. Cronkite's group at Brookhaven National Laboratory was the first to 
develop a powerful 60Co y-ray source [Kuhl et a!., 1964]. By adapting the 
volume of the extracoporeal blood circuit and the flow rate of the blood (see 
formula (1), Ch. 1.3.2), they could easily reach a transit dose of as high as 
900 rad with a dose rate of 2300 radjmin. Although y-sources are less easy to 
handle because of the heavy shielding needed, the dosimetry is most exact. 
Furthermore, the y-emitting radionuclides 192lr and 137Cs have been used to 
construct powerful y-radiators [Pellerin and Remy, 1968; Makoski and 
Hudepohl, 1973). Both 6°Co and 137Cs sources have been applied experimental-
ly and clinically by various investigators. 
C. X-ray sources have also been widely used in ECIB. Like y-rays, they also 
permit accurate dosimetry. Transit doses ranging from 25 to 900 rad have been 
obtained by the various authors applying this type of radiation in experimental 
and clinical ECIB [Cronkite eta!., 1962a; 1962b; Thomas eta!., 1965; Meuret 
et a!., 1969; Birkeland and Munk, 1972]. 
For practical reasons, conventional X-rays have been used in this study. 
D. Besides ionizing radiation, ECIB has also been carried out with ultra-
violet radiation, using cylindrically arranged mercury lamps [Binet eta!., 1968; 
Villeneuve eta!., 1968; Vaugier, 1968]. However, the opacity of the blood with 
respect to ultraviolet rays causes a low degree of uniformity as regards the dose 
distribution in the blood. 
1.3.4 Treatment schedules in ECI B 
A substantial number of different treatment schedules has been applied by 
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the various authors. Effects of continuous ECIB have been compared with 
effects of relatively short lasting repeated sessions of ECIB. A wide range of 
transit doses obtained by different dose rates, extracorporeal blood volumes or 
blood flow rates, has been used [Sipe et a!., 1965; W eeke, 1972a; W eeke, 19 7 4]. 
However, as discussed previously, the main limiting factor in planning a 
treatment schedule is the accumulation of the radiation dose within the red cell 
population. Above a certain dose level, haemolysis will commence and further 
treatment will have to be abolished (Ch. !.4.2). 
In general, repeated short sessions of ECIB spread out over days or weeks 
have been shown to be equally or more effective in producing cell depletion 
than is continuous ECIB, and much safer due to the reduced probability of 
inducing haemolysis. The transit dose should not be too high, since this would 
increase the radiation injury to the erythrocytes. 
1.4 Recent developments in experimental and clinical ECIB 
Since 1962, three International Symposia on ECIB have been held [Rijswijk, 
1967; Paris, 1968; Tel Aviv, 1969). Together with a substantial number of 
publications, they form the basis for a summary of results from experimental 
and clinical ECIB during the past 15 years. This concerns the effects of ECIB 
on the lymphatic apparatus (studies on lymphocyte kinetics by means of 
lymphocyte depletion; immunosuppressive action of ECIB) and some other 
purely clinical applications. Special attention will be paid to the effects of 
ECIB on the various types ofleukaemia. However, side-effects of ECIB will be 
first discussed. These involve both general effects and specific effects, i.e., 
injury to the normal elements in the blood, which may limit the applicability of 
ECIB. 
1.4.1 General side effects of ECIB 
Patients, especially those with chronic lymphocytic leukaemia (CLL), some-
times develop chills, fever and general discomfort during an ECIB session, 
which may even necessitate the termination of treatment [Fliedner, 1967; 
Meuret et al., 1969J. In these cases, exogenous pyrogens (e.g., coming from the 
irradiated silastic shunt) could be excluded as being the cause. Furthermore, 
attempts to demonstrate microbial contamination somewhere along the 
extracorporeal circuit were all negative. However, a positive correlation was 
found between the onset of the general symptoms and the degree oflymphocyte 
destruction in patients with CLL. When the decrease in the number of 
lymphocytes exceeds 20,000 cells per mm" blood during one session of ECIB, 
there is a high risk of developing a febrile reaction [Meuret et a!., 1969]. This 
indicates that breakdown products of destroyed lymphocytes might act like 
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endogenous pyrogens. When ECIB is halted, the general symptoms disappear 
quickly. 
1.4.2 Effects of ECIB on erythrocytes 
As stated earlier, radiation induced injury to erythrocytes is the main limiting 
factor in determining the tolerable radiation dose. In contrast with other cells 
such as thrombocytes and granulocytes, which spend only part of their life span 
in the blood, erythrocytes reside solely in the blood. Since the total dose 
delivered to erythrocytes during one or more sessions ofECIB can be calculated 
(Ch. 1.3.2), the possibility of developing haemolysis can be predicted if the 
radioresistance of the red cells is known. 
The radioresistance of human erythrocytes was investigated by submitting 
them to y-irradiation (60Co) in vitro, labelling them with 51Chromium, and 
transfusing them into the original normal donor and determining their life span 
in the blood [Schiffer et al., 1966]. In the dose range studied (35,000-200,000 
rad), the erythrocyte survival times were found to be functions of the radiation 
dose. Shortening of the life span was observed with a dose of only 35,000 rad, 
which indicates increased haemolysis. The in vitro irradiated erythrocytes 
showed no morphological abnormalities. It should be noted that, in contrast to 
the acute high dose in vitro, frequent lower doses received during ECIB would 
permit repair mechanisms to become operative. In 10 patients with various 
types of leukaemia undergoing ECIB, Schiffer et al. correlated the need for 
blood transfusions with the mean dose accumulation within the red cell 
population. Although individual patients behave in a different way (more or 
less active erythropoiesis; haemolysis due to the leukaemic process itself), 
transfusion requirements apparently increased with increasing radiation dose. 
In a later study on haemolysis in patients with CLL [Andersen et al., 1970], 
a considerable reticulocytosis indicating haemolysis developed and a decreased 
life span of erythrocytes was observed after mean cumulative doses between 
18,500 and 34,000 rad were reached. The radiosensitivity of young erythrocytes 
was also investigated. This was done by injecting the patient with 59Fe a few 
days before the commencement of ECIB. By determining the 59Fe-activity in 
the blood, representing young erythrocytes which had incorporated the isotope 
while still located in the bone-marrow, the radiosensitivity of this particular 
class of cells could be evaluated. It was concluded that young red cells are less 
radiosensitive than the erythrocyte population as a whole. This is in accordance 
with observations on bovine erythrocytes [Schnappauf et al., 1965]. 
With respect to other animal species, data on red cell injury during ECIB 
have been published for the rat [Pellerin et al., 1960; Pellerin and Remy, 1968] 
and the baboon [Storb et al., 1969]. In rat erythrocytes, a mean total dose of 
2 to 3 X 10 5 rad during one ECIB session induced a moderate haemolytic 
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anaemia, which was restored within 10 days. Doses ranging from 4 to 7 X 10 5 
rad caused a more severe haemolysis. However, the rats survived and normal 
erythrocyte levels were again reached 3 weeks after the radiation injury. One 
rat even survived 1.2 X 106 rad [Pellerin and Remy, 1968]. This rather high 
degree of radioresistance of rat erythrocytes is of importance in view of the 
application of ECIB to rats in this thesis. 
1.1.3 Effects of ECIB on platelets 
Mature thrombocytes have been shown to be extremely radioresistant. When 
rabbit platelets were irradiated in vitro with 50,000 rad y-rays, their life span 
in vivo did not differ from nonirradiated ones [von Sebestik et al., 1967]. The 
radioresistance of human platelets was investigated in leukaemic patients 
treated by ECIB [Greenberg et al., 1968]. It was demonstrated that throm-
bocytes which accumulated a mean dose of up to 5000 rad had the same 
survival curves in vivo ( 51Cr-labelling) as before irradiation. In fact, the 
radioresistance was much higher, as was studied in a haematologically normal 
patient. Autologous platelets irradiated in vitro with y-rays in a dose range of 
10 X 103 to 75 X 103 rad exhibited no change in in vivo life span as compared 
with nonirradiated thrombocytes. Furthermore, clinical observations of platelet 
levels in 41 patients (34 with leukaemia and 7 with renal disease) undergoing 
ECIB revealed no thrombocytopenias due to the irradiation. 
A decrease in the platelet count can sometimes be observed during ECIB; 
this can be explained by a certain tendency for platelets to sequestrate in the 
extracorporeal coil [Field and Dawson, 1967]. 
It can be concluded that platelets (in contrast to erythrocytes) are not a 
limiting factor in the application of ECIB because of: ( 1) their high degree of 
radioresistance; and (2) their relatively short life span in the blood (10-12 
days). During repeated sessions of ECIB, the accumulation of radiation dose is 
certainly lower for the platelet as compared with the rather long-lived 
erythrocyte (life span: 120 days). Radiation doses in excess of 75 X 103 rad, 
which might damage circulating platelets when delivered during their life span, 
are not relevant, since injury to erythrocytes would have already become 
intolerable after such doses. 
1.1.1 Effects of ECIB on granulocytes 
To date, no direct radiation injury to normal granulocytes due to ECIB has 
been demonstrated in man [Meuret et al., 1969]. This is not to be expected 
because of the short life span of mature granulocytes in the blood (T /2 ~ 
5.5-10.4 h; see table 2.11) and their relatively high radioresistance. 
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1.4.5 Effects cif ECIB on blood chemistry 
In general, ECIB does not induce significant changes in the chemical com-
position of the blood. However, various authors have reported deviations from 
normal which can sometimes be observed in individual cases. No clear-cut dose-
effect relationships could be established up to now. 
Particularly in leukaemic patients with a large number of cells in the 
peripheral blood, an elevation of serum uric acid can be observed when ECIB is 
initiated. This is due to excessive killing of leukaemic cells. It is then some-
times necessary to give allopurinol to prevent the formation of urate stones, 
which especially threaten patients with impaired kidney function [Lajtha eta!., 
!969]. 
The serum proteins have a high degree of radioresistance; however, a 
temporary increase in o.- and ~-globulins [rabbit: Abramoff eta!., 1961] and 
y-globulin and fibrinogen [calf: Hollard eta!., 1969; man: Meuret eta!., 1969] 
has been observed. A transitory decrease in serum albumin has also been 
reported [rabbit: Abramoff et a!., 1961; man: Lajtha et a!., 1969]. No under-
lying cause could be established for these phenomena. 
Kidney function (urea), liver function (transaminases, alkaline phosphatase) 
and electrolyte levels were unaltered by ECIB, as studied in dogs and man 
[Maginn and Bullimore, 1968]. 
1.4.6 Effects cif ECIB on the lymphatic apparatus 
Lymphocytes represent the most radiosensitive cell population in the peripheral 
blood [Trowell, 1952; Schrek and Stefani, 1964]. Their D 0 is approximately 
70 rad [van Bekkum, 1974]. Based on this knowledge, various workers have 
applied ECIB both experimentally and clinically for two main purposes: (I) 
to induce immunosuppression; and (2) to study lymphocyte kinetics in con-
junction with lymphocyte depletion. 
Most of the experimental work has been performed in the calf by Cronkite's 
group at Brookhaven National Laboratory. Prolonged continuous ECIB with a 
transit dose of900 rad produces a marked lymphopenia [Cronkite eta!., 1962a; 
1962b]. During ECIB, the number of lymphocytes in the blood decreases 
exponentially until a low constant plateau is reached. If the irradiation is con-
tinued, no further reduction is observed. Apparently, an equilibrium is 
established between the destruction and removal of lymphocytes and the 
replenishment from tissue pools. This is confirmed by histological examination 
of the various lymphoreticular organs. If ECIB is continued after the state of 
equilibrium is reached, a significant depletion oflymphocytes from these organs 
becomes apparent, i.e., cells are being mobilized [Cottier et a!., 1964]. The 
degree of depletion with time followed an exponential function with at least two 
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components [Ruchti eta!., 1970]. The first, corresponding to a rapid fall, would 
be related to the elimination of an easily mobilizable pool of lymphocytes. The 
second slow component would correspond to a more sessile pool of lym-
phocytes, which exchanges only very slowly with lymphocytes in the blood 
compartment. By applying planimetry, the cell content of the various tissues 
involved (spleen, lymph nodes and thymus) could be measured and estimates 
could be made of the ratio between the sizes of the easily mobilizable and the 
more sessile tissue pools of lymphocytes. 
Histologically, the following changes have been noted. In the spleen, the 
lymph follicles show a marked decrease in size, which is mainly due to a loss of 
small lymphocytes in the cuffs surrounding the germinal centers. The germinal 
centers themselves remain intact. Loss of lymphocytes was also observed in the 
peripheral zones of the white pulp and in the red pulp. Lymphocyte depletion 
occurred preferentially at the inner border of the cortex ( "paracortical zone") 
in the lymph nodes. In the thymus, the thickness of the cortex decreased in 
most cases. The bone marrow shows no remarkable changes. Disintegrating 
cells are found in the spleen, in the lung capillaries and in the liver sinusoids. 
The histological picture after prolonged ECIB is similar to that produced by 
neonatal thymectomy [Waksman et a!., 1962]. ECIB seems to preferentially 
destroy lymphocytes from thymus-dependent areas ("T lymphocytes"). In the 
peripheral blood, it was observed that the number of small lymphocytes is 
particularly reduced [Sipe eta!., 1965]. These lymphocytes have been described 
as being long-lived recirculating immunocompetent cells, capable of rejecting 
tissue homografts [Gowans, 1965; Ford and Gowans, 1969]. Thus, ECIB has 
important implications with regard to immunosuppression as will be discussed 
later. 
Various transit doses have been used to induce a lymphopenia. With doses 
ranging from 30 to 900 rad, identical degrees of lymphopenia are produced 
after 24 hours, although the condition develops more rapidly with higher 
transit doses [Sipe et a!., 1965]. The time needed for the blood lymphocyte 
level to return to the preirradiation value varies from days to many months. 
This depends on the degree of cell depletion as well as the rate of new cell 
production. In view of the specific destruction of the population of T lym-
phocytes, the thymus is of utmost importance with respect to the recovery 
process. Evidence for this was obtained from the observation that ECIB-
treated thymectomized calves require much more time for complete recovery as 
compared with intact animals [Cronkite et a!., 1968]. 
ECIB-induced lymphopenia has also been described for other animal species 
such as goats [Chanana eta!., 1971), baboons [Storb eta!., 1969], dogs [Wolf 
eta!., 1966; Pichlmaier and Trepel, 1966; Maginn and Bullimore, 1968; Kriek, 
1973], rabbits [Pompidou eta!., 1975] and rats [Pichlmaier and Trepel, 1966; 
Pellerin and Remy, 1968]. 
26 
ECIB (in combination with thoracic duct cannulation, isotope-labelling 
and/or extracorporeal irradiation of the lymph) has opened up a means to 
study various facets of lymphocyte behaviour such as: 1) the size of the 
intravascular and extravascular (mobile or sessile) pools oflymphocytes; 2) the 
average time spent by lymphocytes in the blood; 3) the rate and degree of 
lymphocyte mobilization from tissue stores; 4) pathways of lymphocyte 
migration; 5) lymphocyte production rates; 6) the function of lymphocytes; 
and 7) the factors controlling lymphopoiesis, etc. [Cronkite et al., 1964; 
Cottier et al., 1964; Wagner et al., 1967; Cunningham et al., 1967; Cronkite et 
al., 1968; Field et al., 1972]. 
In considering the mechanism by which lymphopenia develops during 
ECIB, it is presumed that intact irradiated lymphocytes or fragments of these 
are rapidly removed from the circulation by the reticuloendothelial system. 
This presumption is based on the following observations: 1) after in vitro 
incubation oflymphocytes which have passed one time through the irradiation 
field (TD 900 rad), 87% of the cells disintegrate within a six-hour period 
[Cronkite et al., 1962a]; 2) 51Cr-labelled lymphocytes irradiated in vitro with 
1000 rad disappear quickly when infused into the circulation and do not 
recirculate [Jansen et al., 1969]; and 3) direct damage to lymphocytes during 
ECIB was established by the observation of dicentric chromosomal aberrations 
[Field et al., 1972]. The rapid development of lymphopenia indicates the 
occurrence of interphase death. Stress with associated increases in adrenocorti-
cal activity contributing to lymphocyte depletion by ECIB does not seem to 
play a major role, as was concluded from ECIB studies in adrenalectomized 
calves [Joel et al., 1976]. 
Ionizing radiation has been widely applied to induce immunosuppression in 
organ transplantation [van Bekkum, 1974]. ECIB offers the advantage of 
inducing a lymphopenia without damage to other cells. This technique has 
therefore been employed both experimentally and clinically in attempts to 
promote the survival of tissue allografts. 
Data have been published on prolongation of skin allografts in ECIB-
treated calves [Chanana et al., 1966; Chanana et al., 1969], rats [Pichi-
maier and Trepel, 1966] and baboons [Storb et al., 1969]. To evaluate 
possible clinical applications, ECIB was also applied in renal transplantation. 
Survival of allografted kidneys was found to be prolonged when ECIB was 
performed in dogs [Maginn and Bullimore, 1968] and goats [Chanana et al., 
1971]. 
It has substantially less effect on humoral immunological activity. In 
primates [Storb et al., 1969] and calves [Stoner et al., 1969], the antibody 
responses to sheep erythrocytes and tetanus toxoid, respectively, were only 
slightly or not at all depressed. This may be explained by the fact that, in 
contrast to cellular immunity (migrating lymphocytes), the humoral response 
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involves a relatively large contribution of regional lymph nodes which are 
easily reached by circulating antigens. 
ECIB has been clinically applied to patients before and/or after kidney 
transplantation. A favourable circumstance in these cases is that these patients, 
because of renal disease, have already been equipped with an arterio-venous 
shunt for regular haemodialysis. Under these circumstances, ECIB can be 
easily performed. In 1966, two publications appeared on reversal of graft rejec-
tion when ECIB treatment was started after renal transplantation [Wolf eta!., 
1966; Merril eta!., 1966]. Later systematic studies indicate that acute rejection 
episodes can be avoided [Maginn and Bullimore, 1967; Rosengren et a!., 1968; 
Persson eta!., 1969; Weeke eta!., 1970; Birkeland and Munk, 1972; Schmidt 
eta!., 1974]. Furthermore, it was established by means of lymphocyte trans-
formation assays that the mitogenic reactivity of lymphocytes present in the 
blood and the lymph nodes after ECIB showed large individual variations 
without a distinct pattern [Weeke and S0rensen, 1971; Weeke, 1972b; 
Birkeland, 1976; Birkeland eta!., 1976]. 
ECIB has not been of clinical benefit when used for immunosuppressive 
purposes in subacute glomerulonephritis [Andersen eta!., 1968]. 
1.4.7 Effects of ECI B on leukaemia 
As mentioned earlier ( Ch. 1.1), Lajtha and co-workers were the first to 
introduce ECIB as a possible therapeutic measure in the treatment ofleukaemia 
[Lajtha et a!., 1962]. Since that time, several groups of investigators have 
studied the effects of ECIB on various forms of human leukaemia. In general, 
the clinical indications to apply ECIB treatment have been: 
(I) resistance to chemotherapy; 
(2) contraindications for chemotherapy, e.g., toxicity, pregnancy; and 
(3) severe leukocytosis with the risk of developing leukostasis. 
For the theoretical evaluation of the possibilities of using ECIB in leukaemia 
therapy, it is very important to know the factors inherent in the leukaemic 
process which determine its efficacy (table 1.1). The first of these is the number 
of leukaemic cells in the blood. Patients with high white cell counts may be the 
best candidates for ECIB; those with aleukaemic leukaemia may benefit little 
unless there is a high rate of exchange between blood and tissue stores. The 
second consideration is the number of leukaemic cells in tissue stores such as the 
bone marrow, the spleen, the lymph nodes and elsewhere. In early leukaemia, 
this number may be in the order of 1011 [Lajtha et a!., 1962]. In advanced 
disease with hyperplastic bone marrow and enlarged spleen and lymph nodes, 
the number may be in the order of !012 -1013• The third factor is the rate of 
exchange ofleukaemic cells between the tissue depots and the blood. So far, no 
exact data are available on this point. Fourthly, the radiosensitivity ofleukaemic 
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cells is of importance. In vivo assay methods in experimental leukaemia models 
have shown that the D 0 value ranges from 60 to 160 rad [Hewitt and Wilson, 
1959; Whitmore and Till, 1964; Bush and Bruce, 1965]. Using in vitro tech-
niques, data have been obtained on the radiosensitivity of cells derived from 
human leukaemias. In chronic lymphocytic leukaemia (CLL), some cases have 
been reported with cells sensitive to as low a dose as 2 rad [Schrek and Stefani, 
1964]. In view of the fact that other cases are resistant to as much as 1000 rad, 
it can be concluded that there is a large range of sensitivities among the various 
classes ofleukaemia. By studying the blood disappearance of reinfused isotope-
labelled irradiated leukaemia cells, information was also obtained on the 
radiosensitivity when this was compared with the fate of nonirradiated rein-
fused cells [Andersen et a!., 1974]. Furthermore, by following the fate of 
'H-cytidine labelled lymphocytes in CLL during ECIB, a correlation was 
established between the radiosensitivity and the lymphocyte RNA turnover. 
Increased radioresistance and thus a reduced effectiveness of ECIB was found 
to be related to more rapid RNA turnover [Strijckmans et a!., 1969]. The 
fifth concern is the rate of leukaemic cell production; this will be discussed 
later. However, the general concept at present is that acute leukaemia is 
characterized by a rather slow growth rate as compared with normal haemo-
poiesis [Killmann, 1968; 1972]. Finally, the lifespan of leukaemic cells must be 
taken into account. Several studies suggest that, to some extent, leukaemia may 
be a disease of overaccumulation of cells with a long lifespan (see Ch. l.4.7c). 
If this is true, ECIB might be quite effective in reducing the mass of leukaemic 
tissue. It is obvious that precise data on the factors mentioned above have not 
been completely obtained in human leukaemia. 
Systematic experimental ECIB studies have not been performed because of 
the lack of suitable animal models. The most commonly used animal species for 
leukaemia studies, i.e., the mouse, would obviously give rise to insurmountable 
technical difficulties. As regards experimental ECIB, only the group of Cronkite 
has described the effects of ECIB on spontaneous malignant lymphoma and 
lymphocytic leukaemia in 5 cattle [Cronkite eta!., 1965; Joel eta!., 1967a]. 
Repeated sessions of ECIB, with transit doses ranging from 300 to 2000 rad, 
reduced the lymphocyte count in the peripheral blood of all of these animals. 
The daily induction of lymphopenia with return to higher lymphocyte levels 
the next day indicates that the blood lymphocytes were exchanging rather 
rapidly with lymphatic tissue stores. This was also supported by the observation 
that the size of enlarged lymph nodes neither increased nor decreased during 
the period of ECIB treatment. This might mean that production of malignant 
cells was keeping pace with destruction of mobilized cells. The cows showed 
different rates of peripheral recovery after the cessation of ECIB. This might be 
explained in terms of different rates of mobilization from the leukaemic tissue 
mass to the blood. No complete remissions were observed in these studies. 
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As regards human leukaemia, the evaluation of ECIB is rather complex be-
cause of different stages of the process in different patients, concomitant therapy 
regimens, ethical considerations, etc. An attempt will be made to review data 
on the effects of ECIB in various types of human leukaemia. 
a. Chronic lymphocytic leukaemia ( CLL) 
Of all the forms of leukaemia, ECIB treatment in CLL has been studied in the 
greatest detail. A considerable proportion oflymphocytes in CLL are long-lived 
recirculating cells [Schiffer, 1968; Zimmerman et a!., 1968]. However, the 
rate of recirculation of leukaemic cells is rather slow in comparison with that of 
normal lymphocytes [Binet eta!., 1967; Bremer eta!., 1973b; Flad eta!., 1973]. 
By both isotope studies and ECIB-induced depletion patterns, several functional 
cell compartments could be distinguished in CLL. Cells in the circulating 
blood pool (CBP) exchange continuously with a rapid exchangeable pool 
(REP) which is built up by an intravascular noncirculating compartment, like 
the marginal pool ( MP) for granulocytes and an extravascular compartment 
(the rapidly exchangeable tissue pool: RETP), which is not defined anatomi-
cally at present. The REP may be 1.5 to 60 times larger than the CBP [Strijck-
mans eta!., 1968; Schiffer eta!., 1969; Spivak and Perry, 1970; Bremer eta!., 
1973a; Scott eta!., 1973; Neumann et a!., 1974]. The third compartment is the 
slowly exchanging tissue pool (SETP), which contains the bulk of malignant 
lymphocytes (spleen, lymph nodes, bone marrow). 
From these observations, it is clear that, in principle, ECIB might deplete the 
CBP and REP to a large extent, while the SETP would be affected to a much 
lesser degree. With transit doses ranging from 25 to 720 rad, ECIB has indeed 
reduced the number oflymphocytes in the peripheral blood to varying degrees 
in most cases, whereas the decrease in the size of the spleen and the lymph 
nodes (indicating the size of the RETP and SETP) has been variable: some 
patients show a clear-cut size reduction, others do not. Although bone marrow 
infiltration persists in all cases (apparently due to a slow exchange), improved 
normal haemopoiesis has been reported after ECIB treatment [Thomas eta!., 
1965; Wolf and Hume, 1967; Storb eta!., 1968; Begemann eta!., 1968; Garret 
and Lajtha, 1968; Andersen et a!., 1968; Evers, 1969; Meuret et a!., 1971; 
Cronkite, 1971; Girard, 1974]. Another important observation was that ECIB 
does not promote selection of more radioresistant leukaemic cells: later courses 
of ECIB had the same cytolytic effect as did the initial ones. 
Three distinctive patterns of response to ECIB have been described [Field et 
a!., 1970]: 
I) a rapid decrease in the peripheral blood cell count during the course of 
treatment, the count remaining low for a prolonged period afterwards. With 
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this pattern, extravascular exchanging pools are small in relation to the 
circulating pool; the rate of exchange is relatively rapid; 
2) a less rapid decrease in the lymphocyte count, followed by a rather rapid 
return to pretreatment values when ECIB is discontinued. This pattern was 
correlated with a large extravascular pool of cells which exchanged rather 
slowly with the blood; 
3) a slow or negligible decrease in the blood cell count during ECIB. How-
ever, the count continues to fall for a variable period after treatment has 
ceased and remains at a low level for some time before it rises again. This 
phenomenon is observed in patients who have both proliferating precursor cells 
and nonproliferating end cells in their blood [Them! et al., 1973]. Because 
ECIB would preferentially deplete the small proliferating fraction, the popula-
tion of non proliferating cells naturally dies out in the time period after ECIB. 
From these data, the conclusion would be that, although ECIB can deplete the 
body of a significant number of cells in patients with CLL [up to 12 X 10" cells 
being destroyed in one series of treatment; Field et al., 1970], only partial 
remissions are achieved, due to the rather poor exchange of cells between the 
tissues and the blood. The limited number of patients does not permit definite 
conclusions concerning the survival time after ECIB treatment. It has been 
suggested that ECIB should be started in an early stage of CLL before there is 
extensive organomegaly and its sequelae [Cronkite, 1967]. It might then be 
possible to prevent organomegaly by intermittent depletion of the blood and 
the rapidly exchanging pool of lymphocytes. 
b. Chronic myelocytic leukaemia (CML) 
By means of isotope studies in GML, it has been observed that leukaemic 
cells are able to recirculate between blood, bone marrow and spleen [Perry et 
al., 1966; Galbraith, 1966; Chikkapa and Galbraith, 1967; Duvall and Perry, 
1968]. Since leukaemic cells, which have a prolonged blood disappearance 
time in CML as compared with normal granulocytes [Athens et al., 1965], are 
freely exchanging with tissue stores, ECIB might theoretically progressively 
deplete all of the leukaemic cell compartments such as the circulating blood 
pool, the noncirculating marginal pool [Athens et al., 1965] and the tissue 
pools. 
Seven cases of CML treated by ECIB have been described in the literature 
at the time of this writing [Cronkite, 1967; Lajtha et al., 1969]. With transit 
doses ranging from 150 to 500 rad, ECIB reduced the peripheral cell count for 
varying periods of time in all patients. In the early stage of treatment, the 
spleen usually became larger before the blood counts started to decrease. A 
concomitant increase in uric acid excretion has lead to the conclusion that 
radiation-injured cells accumulate in the spleen. The size of the spleen was 
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later substantially decreased in most cases. Although immature granulocytic 
cells sometimes completely disappeared from the blood during a treatment 
course, complete remissions have never been obtained. After cessation of ECIB, 
relapse of the leukaemic process occurred in a matter of days to several weeks. 
Several conclusions can be drawn from these studies in a rather small group of 
patients. Firstly, the transit doses used can cause considerable damage to 
granulocytic leukaemic cells. Secondly, the size reduction in the spleen during 
ECIB indicates the existence of a rapid exchangeable tissue pool in CML. The 
low efficiency of ECIB treatment in GML might be due to inadequate cellular 
exchange, an insufficient transit dose or an inadequate treatment time. 
Further studies in a larger group of patients to evaluate the possible usefulness 
of ECIB in CML are clearly indicated. 
c. Adult acute leukaemia (AL) 
Acute leukaemia is characterized by an accumulation of immature haemo-
poietic cells (maturation defect) in combination with a deficient production of 
mature functioning cells, i.e., erythrocytes, granulocytes and thrombocytes 
[Killmann, 1968]. These two phenomena seem to be related, as is indicated by 
the fact that restoration of the production of mature functioning cells is pre-
ceded by spontaneous or therapeutically induced disappearance of the 
immature leukaemic blast cells (LBC). However, no definitive answers can be 
given as to the causative factors underlying these related phenomena at the 
present time, although some insight into the pathogenesis of the disease has 
been gained during the past decades. Observations relevant to the present study 
will be summarized briefly below. 
For a long time, it has been thought that acute leukaemia is a disease process 
resulting from rapid, uncontrolled cellular proliferation [Wintrobe, 1961 J. 
However, during the past 10 years, it has been shown that LBC are quite 
heterogenous with respect to their kinetic behaviour [Killmann, 1968; 1972]. 
At the present time, it is proposed to distinguish between relatively actively 
proliferating LBC, which proliferate less rapidly than normal neutrophilic 
precursors and "quiescent" cells, which may constitute cells in a long G1 
phase, G 0 cells (out of cycle) and end cells [Cronkite, 1968; Clarkson, 1969; 
Gavosto eta!., 1969; Mauer and Lampkin, 1974]. Nonproliferating G 0 cells are 
believed to originate from the proliferating LBC compartment [Gavosto et a!., 
1964] and to maintain the capacity to proliferate again after a suitable stimulus 
[Saunders and Mauer, 1969; Strijckmans eta!., 1970; Killmann, 1972]. The 
LBC found in the peripheral blood belong mainly to the nonproliferating 
compartment [Killmann, 1968; 1972]. By reinfusion of autologous labelled 
leukaemia cells in acute myelocytic leukaemia (AML), it has been demon-
strated that LBC exchange rather rapidly with a marginal pool which is 1.2 to 
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3.5 times larger than the intravascular circulating pool [Hoelzer et a!., 1972]. 
The reported blood transit times ofLBC (32-46 h; see table 2.11 J are long when 
compared to those of normal granulocytes (5.5-10.4 h; Killmann eta!., 1963; 
Clarkson eta!., 1969; 1970]. From other studies, it has been suggested that 
leukaemic cells leaving the blood can return to the bone marrow and the spleen 
[Killmann eta!., 1971; Rosen eta!., 1975]. Whether or not these cells can start 
to proliferate after lodging in these sites is still a matter of debate, although 
positive evidence has been obtained for other anatomical sites, e.g., the 
development of subcutaneous leukaemic nodules. Another possibility is that 
cells are released into the circulation again ("recycling") after lodging in 
spleen and bone marrow [Tarocco eta!., 1972]. 
Based on this knowledge, it seems justified to apply ECIB to patients with 
acute leukaemia according to the indications mentioned above. Theoretically, 
there may be a chance to induce at least a partial remission. Several reports on 
the effects ofECIB on various types of human acute leukaemia have appeared. 
In 1962, Lajtha and co-workers performed the first pilot study in 2 patients, one 
with acute myelomonoblastic leukaemia and another with acute monocytic 
leukaemia [Lajtha eta!., 1962]. These patients were submitted to only 2 and I 
short lasting ECIB sessions, respectively. No apparent effect on the course of the 
disease was noted. However, of some importance was the observation that the 
whole procedure of ECIB was well tolerated and without any harmful side-
effects. Another early attempt was made with 2 children with acute myelo-
monocytic leukaemia. However, these patients died very shortly after ECIB 
was applied [Field and Dawson, 1967]. From this and other early studies, it was 
concluded that the treatment should not be started too late in the course of the 
disease [Evers and Haanen, 1967; Meindersma and Barendsen 1967]. 
The group of Cronkite has reported on the effects of ECIB in 14 adults with 
AML [Schiffer et a!., 1968]. They received repeated 4-hour sessions (transit 
dose: 236 to 535 rad) up to a total irradiation time of 57 to 880 hours. The 
median survival time of 8.0 months for patients treated with ECIB was as good 
as other published survival data from patients treated with chemotherapy at 
that time. Some cases with a rather long survival time have been reported 
(16.5 and 18 months). From this study, there appeared to be a correlation 
between increased survival time and a transit dose exceeding 340 rad. In 75 per 
cent of these patients, there was a marked decrease in the number ofleukaemic 
cells in the peripheral blood. However, no complete remissions were achieved in 
any case. Some patients showed an increase in the number of platelets, whereas 
in some patients the size of the spleen also decreased, as measured by spleen 
scanning. One pregnant patient was carried through to delivery by ECIB and 
thus avoided possible fetal injury due to chemotherapy. 
Lajtha and co-workers described the results of ECIB treatment using 
continuous irradiation (I to 5 days) in 8 patients with AML [Lajtha et a!., 
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1969]. Their findings can be summarized as follows: 5 patients treated early 
after diagnosis (5 to 8 weeks) all showed a decrease in the peripheral number of 
LBC which was maintained for some weeks. In some of these patients, the 
response to subsequent chemotherapy seemed to be more pronounced after a 
series of ECIB. In 3 patients where ECIB was started in a later stage of the 
disease (7 months after diagnosis), only a short-lasting reduction in the white 
cell count was observed. In none of the cases were significant changes in the 
bone marrow noted. This may indicate that there was virtually no exchange of 
LBC between the marrow and the blood. The conclusion of Lajtha and co-
workers was that ECIB might be especially beneficial if applied to patients who 
have not responded to the usual chemotherapeutic measures within 1 or 2 
Table 1.4 Changes in proliferation parameters in acute myelocytic leukaemia measured before and 
after ECIB 
duration of 
LI-BM (%) MI-BM (%) 
patient no. ECIB (h) pee post pre post 
l 18 3.4 19.6 0.2 3.2 
2 6 17.0 52.2 0.1 5.5 
3 20 3.1 3.6 0.2 0.2 
4 23 6.1 5.5 0.2 0.2 
5 12 18.4 29.5 2.1 2.4 
6 24 8.2 18.1 l.l 1.4 
7 16 9.4 12.2 0.6 1.2 
Ll-BM: labelling index of leukaemic bone marrow cells after in vitro incubation with 
tritiated thymidine 
MI-BM: mitotic index ofleukaemic bone marrow cells 
pre/post: before/after ECIB 
Patients no. 1-6: Chan and Hayhoe (1971); patient no. 7: Ernst et al. (1971) 
Table 1.5 Changes in proliferation parameters in acute myelocytic leukaemia measured during ECIB 
Ll-BM (%) MI-BM (%) LI-blood (%) 
hours after patient no. patient no. patient no. 
start of ECIB 5 6 7 5 6 7 7 
0 18.4 8.2 9.4 2.1 l.l 0.6 0.8 
2 9.2 0.3 0.6 
4 17.6 18.4 1.8 0.9 
8 19.8 11.9 1.6 1.5 0.7 
12 29.5 19.7 2.4 1.2 
16 12.2 1.2 0.6 
24 18.1 1.4 
LI-BM/blood: labelling index ofleukaemic bone marrow/blood cells after in vitro incubation 
with tritiated thymidine 
MI-BM: mitotic index of leukaemic bone marrow cells 
Patients no. 5 and6: Chan and Hayhoe (1971); patient no. 7: Ernst et al. (1971); see 
table 1.4 
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months after diagnosis. Essentially similar findings were reported by 3 other 
groups of investigators treating a total of 10 AML patients [Souhami et a!., 
1969; Chan and Hayhoe, 1971; Andersen eta!., 1974]. Temporary clinical 
improvement was sometimes seen. In some patients, however, the dissemination 
of the disease seemed to be accelerated by the ECIB procedure; e.g., extensive 
leukaemic infiltration of the skin was observed some days after irradiation was 
discontinued. A rapid increase in peripheral LBC was also noted in these 
patients after cessation of ECIB. This could possibly be accounted for by 
increased proliferation of LBC in the marrow or by a stimulation of their 
release from the marrow. 
Only 4 cases of acute lymphocytic leukaemia (ALL) treated by ECIB have 
been reported [Thomas et al., 1965; Garret, 1967; Souhami et a!. 1969]. 
These patients were in the terminal stage of the disease. Generally, ECIB 
induced a reduction in the peripheral LBC count; however, no complete 
remissions were observed. After cessation of ECIB, chemotherapy with 
6-mercaptopurine appeared to be much more effective than usual in 2 patients, 
suggesting that the irradiation resulted in an increase in sensitivity to this drug. 
From the observation that several patients after ECIB show a rapid rise in 
the number of peripheral LBC, an accelerated dissemination of the disease and 
an increased sensitivity to certain drugs, the possibility was considered that 
destruction of LBC by ECIB might stimulate the bone marrow to increase its 
proliferative activity, possibly through a feedback mechanism. This hypothesis 
was tested by measuring the mitotic index (MI) and the in vitro tritiated 
thymidine labelling index (LI) of marrow LBC before, during and after ECIB 
[Chan et al., 1969; Chan and Hayhoe, 1971; Ernst et al., 1971]. A total number 
of 7 patients with AML were studied (table 1.4). The duration of the ECIB 
session varied from 6 to 24 hours. In 5 of the 7 studies, a clear-cut increase in the 
LI was observed, occurring in some patients as early as 4 to 6 hours after the 
initiation ofECIB (patient no. 2, table 1.4; patients no. 5, 6 and 7, table 1.5). 
In the patients with an increased LI, the MI was also increased, although these 
changes were less consistent than the changes in the LI. However, since the 
duration of mitosis may be as short as I /20 of that of the synthesis of DNA, the 
MI is a less reliable indicator of cellular proliferation than the LI. On the other 
hand, an increased LI might also be due to synchronization of the LBC in the 
marrow by ECIB. This seems to be less probable, because the same effect was 
observed in different patients, in different stages of the leukaemia, at different 
times following ECIB performed with different dose rates. Of the 2 patients who 
did not show changes in the LI or MI, one had no demonstrable circulating 
LBC at the time ECIB was performed. In the second patient, who had a high 
peripheral LBC count, the kinetic behaviour of the leukaemic cell population 
appeared to have been different, although a transient increase in the LI and 
MI might have been missed in this study. 
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The major conclusion resulting from these studies is that at least part of the 
quiescent, nonproliferating LBC population does not consist of end cells but of 
cells which may be recalled into the proliferative cycle (recruitment) by an 
appropriate stimulus. In this instance, the acute depletion of peripheral LBC 
by ECIB seems to be the causative factor. In AML, an analogous stimulus may 
be provided when LBC are merely removed from the peripheral blood 
(leukapheresis). However, the increase in LBC proliferation measured by 
means of the LI takes a much longer time with this procedure, i.e., in the 
order of several weeks after repeated sessions of leukapheresis are started 
[Reich et al., 1971; Hoelzer et al., 1974b]. This difference between ECIB and 
leukapheresis might be explained by the fact that, in ECIB, destroyed cells 
remain within the body and may release some factors which stimulate cell 
proliferation in a more effective way, whereas, in leukapheresis, the cells are 
merely removed. These studies support the hypothesis that a feedback mecha-
nism exists between the blood and the bone marrow in acute leukaemia. 
The observations mentioned above might have important implications as 
regards more effective chemotherapy with cycle-active drugs subsequent to 
ECIB. The small group of patients studied all showed a decrease in the number 
ofLBC in the blood, which seemed to be more rapid and more sustained than if 
chemotherapy was used without preceding ECIB. The chemotherapy employed 
consisted of cytosine arabinoside (Ara-C) or a combination of Ara-C, metho-
trexate (MTX), 6-mercaptopurine and prednisone [Chan and Hayhoe, 1971] 
or MTX and vincristine [Ernst et al., 1971]. However, no complete remissions 
could be induced. 
d. Lymphoreticular neoplasms 
Only a few cases of lymphoreticular neoplasms treated by ECIB have been 
reported. These include 2 patients with widespread lymphosarcoma [Dawson 
et al., 1967], one patient with a reticulum cell sarcoma [Sharpe et al., 1967] and 
one patient suffering from Hodgkin's disease [Sharpe et al., 1968]. In the 
2 lymphosarcoma patients, a small, but sustained, decrease in the elevated 
peripheral lymphocyte count together with a reduction in size of enlarged 
lymph nodes was observed. The lymph nodes, however, returned to their 
original size within a few days after ECIB was discontinued. It was suggested 
that this was due to redistribution of surviving lymphoid cells rather than to an 
accelerated rate of cellular proliferation. In the 2 other patients, who had a 
normal number of cells in the blood, the objectives of the ECIB treatment were 
to gain insight into the dosimetry of the ECIB procedure and lymphocyte 
kinetics, e.g., the mean residence time of lymphocytes in the blood and the size 
of the extravascular pool oflymphocytes in the body. Both of these parameters 
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were studied by analysing chromosomal aberrations within lymphocytes 
induced by ECIB. 
1.5 Contents of the present study 
The study to be presented will be divided into the following parts. In Chapter 
2, the rat leukaemia model will be described in detail in terms of morphological 
and functional characteristics. 
Chapter 3 will deal with leukocyte mobilizing agents (LMA). Cell 
mobilization studies in both normal and leukaemic animals will be discussed. 
Results of the clinical application of LMA to patients with leukaemia will also 
be reported. 
In Chapter 4, the model which was developed in order to apply repeated 
sessions of ECIB to rats will be discussed, including the cannulation and ECIB 
procedures as well as physical entities such as radiation equipment and 
dosimetry. The effects of ECIB on the rat leukaemia will be evaluated by 
means of haematologic and kinetic parameters. Long-lasting sessions of ECIB 
will be compared with repeated short-lasting ones. In addition, the efficacy of 
eel! mobilization in combination with ECIB will be discussed. 
Finally, in Chapter 5, a general discussion and conclusions together with 
recommendations for application of ECIB in the future will be presented. 
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CHAPTER 2 
THE RAT LEUKAEMIA MODEL 
2.1 Introduction 
As mentioned earlier (see Ch. 1.1), the studies were performed in a rat model 
for acute myelocytic leukaemia. The leukaemia originated in a female rat of 
the inbred Brown-Norway strain at Rijswijk (BNjRij) in 1971 following 3 
intravenous injections of 2 mg 9, 10-dimethyl 1,2-benzanthracene (DMBA) 
100 days earlier. In general, such a model should: (1) be transplantable within 
the given animal strain; and (2) have a reproducible growth pattern through-
out the subsequent transplantation generations. The model to be described 
meets both prerequistites (van Bekkum, personal communication). It proved 
to be transplantable in the BN rat strain by means of cellular transfer. Because 
of its myelocytic nature (see Ch. 2.4), it has been named the BN myelocytic 
leukaemia (BNML). 
In this chapter, the model, which resembles human acute myelocytic 
leukaemia in many aspects, will be analysed in detail with respect to morpholo-
gical and functional characteristics. The materials and methods which were 
generally used will be first described. 
2.2 General experimental procedures 
2.2.1 Experimental animals 
The experiments were carried out with the inbred Brown-Norway (BN) rat 
strain produced in the Rijswijk colony. Male rats between 15 and 20 weeks of 
age were used. \'\Tater and food were always supplied ad libitum during the 
experiments. 
2.2.2 Preparation of cell suspensions 
Spleen 
After excision and cleaning, spleens were cut into small pieces with scissors. 
The pieces were subsequently squeezed through nylon gauze. In this way, a 
monocellular suspension using Simms' solution was obtained. 
Bone marrow 
Femurs were removed and cleaned of adherent muscle tissue. Then the 
proximal ends were cut with scissors and the femoral shafts were emptied by 
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repeated flushing with Tyrode's solution using a bent needle placed on a 
syringe. The collected bone marrow was filtered through nylon gauze. 
Blood 
To obtain large amounts of blood, the abdominal aorta was punctured under 
ether anaesthesia. Seventy to eighty percent of the total circulating blood 
volume can be collected in this manner. To prevent coagulation of the blood, 
sodium citrate (Natrii Citras 3.1 %, ACF Chemiefarma, Holland) was added up 
to a final concentration of 20%. 
Cell counting 
The number of nucleated cells present in cell suspensions was counted in a 
Biirker type haemocytometer using Turck's solution (0.01% crystal violet and 
I% acetic acid in saline). Tbe number of dead cells was determined by means 
of eosin (0.2%) uptake. 
2.2.3 Leukaemia transfer 
In most of the experiments, the leukaemic spleen was used as a source of 
leukaemic cells for transplantation. The required number of cells, obtained 
through dilution of a monocellular suspension, was then injected intravenously 
into a tail vein in a volume of l mi. 
In order to maintain a reproducible growth pattern of the leukaemia, no 
more than two subsequent transplant generations were allowed. After each 
second transplantation, leukaemia transfer was performed with cells from a 
large frozen stock of identical batches. Leukaemic cells were frozen in sterile 
plastic ampoules of 5 ml volume (4-5 X 107 cellsjml). Cells were suspended in 
Simms' solution supplemented with the cryoprotective agent dimethyl-
sulphoxide (DMSO) (10%) and with calf serum (20%). Cells were cooled at a 
rate of freezing of I 'Cjmin which was controlled by a thermocouple placed 
into an identical ampoule situated in the freezing chamber. As soon as the 
cooling temperature reached -50 'C, the ampoules were stored in a liquid 
nitrogen container. To thaw the frozen suspensions, the ampoules were placed 
in a 40 'C waterbath. The cells were then diluted with Simms' solution at an 
ultraslow stepwise rate described by Schaefer et a!. (1972). The cells were 
washed and counts were performed. Viability of the leukaemic cells as checked 
by both eosin uptake and bio-assays was not altered by the freezing and 
thawing procedure. 
In this way, all experiments could be carried out within 5 transplantation 
generations. 
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2.2.4 Haematological parameters 
Blood sampling 
For haematological follow-up during the experiments, blood samples were 
obtained either from the tail by cutting off its tip or from an extracorporeal 
aorta by-pass to be described later (see Ch. 4.2). The blood was collected in 
small plastic vials containing some grains of dipotassium ethane-diamino-
tetra-acetic-acid (EDTA; British Drug Houses Ltd., England) to prevent 
coagulation. 
Blood cell counting 
Total leukocytes and erythrocytes were counted with a coulter counter model B 
(Coulter Electronics Inc., USA) after appropriate dilution of the blood sample 
with Isoton (0.1% sodium azide, Coulter Electronics Ltd., England). Zaponin 
(2.5% acetic acid, Coulter Electronics Ltd., England) was added to lyse the 
red cells before counting leukocytes. Platelets were counted in a haemocyto-
meter using Feissly's stain (3% cocaine HCl, 0.1% sodium azide; Apotheek 
Haagse Ziekenhuizen, Holland). After vital staining with brillant cresyl blue 
(3.3% in absolute alcohol), the number ofreticulocytes per 1000 erythrocytes 
was determined. 
Haematocrit 
Microcapillaries filled with blood were centrifuged for 5 min at 11,500 rpm 
(13.5 g). Haematocrits were then determined by means of a microcapillary 
reader (International Equipment Co., Boston, Mass., USA). 
Cytology 
Blood smears were prepared according to standard methods. After drying in 
air, the cells were stained with May-Grii.nwald stain for 3 min and, after 1 min 
in a pure phosphate buffer solution (pH 6.9), stained for 15 min with Giemsa 
solution (diluted 1:26 with the same buffer). One min washing with glass-
distilled water and drying in air completed the procedure. 
The cytological composition of the bone marrow was studied after precipita-
tion of femoral bone marrow cell suspensions according to the method described 
by Sayk [Sayk, 1960]: 20 fll of Tyrode's solution containing 10 5 cells were 
mixed with 4 drops of Hanks' Balanced Salt Solution supplemented with 20% 
fetal calf serum; the cells were then sedimented onto glass slides for 25 min at 
room temperature. After drying in air, the slides were fixed in absolute 
methanol for 3 min and stained as described above. 
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2.3 Cytogenetics and DNA content 
Cytogenetic analysis of leukaemic cells indicated the presence of a specific 
chromosome marker in the BNML, i.e., a fusion between chromosomes 2 and 
7 (Drs.J. C. Klein and A. Th. van der Velden, Rijswijk). All BNML cells have 
a diploid number of chromosomes (n = 42). 
The DNA content of BNML cells was determined in single Feulgen-stained 
smears with the Barr and Stroud integrating microdensitometer (fig. 2.1; 
Dr. G. Haemmerli, Zurich). The histogram revealed that the majority of 
BNML cells contained a slightly increased amount of DNA (2.3 n) as compared 
with normal rat lymphocytes (2.0 n). Because of the diploidy of the leukaemic 
cells, this might be due to either an increased amount of DNA per chromosome 
or the presence of a large proportion of BNML cells in early DNA synthesis 
phase. 
0 
. 
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DNA content ( orbitrory units) 
Fig. 2.1 DNA content of BN myelocytic leukaemia cells as measured by the integrating microdensito-
meter (Haemmerli, 1974). 
2.4 Cytological and cytochemical characterization 
2.4.1 Cytology 
With light microscopy, the leukaemic cells in the blood can be described as 
follows (fig. 2.2). They are large cells (diameter 11-16 !L) with a relatively 
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large oval or kidney-shaped nucleus showing a coarse chromatin pattern. The 
nucleus often contains a large irregular nucleolus and is surrounded by a rim of 
dark blue cytoplasm containing many coarse purple granules. Auer rods are 
not observed. It was noted that many leukaemic cells in a blood smear were 
damaged and showed extensive karyorrhexis or even complete loss of cell 
structure. This may indicate a greater fragility of the BNML cells as compared 
to normal leukocytes. Leukaemic cells in the bone marrow have the same 
morphological features. 
Electron microscopy (Dr. H. Felix, Zurich) reveals the following charac-
terisistics (fig. 2.3). Besides a normal number oflysosomes and mitochondria, an 
abundance of endoplasmic reticulum is observed in the cytoplasm; it shows 
dilated cisternae. The Golgi apparatus, which is larger than normal, also 
shows dilated cisternae and vacuoles. In addition, a great number of large 
granules is present in the cytoplasm, most of them being extracted as artifacts. 
An appreciable number of cytoplasmic microtubules and only a few microfila-
ments are also evident. 
According to the morphologists, the nucleus, the granules and the large 
Fig. 2.2 Light microscopic preparation of leukaemic promyelocytes in the peripheral blood (X 2100). 
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Fig. 2.3 Electron microscopic preparation of a leukaemic promyelocyte in the peripheral blood 
(x 18000; Dr. H. Felix, ZUrich). 
quantity of endoplasmic reticulum are typical for cells of a promyelocytic 
leukaemia [Bernard et a!., 1963; Tan eta!., 1972; Valdivieso eta!., 1975; 
Spremolla et a!., 1976]. 
2.4.2 C:;vtochernistcr 
The cytochemical characterization of the BNML is summarized in table 2.1. 
The cells studied were obtained from terminal stage leukaemic blood. Ac-
cording to a generally accepted classification [Hay hoe, 1969; Flandrin and 
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Table 2.1 C)!tochemical characterization of the BN acute myeloc.ytic leukaemia 
stain reaction 
peroxidase (Graham~Knoll) 
esterases 
naphthol-AS-D-chloroacetatc 
IX-naphthyl acetate 
Sudan Black 
PAS 
~-glucuronidase 
phosphatases 
acid 
alkaline 
* PAS: periodic acid Schiff: light diffuse discoloration. 
++ 
+ 
+ 
+++ 
+* 
++ 
Daniel, 1973], the observed reactions confirm the promyelocytic nature of the 
leukaemic cells. 
2.5 Histological pattern of spread 
Rats were inoculated with 107 BNML cells and sacrificed at various times until 
spontaneous death occurred at the 28th day. Organs and tissues were fixed in 
4% buffered formaldehyde. Microscopic preparations stained with haema-
toxylin-phloxin-safran were produced by standard procedures in the Depart-
ment of Pathology of the Institute for Experimental Gerontology TNO. The 
major histological findings during leukaemia development are summarized 
below. 
2.5.1 Bone marrow 
During the first week after inoculation, no apparent changes from normal are 
observed in the femoral bone marrow. At day 8, myeloid hyperplasia is noted. 
Some small foci of leukemic blast cells also appear at this time. Between days 8 
and 18, the tumour cell deposits grow out as large clusters at the expense of 
normal haemopoiesis (fig. 2.4). The number of megakaryocytes decreases 
steadily and erythropoiesis and myelopoiesis are also disappearing. After day 
18, only a very few small foci of normal haemopoiesis are left. During the last 
7 days before death, the entire bone marrow cavity consists of leukaemic cells. 
In addition, there is also periosteal and intermuscular infiltration with leukae-
mia (fig. 2.5). An increasing amount of necrotic debris is observed in the bone 
marrow cavity. 
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Fig. 2.4 A large cluster of leukaemic cells (Tight) with remaining normal haemopoiesis (left) in the 
femoral bone marrow (X 122,5; day 10 after inoculation). 
Fig. 2.5 Intermuscular infiltration with leukaemic cells (X 122,5; day 23 after inoculation). 
2.5.2 Spleen, lymph nodes and thymus 
Spleen 
Although a very few small foci of normal haemopoiesis exist until day 8, in 
particular, the number of megakaryocytes and erythropoietic cells in the red 
pulp increases after this day. At the same time, the first clusters of tumor cells 
appear in the red pulp. The white pulp shows normal active lymph follicles. At 
the 18th day, most of the red pulp has been replaced by leukaemic cells. Foci of 
Fig. 2.6 Replacement of the red- and the white pulp in the spleen by leukaemic cells. Remnants of a 
normal lymph follicle are observed at the lower left part of the picture (X 122,5; day 
18 after inoculation). 
active normal haemopoiesis are observed within the tumour mass. The white 
pulp also shows considerable changes from normal at this time. The number of 
follicles has decreased, which is explained by the fact that many of them have 
been partly or completely replaced by the leukaemia (fig. 2.6). However some 
follicles are still intact. From day 18 until death, virtually the whole spleen is 
replaced by leukaemic tissue. Only some remnants of normal follicles and a few 
small clusters of haemopoietic cells are left. 
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Lymph nodes 
Up to day 14, no apparent changes from normal are visible. Thereafter, a 
preferential pattern of infiltration is observed; i.e., some nodes, such as the 
para-aortic and liver hilus nodes, become heavily infiltrated with leukaemia 
cells, whereas others remain intact and active without any signs of leukaemia, 
e.g., the mesenteric, axillary and inguinal lymph nodes and the Peyers' 
patches. When a node is affected, the first clusters of tumour cells are observed 
in the sinusoids. From there, a diffuse infiltration occurs throughout the entire 
lymph node, ending up in a complete loss of normal architecture by total 
replacement with leukaemic cells. 
Thymus 
In the terminal stage ofthe disease, some diffuse infiltration with BNML cells is 
noted in the cortex and in the medulla. At the same time, the cortex shows 
complete atrophy. 
2.5.3 Liver 
The first individual leukaemic cells can be recognized in the sinusoids at day 4. 
At the 8th day, randomly distributed aggregates of about 10 tumour cells are 
observed (fig. 2. 7). Signs of normal haemopoiesis, in particular erythropoiesis, 
although not excessive, are also noted. From day 14 onwards, a second wave of 
invasion occurs with the portal triads as the preferential sites (fig. 2.8). From 
there, sheets of leukaemic cells diffusely infiltrate the sinusoids. During the last 
week of the disease, the whole organ is heavily infiltrated and there is degenera-
tion and death of many individual hepatocytes. Normal haemopoiesis com-
pletely disappears in this terminal period. 
2.5.4 Lungs 
The first perivascular aggregates of leukaemic cells become apparent between 
days 8 and 14 (fig. 2.9). At day 14, these deposits of tumour cells have started to 
infiltrate into the interstitial lung tissue, thereby causing obliteration and 
destruction of alveoli (fig. 2 .10). Some subpleural leukaemic infiltrates are also 
noted at this time (fig. 2.11). During the last 2 weeks of the disease, the process 
of infiltration continues. Peribronchial lymphatic tissue is partly or completely 
infiltrated by BNML cells. The interalveolar septa are markedly thickened; 
both emphysema and atelektasis occur. Intra-alveolar haemorrhages are 
frequently observed. The pattern of tumour growth takes the form of large 
nodular aggregates (fig. 2.12). 
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Fig. 2.7 Small aggregates of leukaemic cells in the shtUsoids of the liver (x292; day 8 after inocu~ 
lation). 
Fig. 2.8 i\1assive infiltration with leukaemic cells of the liver parenchyma starting at the portal triads 
(x 122,5; day 18 after inoculation). 
Fig. 2.9 
" 
I 
.1".1 
.!'+ 
........ 
. <1<'~1!:'; ,;,+ 
f (il'l.i 
;...·.-·-· 
Aggregates of leukaemic cells around a small venule in the lungs (X 292; day 8 after inocu-
lation). 
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Fig. 2.10 Infiltration with leukaemic cells qf the lung parenchyma causing obliteration and destruction 
of alveoli ( x 122,5; day 18 after inoculation). 
Fig. 2.11 Subpleural infiltrate with leukaemic cells (x46,5; day 18 after inoculation). 
Fig. 2.12 Nodular aggregates if leukaemic cells in the lung parenchyma (x292; day 23 after in-
oculation). 
2.5.5 Kidneys 
No apparent signs of kidney involvement are present up to the 18th day. 
However, tumour cell deposits are observed in the adipose tissue surrounding 
the pelvis (fig. 2.13). From day 18 onwards, leukaemic cells are observed 
around vessels in the cortex, from where they infiltrate into the parenchyma 
leading to local destruction of tubules (fig. 2.14). This process continues as the 
leukaemia progresses. In the terminal stage, many foci of tumour cells are 
observed in the cortex and solid sheets of BNML cells are also present in the 
hilar region. However, the glomeruli remain rather well preserved. The medulla 
shows no signs of leukaemia throughout the entire disease period. 
2.5.6 Miscellaneous 
All other organs which were examined histologically during leukaemia 
development, such as the skin, the skeletal muscles, the heart, the intestines, the 
pancreas, endocrine and exocrine glands, the genitals and the adrenals, 
remained free of leukaemia infiltration. The central nervous system (CNS) 
generally also remains unaffected. In earlier transplantation generations, 
nodular aggregates of leukaemic cells compressing nerve roots develop along 
the spinal cord. This may result in paralysis of the upper and lower limbs. No 
clear signs of meningeal involvement are present. However, haemorrhages are 
occasionally observed in the spinal cord. 
2.5.7 Discussion 
Essentially, the infiltration pattern of leukaemic cells into the various organs 
runs the same course as in human AML [Robbins, 1968; Gunz and Baikie, 
1974]. The following phenomena, however, deserve some more attention. 
After inoculation, the first microscopic signs of leukaemia are found in the 
bone marrow, the spleen, the liver and the lungs. In fact, as will be described 
later (see Ch. 2.6.3), the majority of injected BNML cells initially lodges in 
these organs. The bone marrow and the spleen are the first organs to be com-
pletely replaced by leukaemic tissue. After the number of leukaemic cells in 
these organs have exceeded a certain critical level, around day 14 a release to 
the circulating blood occurs (see Ch. 2.6.2) followed by a second wave of 
invasion into the various organs. This release may be enhanced by changes in 
the vascular structure induced by leukaemic cells as has been described for 
the L5222 leukaemia [Hoelzer et al., 1974c]. The secondary phenomenon is 
clearly demonstrated by the lymph nodes and the kidneys, which show signs of 
leukaemia only after days 14-18, and by the liver where leukaemic cells appear 
around the portal triads after day 14. 
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Fig. 2.13 Deposits ofledaemic cells in the adipose tissue surrounding the renal pelvis (x292; day 18 
after inoculation). 
Fig. 2.14 Massive infiltration with leukaemic cells of the renal cortex with local destruction of tubules 
(X 122,5; day 28 after inoculation). 
Another striking phenomenon is the gradual disappearance of normal 
haemopoiesis. This will be discussed in more detail (see Ch. 2.6.5). Histology 
shows that the number of normal haemopoietic elements in the bone marrow 
decreases after day 8. This might be partly due to an increased release to the 
peripheral blood, as indicated in fig. 2.19, where the number of mature 
granulocytes in the blood rises after day 8. At the same time, an increasing 
number of foci of normal haemopoiesis is observed in the liver and especially 
in the spleen. In the late stage of the disease, haemopoiesis is maintained to a 
certain degree by these two organs, as the bone marrow is completely replaced 
by leukaemic cells. Finally, normal haemopoiesis in the liver and the spleen also 
decreases because of massive infiltration with leukaemic cells. 
The heavy infiltration of specific sites of the lymphatic apparatus by 
leukaemic cells needs some more discussion. Especially the spleen, the para-
aortic and liver hilus lymph nodes and the bronchus-associated lymphatic 
tissue in the lungs are completely replaced by leukaemia. This probably 
reduces the cellular and humoral immune reactivity of the leukaemic rat. 
However, the T cell mitogenic reactivity, measured by means ofPHA or Con-A 
stimulation, was unchanged in the mesenteric lymph nodes (Dr. A. M. Kruis-
beek, Rijswijk). These lymph nodes are free of leukaemia during the entire 
disease period. In the thymus, enhanced mitogenic responses were noted in the 
terminal stage. This might be explained by the fact that the number of reactive 
T lymphocytes in the medulla shows a relative increase as the number of 
nonresponsive cortical lymphocytes decreases. The same phenomenon is 
observed in corticosteroid treated animals which show a considerable immu-
nosuppression [Andersson et al., 1972]. Thus, an enhanced thymocyte 
mitogenic response might well correlate with an overall impaired immuno-
reactivity. 
The selectivity oflymph node involvement can be explained by the individual 
drainage areas, e.g., the para-aortic nodes drain the lower limbs which contain 
many leukaemic cells in the bone marrow; the liver hilus nodes receive afferent 
lymph from the leukaemic liver and possibly also from the leukaemic spleen. 
Moreover, direct evidence for transport of leukaemic cells via lymphatics has 
been obtained by the observation that the thoracic duct fluid contains in-
creasing numbers ofBNML cells during leukaemia development. As compared 
with other organs, the thymus shows a remarkable resistance to invasion by 
leukaemic cells. This has also been described for other rat leukaemia models 
such as the Shay myelocytic leukaemia [Harris et al., 1958; Kelenyi, 1959], the 
L5222 leukaemia [Hoelzer et al., l973a J and the SAL myelocytic leukaemia 
[Wrathmell, 1976]. Cortex atrophy may be due to an increased production of 
corticosteroids by tumour bearing animals [Fachet et al., 1975], caused either 
by stress or leukaemia-induced toxicity. 
The fact that the CNS remains free of leukaemia seems to be specific for the 
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BNML; CNS involvement is a prominent feature in other rat leukaemia models 
[Rosin and Zajicek, 1961; Calvo and Hoelzer, 1976]. 
Finally, death is due to a combination of several factors. Severely depressed 
normal haemopoiesis which quickly leads to thrombocytopenia (see Ch. 2.6.2) 
causes bleeding at various sites (gastrointestinal tract, respiratory tract, spinal 
cord, etc.). The infiltrated lungs with often superimposed infections also present 
serious problems with respect to cardiovascular function. The heavy infiltration 
of the liver and the kidneys is quite likely to lead to impaired function of these 
organs. In summary, bleeding, infections and impaired organ functions are the 
responsible factors in the death of the animal. 
2.6 Kinetics of leukaemic growth 
Various in vivo assays were performed to quantify the leukaemic growth 
process. These included: 
I) cell titrations; 
2) growth rate of whole organs; 
3) distribution kinetics; 
4) proliferation kinetics. 
2.6.1 Cell titrations 
Dose-survival time 
Rats were inoculated with varying numbers ofBNML cells (103-107) obtained 
from either the blood, the spleen or the bone marrow. Average survival times 
were calculated and dose-survival curves were plotted after linear regression 
analysis by computer. 
From fig. 2.15, it is clear that BNML cells harvested either from the spleen, 
the blood or the bone marrow show an identical dose-survival relationship. 
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Fig. 2.15 Dose-survival time curves for BNA1L cells from different sources. Each point represents 
means (±SE) of 5-11 rats. 
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After extrapolation, one single cell would be expected to cause death after about 
60 days. A total tumour load of 1012 cells would be incompatible with life, as is 
deduced from extrapolation towards the X-axis. This would correspond to 
approximately I kg of tumour tissue, which is apparently unreal. The actual 
tumour cell mass will be dealt with later (Ch. 2.6.5). 
The linear relationship between log cell dose and survival time provides a 
means to determine the number of BNML cells in a given organ. 
Dose-spleen weight 
Graded numbers ofBNML cells (10'-108 ) were inoculated into various groups 
of rats. The animals were sacrificed twenty-five days later. The spleens were 
removed an their fresh weights determined. 
The relationship between the spleen weight and varying doses of BNML 
cells can be characterized as follows (fig. 2.16). For each tenfold increase in the 
number of inoculated cells, the spleen weight increases by a factor of about 2 
(1.7-2.2). However, this holds only for doses up to 107 cells. For doses below 
this, the curve can be used to determine the number of BNML cells in a given 
cell suspension. A higher cell dose ( 108 ) docs not cause a further increase in the 
spleen weight; a plateau has apparently been reached. The implications of 
these findings will be discussed below (Ch. 2.6.5). 
TD50 
The effective dose of BNML cells which kills 50% of the animals (TD50) was 
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Fig. 2.16 Spleen weight at day 25 after inoculation with graded numbers of BNML spleen cells. 
Each point represents means (±SD) of 5 rats. 
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determined by injecting rats with low numbers of cells obtained from terminal 
stage femoral bone marrow (84% leukaemic cells; 17% dead cells) and scoring 
the number of deaths within 150 days after inoculation. All remaining rats 
survived beyond this period. Each cell dose was injected into a group of 6 rats. 
The data were evaluated by means of pro bit analysis. In these experiments, 
siliconized glassware (Siliclad, Clay Adams, Parsippany, USA) was used to 
prevent cells from sticking to the wall of the bottles. 
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Fig. 2.17 Per cent if rats k£lled by low doses of BNJ\!IL bone marrow cells. 
Each point was obtained from 6 rats receiving the same cell dose. 
Borizontal bars represent 95% confidence limits. 
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Fig. 2.18 Survival after injection with low doses of BNlvfL bone marrow cells. 
56 
Each point represents means of 1-6 rats. 
Vertical bars represent 95% confidence limits. 
From fig. 2.17, a TD50 value of 24.7 cells is obtained within 95% confidence 
limits ranging from 9.0 to 48.6 cells. The dose-survival curve was plotted by 
linear regression analysis (fig. 2.18). Although none of the rats which received 
1 BNML cell died, the mean survival time calculated after extrapolation of 
this curve would be 78.3 days if one leukaemogenic cell was inoculated. This 
figure is somewhat larger than the one obtained from the dose-survival study 
using larger inocula (fig. 2.15). All rats that died in the TD50 experiment 
showed the classical BNML picture. 
2.6.2 Growth rate of whole organs 
Peripheral blood 
Rats were inoculated with 107 BNML cells and killed at regular intervals up to 
day 28. The following parameters were determined: total and differential 
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Fig. 2.19 Changes in the number of cells in the peripheral blood after inoculation with 101 BNML 
spleen cells. 
Each point represents means (±SE) of 5-7 rats. 
Day 0: non-leukaemic controls. 
57 
counts of the peripheral blood, number of erythrocytes, reticulocytes, platelets 
and haematocrit values. 
Changes in the absolute number of total leukocytes, leukaemic cells, lym-
phocytes and granulocytes during the development of the leukaemia are 
plotted in fig. 2.19. Granulocytes show a moderate increase from the beginning. 
At the terminal stage, a two to threefold increase in the initial number is noted. 
After an initial drop, the number of lymphocytes again increases to remain at a 
fairly constant normal level. Leukaemic cells are detected only at the end of 
the second week. They show a rapid exponential increase (Td = 16.8 h) up to 
day 21. Thereafter, the curve begins to level off. Besides granulocytes, leukaemic 
cells are mainly responsible for the observed elevated total leukocyte counts 
during the last 2 weeks of the disease. 
Table 2.2 Differential blood cell counts* after inoculation with 107 BNML spleen cells 
days after inoculation 
0 4 8 14 18 
myeloblasts 0.3 1.7 1.7 
promyelocytes 0.7 1.7 
myelocytes 0.3 1.0 1.3 3.3 
metamyelocytes 0.3 2.7 1.3 3.3 
JI neutrophils 0.7 2.3 0.3 8.3 5.3 
PM~ neutrophils 3.3 5.3 9.0 3.0 6.0 
eosinophils 1.0 2.0 4.0 1.3 1.3 
lymphocytes 93.7 89.3 80.3 80.3 70.3 
monocytes 1.0 0.7 1.0 
normoblasts 0.3 0.3 
* Expressed as% of the total number of nucleated cells (see fig. 2.19). 
Each value represents means of 3 rats. 
j1 = juvenile. 
PM2 = polymorphonuclear. 
Day 0 = non~leukaemic controls. 
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2.7 
49.0 
4.3 
2.0 
2.0 
1.7 
0.3 
37.7 
0.3 
28 
1.7 
63.7 
2.7 
2.0 
1.0 
1.3 
24.3 
2.3 
Differential counts for the peripheral blood are presented in more detail in 
table 2.2. The most striking event is the rapid increase in leukaemic pro-
myelocytes from day 14 onwards. Another interesting phenomenon is the 
appearance of immature myelocytic cells such as myeloblasts, myelocytes and 
metamyelocytes. On the other hand, lymphocytes show a relative decrease 
during leukaemia development. Normoblasts appear in the blood during the 
last 2 weeks of the disease. 
Fig. 2.20 shows the changes in the number of erythrocytes and reticulocytes 
and haematocrit values during leukaemia development. Erythrocytes and 
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Fig. 2.20 Changes in the number if er:_vthrocytes and reticulocytes and haematocrit values after inoculation 
with 107 BNML spleen cells. 
Each point represents means (±SE) of6 rats. 
Day 0: non-leukaemic controls. 
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Fig. 2.21 Changes in the number of platelets in the peripheral blood after inoculation with 107 BN ML 
spleen cells. 
Each point represents means (±SE) of 6 rats. 
Day 0: non-leukaemic controls. 
haematocrit values show a decrease towards the later stage of the disease. A 
decrease in the number ofreticulocytes is apparent from day 8 onwards. 
Platelets show a rapid decline beginning at day 8 after inoculation (fig. 
2.21). 
Bone marrow 
Fig. 2.22a shows the changes in total cellularity in the femoral bone marrow 
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Fig. 2.22a Changes in femoral bone marrow cellularity after inoculation with 107 BNML spleen cells. 
Each point represents means (±SE) of3 femurs. 
Day 0: non~leukaemic femurs. 
10 r ............ ,_~·.....,..._. ,,, "",,,,,,, ""· 
I ,.~-9:::-::-:-::~---- 0 
/ I T 
1,' promyelocytes 
11 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
,'Td"'432h 
I 
A 
t----
0 12 16 20 24 28 
time oher inoculation ( doys) 
Fig. 2.22b Changes in the absolute number of leukaemic promyelocytes in the femoral bone marrow after 
inoculation with 107 BNML spleen cells. 
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Each point represents means (±SE) of 3 femurs. 
Day 0: non-leukaemic controls. 
during leukaemia development expressed in terms of viable and nonviable 
nucleated cells. After an initial decrease in total cellularity, a small increase is 
observed around day 14; this is followed by a decrease again during the last 2 
weeks of the disease. The proportion of nonviable cells relative to the total 
number of cells tends to increase as the leukaemia progresses. 
Table 2.3 D!fferential bone marrow cell counts* after inoculation with 107 BNML spleen cells 
days after inoculation 
0 6 12 16 18 23 28 
myeloblasts 2.0 1.0 0.7 0.3 0.1 0.3 0.4 
promyelocytes 2.4 4.8 44.8 84.7 90.1 96.7 98.0 
myelocytes 5.0 4.6 1.6 0.6 0.3 0.1 0.1 
metamyelocytes 9.6 11.3 4.0 1.9 0.7 0.3 0.1 
j1 neutrophils 22.6 21.3 10.5 4.5 5.9 0.6 0.2 
PM~ neutrophils 2.5 2.2 1.1 0.7 0.6 0.3 0.1 
eosinophils 3.6 I 0.1 12.1 1.9 1.4 0.3 0.2 
erythroblasts 4.8 2.6 0.9 0.2 
normoblasts 21.6 17.2 6.4 1.3 0.8 0.3 0.1 
megakaryocytes 1.0 1.0 0.6 
lymphocytes 23.2 22.8 17.4 3.6 1.2 0.5 
monocytes 0.2 0.3 0.3 
plasma cells 1.2 0.4 0.7 0.3 
* Expressed as % of the total number of nucleated cells (see fig. 2.22a). 
Each value represents means of 3 rats. 
J' =juvenile. 
PM' = polymorphonuclear. 
Day 0 = non-leukaemic controls. 
Table 2.3 shows the differential bone marrow cell counts. The most striking 
events can be summarized as follows. Normal haemopoiesis for all cell lines is 
severely depressed during leukaemia development. Lymphocytes, monocytes 
and plasma cells completely disappear. Leukaemic promyelocytes increase 
steadily from day 12 onwards and finally almost completely replace the normal 
bone marrow elements. The absolute numbers of leukaemic promyelocytes 
were calculated from total and differential cell counts. These are plotted in 
fig. 2.22b. Their doubling time between days 6 and 12 is 43.2 h. 
Apart from the morphological analysis, bioassays were performed to quantify 
the number of leukaemic cells in the bone marrow during the early stage after 
tumour inoculation. At 3 h, 24 h, 72 hand 144 h after injection with 107 BNML 
cells, rats were killed and 10' femoral bone marrow cells were injected into new 
recipients. The number of leukaemic cells in these inocula, which cannot be 
quantified on a morphological basis, could be derived by scoring survival times 
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Fig. 2.23 Changes in the number of leukaemic cells in the femoral bone marrow after inoculation with 
107 BNML spleen cells (bio-assa_y). 
Each point represents means (±SE) of 6 rats. 
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Fig. 2.24 Changes in body weight after inoculation with 107 BNML spleen cells. 
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Each point represents means (±SD) of 6 rats. 
Day 0: non-leukaemic controls. 
and comparing these with standard dose-survival curves produced with the 
initial leukaemic cell suspension consisting of more than 90% leukaemic cells. 
From the known initial total number of cells per femur, the absolute number of 
leukaemic cells could be calculated. These are given in fig. 2.23. From the 
curve which was plotted after linear regression analysis, the doubling time 
(T<t) of the leukaemic cell population was derived: T a = 16.8 h. 
Body weight 
From fig. 2.24, it is clear that no significant changes in body weight occur 
during the entire disease period. Therefore, changes in individual organ weights 
can be directly compared without relating them to changing body weights. 
Liver, spleen and thymus 
Changes in the fresh weights of the liver, the spleen and the thymus during 
leukaemia development are presented in fig. 2.25. 
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Fig. 2.25 Changes in the weight of the liver, the spleen and the thymus after inoculation with 107 BNML 
spleen cells. 
Each point represents means (±SD) of6 rats. 
Day 0: non·leukaemic controls. 
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Fig. 2.26 Changes in spleen cellularity after inoculation with 107 BNM L spleen cells. 
Each point represents means (±SE) of 3 spleens. 
Day 0: non-leukaemic spleens. 
After an initial lag period of 14 and 8 days, respectively, both the liver 
(day 14--28) and the spleen (day 8-28) show a phase of exponential growth after 
inoculation with BNML cells. At death, the liver weight is 2 to 3 times normal 
and the spleen weight has increased by a factor of 8. The weight of the thymus 
decreases significantly in the terminal stage. 
Changes in spleen cellularity during the development of the BNML are 
shown in fig. 2.26. A rapid increase in the total number of nucleated spleen 
cells is observed after day 8. From day 18 until death, a plateau is noted. 
Although the absolute number of nonviable cells increases with increasing 
cellularity, the same percentage level is maintained, i.e., about 30% of the total 
number of cells are dead. In table 2.4, splenic cellularity as a function of time 
after leukaemia inoculation is expressed as the number of cells per gram of 
spleen. One gram of splenic tissue contains approximately 10 9 nucleated cells at 
all stages of the disease. 
Table 2.4 Changes in splenic cellularity after inoculation with 107 BNML spleen cells 
days after spleen weight number of number of cells 
inoculation (g) cells ( x 1 0") ( x 1 09 ) per gram spleen 
8 0.555±0.024 0.59±0.04 1.06±0.11 
14 0.942 ± 0.048 0.99±0.13 1.05±0.15 
18 2.212±0.065 2.65±0.18 1.20±0.07 
23 3.012±0.302 3.19±0.44 1.06±0.01 
28 4.160±0.382 3.90±0.26 0.94±0.08 
Values represent means (±SE) of 5 measurements. 
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By means of a bioassay (dose-survival), the absolute number of leukaemic 
cells was determined in the spleen during the first week after leukaemia transfer 
by the same method as described for the femoral bone marrow. From fig. 2.27, 
a doubling time (Td) of 37.2 h was derived. 
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Fig. 2.27 Changes in the number of leukaemic cells in the spleen after inoculation with 107 BNML 
spleen cells (bio-assay). 
Each point represents means ( ± SE) of 6 rats. 
2.6.3 Distribution kinetics 
The distribution of injected leukaemic cells within the organism was performed 
with BNML cells obtained from the blood after in vitro separation and labelling 
with 51Chromium. The reasons for choosing this particular isotope will be 
discussed later (see Ch. 2.6.5). Various functional compartments can be 
quantified by determination of patterns of blood disappearance and organ 
uptake, as will also be described (see Ch. 2.6.5). Moreover, quantitative infor-
mation can be obtained on cell traffic, e.g., transit times and turnover rates in 
the various compartments. 
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Technical aspects of cell separation, labelling and m vzvo follow-up will be 
first described. 
Cell separation 
To obtain leukaemic cells from the blood of terminal stage rats, a two-step 
separation procedure was used. The objective was to remove the erythrocytes, 
which also bind "Chromium. The cells were first allowed to sediment sponta-
neously after mixing with Haemaccel (Behring Pharma, Amsterdam, Holland) 
in a concentration of 1 volume of cell suspension per 2 volumes of Haemaccel. 
The calcium ions present in the Haemaccel solution were neutralized by 
adding 0.5 g EDTAj!OO ml Haemaccel to prevent blood coagulation after 
mixing. Sedimentation was allowed to take place for 15-30 min at roon1 
temperature in centrifuge tubes placed at an angle of 30 oc to the horizontal 
surface. The supernatant which contained the leukocytes was removed and 
Haemaccel was again added to the remaining sediment. After this second 
sedimentation (which was meant to increase the total cell yield), both super-
natants were pooled. With this procedure, the total recovery was between 90 
and I 00% of the original number of cells present. After the cells were washed 
once with 0.9% NaCI (10 min, 700 g), the suspension was carefully layered 
onto a mixture of Ficoll 400 (MW 400,000; Pharmacia Fine Chemicals, 
Uppsala, Sweden) and Isopaque (Nyegaard and Co, Oslo, Norway), with a 
density of 1.077 gfcm3 • One volume of cell suspension containing 0.5-1.5 X 108 
leukocytes per ml plus one volume of Ficoll-Isopaque was then centrifuged 
(20 min, 700 g). The leukocyte layer at the interface was removed and washed 
twice with 0.9% NaCI. The total cell yield after this second separation step was 
between 60 and 70%. The leukocytes, of which 5-15% were scored as dead 
cells, consisted mainly of leukaemic cells (60-80%); however, contamination 
with granulocytes and lymphocytes seemed to be inevitable. Erythrocytes were 
efficiently removed. In the final suspension, they represented about 2-8% of 
the total number of blood cells present. Platelets were virtually absent. 
51Chromium-labelling 
Ten ml of the cell suspension containing 3-10 X 107 cellsfml were placed in a 
water bath at 37'C. 51Chromium (Na2Cr0,; specific activity 50-400 mCifmg 
Cr; The Radiochemical Centre, Amersham, England) was added in a concen-
tration of 40 1-'Ci/108 cells. In no case did the Na,Cr04 concentration exceed 
0.8 1-'gfml. After 45 min incubation with intermittent mixing, 30 mg ascorbic 
acid (Lamers and Idemans, 's-Hertogenbosch, Holland) per 200 fCCi 51Cr was 
added. Ascorbic acid reduces the remaining free hexavalent chromium to the 
trivalent state which is incapable of further cell binding [McMillan and Scott, 
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1968]. The cell suspension was then washed 3 times with 0.9% NaCl (10 min, 
700 g). This resulted in the effective removal of about 98-99% of the excess 
51Cr in the supernatant. A final cell count was made and the cell suspension 
was diluted to an appropriate concentration. The percentage of dead cells at 
the end of the procedure was between 10 and 20%. The total cell yield 
calculated from the initial number before separation was betweeen 50 and 60%. 
Separation and labelling take about 3 hr. 
Determination of cell distribution in vivo. 
Before the suspension was injected, several samples were taken for calculat-
ing the total amount of cell-bound 51Cr to be injected per rat. In a given 
sample, the y-radioactivity emitted by the isotope, expressed as counts per min 
( cpm), was measured in a well-type scintillation counter (Model4227, Nuclear-
Chicago Corp., Des Plaines, Ill., USA). The background radioactivity was 
subtraced from each counted sample. Each rat received a fixed volume of the 
suspension (usually 1 ml injected within 10 sec) either intravenously or intra-
arterially through an exteriorized cannula which was inserted into the abdomi-
nal aorta (see Ch. 4.2). Depending on the type of experiment, arterial blood 
samples (0.2 ml) were then taken at regular time intervals from the canula or 
directly from the abdominal aorta by puncture after general anaesthesia with 
ether. The 51Cr activity of the samples was then determined. To determine the 
organ uptake of labelled leukaemic cells at a given time after injection, rats 
were killed by an ether overdose and the organs were removed and their fresh 
weights determined. The whole organ or a weighed part of it was then mea-
sured and recalculated for 51Cr y-activity. To establish bone marrow uptake, 
the count for one femur was determined after it had been carefully cleaned of 
adherent muscles. 
The total number of 51Cr-labelled leukaemic cells per circulating blood 
volume (1) and per organ (2) as a percentage of the injected radioactivity was 
calculated as follows. 
(1) Blood: 
V"xcpm, Recovery = --···~-- X 100%, 
Vs X cpminL 
where vb is the circulating blood volume (ml), v, is the volume of the blood 
sample (ml) and cpm, and cpminL represent the radioactivity in the blood 
sample and the total amount of injected radioactivity, respectively. 
(2) Organs: 
U k w,xcpm, pta e = =-'---'-~ 
VVs X cpmini. 
X 100%, 
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where Wt stands for total organ weight (mg) and W, for the weight (mg) of the 
organ sample on which the counts ( cpm,) were made. 
Experiments 
a. Kinetics of organ uptake of 51Cr-labelled BNML blood cells during 24 h 
after infusion. 
51Cr-labelled BNML blood cells were injected i.v. into 30 rats at day 23 after 
inoculation with 107 BNML cells. Groups of 3 rats were sacrificed at regular 
intervals (1, 5, 15 and 30 min, 1, 2, 4, 8, 19 and 24 h after infusion) to determine 
the amount of labelled cells present in the circulating blood and in the various 
organs at that particular time. 
Blood disappearance and organ uptake of labelled leukaemic blood cells are 
plotted in figs. 2.28, 2.29 and 2.30. After a rapid initial cell loss from the 
circulating blood, the blood disappearance curve shows 2 main components 
(fig. 2.28). The migration of cells to the spleen, the kidney, the femoral bone 
marrow (fig. 2.29) and the liver (fig. 2.30) is characterized by a rapid uptake 
within the first 2 h. A plateau is reached between 2 and 4 h. From 4 h onwards, 
a very slow decrease in radioactivity is noted in these organs. 
A different picture is seen in the lungs (fig. 2.30). Shortly after infusion, about 
40% of the infused cells are trapped in this organ. This is followed by a rapid 
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Fig. 2.28 Blood disappearance of 51Cr-labelled BNML cells after i.v. infusion into rats at day 23 after 
inoculation with 107 BNML spleen cells. 
Each point represents means (±SE) of 3 rats. 
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Fig. 2.29 Organ uptake of 51 Cr-labelled BNA1L cells after i.v. infusion into rats at day 23 after in-
oculation with 107 B N M L spleen cells. 
Each point represents means ( ~ SE) of 3 rats. 
disappearance characterized by 2 main components: up to 2-4 h, a rather 
rapid release occurs; from 4 h up to the end of the observation period, a plateau 
is established. 
b. Distribution of 51Cr-labelled BNML blood cells infused at various stages 
after leukaemia inoculation. 
Three groups of 5 rats each received labelled BNML blood cells i.a.: group I 
without previous inoculation with leukaemic cells (day 0, controls), and groups 
2 and 3 at the lOth and 28th day (terminal stage) respectively, after 107 BNML 
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Fig. 2.31 Blood disappearance of 51 Cr-labelled BNML cells after i.a. inj1<sion into rats at various 
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cells. An aorta cannula was inserted 5 days earlier. In each experiment, the 
radioactivity in the blood was determined at l, 5, 15 and 30 min and 1, 2, 4, 
10, 19, 21 and 24 h after infusion. Immediately after the last blood sample, the 
rats were killed to establish the organ uptake. 
The blood disappearance curves are plotted in fig. 2.31. Note that the results 
from the previous experiment (day 23) are also inserted. The initial recovery 
from the circulating blood pool (CBP) increases and the recovery at 24 h 
decreases as the leukaemia progresses. The half value times of the first (T' /2) 
and second (T" /2) component of the exponential blood disappearance curve are 
in the same range at days 0, 10, and 23, as computed by linear regression 
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Fig. 2.32 Organ uptake of 5'Cr-labelled BNlVfL blood cells after i.a. infusion into rats at various stages 
after inoculation with 107 BNML spleen cells. 
The uptake was measured at 24 h after infusion of labelled cells. 
Each point represents means (±SE) of 3~5 rats. 
Day 0: non-leukaemic controls. 
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Fig. 2.33 Uptake of 51Cr-labelled BNML blood cells per gram organ qfter i.a. irifusion into rats at 
various stages after inoculation with 107 BNA1L spleen cells. 
The uptake was measured at 24 h after infustion of labelled cells. 
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Fig. 2.34 Relationship between the uptake of 51 Cr-labelled BNML blood cells per gram organ and the 
total organ weight at various stages after inoculation with 101 BNML spleen cells. 
The uptake was measured at 24 h after infusion of labelled cells. 
Each point was derived from the means of 3-5 rats. 
Day 0: non-leukaemic controls. 
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analysis. However, both values have decreased significantly 1n the terminal 
stage (day 28). 
In fig. 2.32, the uptake of cells by various organs at 24 h after infusion 
during the various stages is presented. The liver and the lung take up more cells 
in the terminal stage of the leukaemia, whereas the spleen and particularly the 
femoral bone marrow show a significantly decreasing uptake starting after day 
10. However, as the weights of various organs increase during leukaemia 
growth, it is useful to express the uptake per gram organ. This relationship is 
shown for the spleen and the liver in fig. 2.33. In both organs, the per cent 
uptake of labelled cells per gram decreases as the leukaemia develops. The 
greatest reduction is found in the spleen: from 16.5%/g at day 0 to l.l %/gat 
day 20. As is shown in fig. 2.34, the uptake of cells per gram organ decreases 
exponentially as a function of the organ weight. 
2.6.4 Proliferation kinetics 
Two major approaches for gaining insight into the cellular kinetics of prolifera-
tion will be described: 
a) the tritiated thymidine labelling index at various stages of the disease, 
which gives a rough indication of the growth fraction of leukaemic cells; 
b) the per cent labelled mitoses curve, from which the cell cycle parameters can 
be derived. 
a. Tritiated thymidine labelling index (LI). 
Eighteen BN rats were inoculated with l 07 BNML cells. At days 4, 8, 14, 
18, 23 and 28, a group of 3 rats received l [LCi tritiated thymidine (3H-TdR) 
per gram body weight i.p. (specific activity 2 Cifmmol; The Radiochemical 
Centre, Amersham, England). Three normal rats served as controls. Thirty 
minutes after 3H-TdR injection, the three rats were sacrificed and impression 
slides of the leukaemic spleen were made on coated glass slides (K 2 nuclear 
research emulsion, !!ford, Essex, England) for direct autoradiography. After an 
exposure time of 5 weeks, the preparations were developed according to 
standard procedures [Hermens, 1973] and stained with haematoxylin-eosin. 
The number of labelled leukaemic cells in each preparation was counted and 
divided by the total number of leukaemic cells. A total number of 500 to 600 
cells was counted per slide. In this way, the labelling index (LI) was obtained, 
which is a direct measure of the proportion of leukaemic cells in S phase, i.e., 
which have incorporated 3H-TdR relative to the total number of cells present 
at the time oflabelling, or: 
LI = r:umber of labelled cells 
total number of cells 
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Table 2.5 Tritiated thymidine labelling index { LI) of BNML cells in the spleen 
days after inoculation 4 8 14 18 23 28 
with 107 BNML spleen cells 
fraction of labelled * * 0.42 0.39 0.43 0.30 
BNML cells (LI) 
* LI not measurable. 
Each value represents means of 3 rats. 
The LI of BNML cells in the spleen at various stages of the disease are pre-
sented in table 2.5. Each value represents the average of 3 rats. No values for 
the LI at days 4 and 8 can be given with any certainty because of the low con-
centration ofBNML cells at that time. A rather constant LI is observed between 
days 14 and 23. A significantly lower value is obtained at day 28. 
b. Per cent labelled mitoses (PLM) curve. 
At the 18th day after inoculation with 107 BNML cells, 44 rats received 
I [LCi 3H-TdR per gram body weight i.p. (specific activity 2 Cijmmol; Tbe 
Radiochemical Centre, Amersham, England). Every hour thereafter, up to 
44 h, one rat was sacrificed, with the exception of the first animal, which was 
sacrificed 0.5 h after injection with 'H-TdR. Unfortunately, no rat was killed 
at 24 h. Impression slides of the leukaemic spleen were made on coated glass 
slides and processed for direct autoradiography as described above (a). The 
preparations were screened for labelled and unlabelled mitoses, i.e., cells in the 
metaphase or early anaphase. Up to a total of 100 mitoses were counted per 
slide. Cells containing more than 4 grains were considered to be labelled. The 
per cent labelled mitoses was calculated as follows: 
PLM = Ntab.~lledmi~.?ses ______________ X lOOO/o 
N labelled+ unlabelled mitoses 
Except for the impression slides of the spleen, the other internal organs were 
fixed in Bouin. No further autoradiographic analysis of these specimens could 
be performed due to the lack of facilities. Besides, it appeared to be very 
difficult to label leukaemic cells in the bone marrow, because of the very poor 
isotope uptake in that tissue. 
Fig. 2.35 shows the PLM values plotted against the time after 3H-TdR 
injection. Two peaks can be clearly distinguished: the first appears between 
t = 5 h and t = 8 h; the second, without a clear cut plateau, is observed at 
t = 20 h. From the graph, the cell cycle parameters can easily be derived 
[Howard and Pelc, 1951; 1953]. They are summarized in table 2.6. Grain count 
analysis showed that, at t = 20 h, labelled mitoses contained approximately 
40% fewer grains than at t = 5 h. 
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Fig. 2.35 Per cent labelled mitoses (PLM) curve for BNML cells in the spleen at day 18 after inM 
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Table 2.6 Cell kinetic parameters of the BN acute myelocytic leukaemia at the 18th dqy after inoculation 
with 107 BNML spleen cells 
G1 duration 
S duration (Ts) 
G 2 +-! M duration 
cycle time (Tc) 
hours 
0.8 
10.0 
3.2 
14.0 
+ 
The data were derived from a percent labelled mitoses curve prepared from impression slides 
of the spleen (see fig. 2.35). 
2.6.5 Discussion 
The BNML may be regarded as one of the most realistic animal models 
presently available for human acute (pro)myelocytic leukaemia. In summary, 
this statement is based on the following facts: 
1. there is cytological and cytochemical evidence for the promyelocytic nature 
of the disease (see Ch. 2.4); 
2. in contrast with many other animal leukaemia models, the BNML has a 
rather slow growth pattern showing central and peripheral spread com-
parable with the human disease; and 
3. normal haemopoiesis gradually disappears during the development of the 
leukaemia, which also holds for human AML. 
The third argument deserves some more attention at this point. 
An impression of the state of normal haemopoiesis can be obtained by 
determining the number of erythrocytes, leukocytes and platelets in the 
peripheral blood. However, research during the past few years has provided 
means to study the blood cell precursor compartment in the haemopoietic 
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organs. Pluripotent haemopoietic stem cells (HSC) can be assayed by their 
capacity to form colonies in the spleen (CFUs) after injection into lethally 
irradiated animals. This spleen colony assay can be applied to mice [Till and 
McCulloch, 1961] and rats [Comas and Byrd, 1967]. In vitro tissue culture 
techniques have provided another possibility to study the precursor com-
partment (CFUc). With these methods, which are also applicable to man, 
myeloid precursor cells or perhaps even HSC can be assayed [van Bekkum and 
Dicke, 1972; Robinson, 1974]. 
In the BNML model, the in vitro colony formation of bone marrow cells was 
studied during leukaemia growth [fig. 2.36; van Bekkum eta!., 1976a]. As the 
BNML cells are unable to form colonies, the observed in vitro growth is derived 
from normal primitive precursor cells (CFUc). Fig. 2.36 shows a decline in the 
number of colonies starting at day 6-8 after inoculation, i.e., from the time of 
the first microscopic appearance of leukaemic cells (see Ch. 2.5.1, table 2.3). 
Hardly any colonies could be detected in the last 14 days of the disease. 
Based on the fact that BNML cells have a much slower growth rate in vivo as 
compared with normal HSC, in vivo CFUs assays could be developed to 
selectively score normal HSC. Spleen colony assays from the femoral bone 
marrow showed a similar disappearance pattern for HSC (CFUs) during 
leukaemia development [fig. 2.37; Colly and Hagenbeek, 1976]. After day 16, 
less than I% of the original number of CFUs were recovered. This absolute 
numerical decrease in HSC in the bone marrow was further supported by 
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Fig. 2.36 Characteristic pattern of in vitro colony formation by bone marrow cells during progression 
of the B N leukaemia. 
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• thin agar layer culture (TALS); 6 Robinson culture system. Assays were 
performed on pooled total bone marrow from 2 rats, 2-3 culture plates per point. 
Vertical bars indicate SE. 1: death of leukaemic rats (van Bekkum et al., 1976a). 
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Fig. 2.37 Changes in the number of colony forming units spleen (CFUs) in the bone marrow, the blood 
and the spleen r:h..ring progression of the BN leukaemia. 
Each point represents means (±SE) of 2-3 experiments with 8-IO recipient mice 
per spleen colony assay. 
Day 0: non-leukaemic controls (Colly and Hagenbeek, 1976). 
electron microscopical preparations of bone marrow fractions which contained 
the highest concentrations ofHSC (density gradient centrifugation technique). 
Stem cell counts based on morphological identification were considerably 
lower in these fractions than those of normal marrow fractions, i.e., less than 
1-10% of the normal number ofHSC could be recovered [van Bekkum et al., 
l976b]. However, at the time of the sudden decrease in HSC in the bone 
marrow, a dramatic increase is observed in the blood and in the spleen (fig. 
2.37). 
The explanation might be that normal HSC are forced to emigrate from the 
bone marrow to the blood as the marrow is being replaced by leukaemic cells. 
They subsequently lodge at sites suitable for further proliferation, i.e., the 
spleen and also the liver which histologically actually show signs of extra-
medullary haemopoiesis during the second half of the disease (see Ch. 2.5). In 
table 2.7, the absolute number of normal haemopoietic stem cells (CFUs) 
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Table 2.7 Quantitation of the total number of normal haemopoietic slet,t cc;lls (CFUs) in the bone 
marrow, the blood and the spleen in normal and leukaemic rats 
day 0 
bone marrow 
blood 
spleen 
day 23 
bone marrow 
blood 
spleen 
total number 
of cells 
(X 10') 
1000 
13 
60 
500 
38 
400 
CFUsflO' 
750 
13 
8 
5.5 
1000 
300 
total number 
of CFUs/organ 
(X 10') 
187,500 
42 
120 
+ 
187,662 
688 
9,500 
30,000 
--- + 
40,188 
Day 0: non-leukaemic controls; day 23: after inoculation with 107 BNML cells. CFUs: 
colony forming unit spleen. The total bone marrow cellularity was derived from data on 
1 femur (see fig. 2.22a), representing 1.2% of the total bone marrow. The total number of 
leukocytes in the blood was obtained by multiplying the number ofleukocytesjml (see fig. 2.19) 
with the total blood volume (12.5 ml). Splenic cellularity was derived from spleen weight 
(see fig. 2.25), i.e. l g= 109 cells (see table 2.4). CFUs/10 7 : see fig. 2.37. To calculate the 
absolute number of CFUs per organ a measured f-factor of 0.004 was used (Colly and Hagen-
beek, 1976). 
present in the various organs is roughly quantified. There is apparently a 
redistribution of stem cells. However, at day 23 after inoculation, their total 
number has decreased to 21% of the original value at day 0. This is due to the 
excessive absolute numerical decrease in CFUs in the bone marrow. In this 
tissue, only 0.4% of the initial stem cell pool is left at day 23. Normal haemo-
poiesis is almost completely replaced by the leukaemic cell population. 
However, because no measurements were performed on other organs where 
extramedullary haemopoiesis takes place (such as e.g. the liver), the total 
number of stem cells at day 23 might be significantly greater than the one given 
in table 2. 7. This would certainly reduce the difference between days 0 and 23 
to some extent. Despite the remaining population of normal stem cells, normal 
haemopoiesis still becomes defective (figs. 2.20 and 2.21). Theoretically, this 
might be due to: 
a. direct cell to cell interaction between leukaemic cells and normal cells. 
However, mixed in vitro culture studies of leukaemic and normal bone 
marrow cells did not reveal a depression of normal colony formation [van 
Bekkum et al., 1976a]; 
b. humoral factors produced by leukaemic cells which would inhibit prolifera-
tion of normal HSC. The observation that colony formation by normal 
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bone marrow in diffusion chambers implanted into leukaemic hosts was 
not affected did not support this hypothesis [van Bekkum et a!., 1976a J; 
c. normal precursor- c.q. stem cells being transformed into leukaemic cells; 
whether or not this plays a significant role is not clear at the moment; 
d. altered kinetics of proliferation of HSC at extramedullary sites, e.g., a 
decreased growth fraction, a prolonged cell cycle time andjor an increased 
cell loss rate possibly because of a suboptimal microenvironment. 
In summary, the BNML is characterized by decreasing normal haemopoiesis 
as the leukaemia progresses. The major mechanism responsible for this could be 
a forced disappearance of normal blood cell precursors from the bone marrow 
because of the piling up of leukaemic cells. Although extramedullary haemo-
poiesis temporarily takes over part of the bone marrow production, it finally 
falls short in meeting the demands. This pattern is very similar to the one which 
has been described for many cases of human AML [van Bekkum and Dicke, 
1972; Moore, 1974; van Bekkum eta!., 1976a]. Other authors studying trans-
plantable animal leukaemias have also described decreasing normal haemo-
poiesis in the bone marrow, although not to the zero level, during leukaemia 
development fL5222 myelomonocytic leukaemia in the BD IX rat, Hoelzer 
eta!., 1973b and c; 1974d; RF mouse myelomonocytic leukaemia, Tanaka et 
a!., 1973]. 
As regards bone marrow cellularity, the total number of cells shows a slow 
and slight decrease during leukaemia development with an increased propor-
tion of nonviable cells at the terminal stage (fig. 2.22a). 
The rapidly decreasing numbers ofHSC in the bone marrow between days 8 
and 14 (fig. 2.37) is followed by a decline in the number of normal erythro-
poietic and myelopoietic cells and megakaryocytes in that organ (table 2.3). 
Erythroblasts and normoblasts show a significant decline from day 6 onwards. 
The bone marrow transit time for erythropoietic cells of 2 days fits in with 
these observations [Bond eta!., 1965]; i.e., ifhaemopoiesis at the stem cell level 
significantly decreases, this will be rapidly followed by a numerical decrease in 
committed precursor cells, proliferating, differentiating and mature cells. After 
day 16, erythropoietic cells have almost completely disappeared from the bone 
marrow. Normoblasts are observed in the blood from day 14 until death 
(table 2.2). This indicates that their disappearance from the bone marrow is 
probably caused by a combination of defective production and apparent 
spontaneous or forced release. In the peripheral blood, the first sign of defective 
erythropoiesis is the decreasing number of reticulocytes (fig. 2.20). However, 
they do not reach the zero level; some normal extramedullary erythropoiesis is 
preserved. Erythrocytes (and haematocrit values) remain at a fairly constant 
level up to day 23 (fig. 2.20). Thereafter, a rapid decline to 65% of the original 
number is noted within a period of 5 days. This decrease cannot be solely 
explained by diminished production. With an erythrocyte life span of about 
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50 days [Belcher and Harriss, 1959], a complete cessation of erythropoiesis 
would result in a fall in red cell count of only 2% per day. Thus, other factors 
must be taken into account. A decreased life span of erythrocytes due to the 
leukaemic state (intrinsic defects, haemolysis) has been ruled out by 51Chro-
mium-labelling studies. The blood disappearance curves of labelled red cells 
from leukaemic donors infused into normal or leukaemic rats were identical 
with those of erythrocytes obtained from normal rats. Therefore, besides 
defective production, loss of erythrocytes by bleeding, which is a prominent 
feature in the terminal stage, seems to be the major factor responsible for the 
developing anaemia. 
Decreasing thrombopoiesis is also an early sign of defective haemopoiesis. 
Normally, 40 per cent of the rat platelets are lost and replaced per day [Ebbe 
and Stahlman, 1965]. This means that a change in marrow megakaryocytes is 
quickly reflected in the platelet count in the blood, since the bone marrow 
transit time for megakaryocytopoiesis in the rat is only 2-3 days [Ebbe et al., 
1966]. Indeed, megakaryocytes are no longer observed in the bone marrow 
after day 12 (table 2.3). Between days 12 and 18, the number of platelets in the 
blood is rapidly decreasing (fig. 2.21). However, this decrease is not as rapid as 
would be expected from a complete cessation of thrombopoiesis. Therefore, it 
can be concluded that extramedullary production of platelets in the spleen 
and the liver (see Ch. 2.5) will partly compensate for the lack of thrombo-
poiesis in the bone marrow during this period. From day 23 until death, extra-
medullary production fails completely; the platelet count in the blood then 
drops by approximately 30-40% per day. The severe thrombocytopenia 
together with the probably decreased production of clotting factors by the 
heavily infiltrated liver may well explain the haemorrhagic diathesis which is 
observed in the terminal stage of the leukaemia. In addition, Hilgard (1977) 
found signs of disseminated intravascular coagulation and thrombotic micro-
angiopathy in the terminal stage of the disease. Both phenomena are well-
known to occur in human acute promyelocytic leukaemia [Nagai et al., 1973; 
Gralnick and Sultan, 1975; Sakuragawa et al., 1976]. 
In the bone marrow, lymphocytes, monocytes and plasma cells decrease 
gradually during leukaemia development (table 2.3). This may be due to a 
decreased production and an increased release. Evidence for an increased 
release of lymphocytes is obtained from fig. 2.19, where an elevated blood 
lymphocyte count is observed after day 8. It may be noted that, in the terminal 
stage, the thymus, which is one of the major lymphatic organs, regresses. 
Despite the diffuse infiltration with leukaemic cells (see Ch. 2.5.2), the thymus 
shows a significant reduction in weight (fig. 2.25), which is due to the excessive 
atrophy of the thymic cortex (see Ch. 2.5.2). 
Similar to normal erythropoiesis, granulopoiesis in the bone marrow shows a 
significant decline starting after day 6 (table 2.3). There is a marked reduction 
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in the number of all white cell precursors. Apart from diminished production, 
increased release to the blood will be responsible for this phenomenon (see fig. 
2.19). After day 8, the number of granulocytes in the blood starts to increase to 
end up in a two to threefold increased number. In the late stage of the disease 
when myelopoiesis in the bone marrow is virtually absent, the elevated number 
of peripheral granulocytes will be due to increased production in extramedulla-
ry sites, since their blood transit time is rather short (6.1-11.4 h; see table 2.11). 
It might be that the remaining normal haemopoietic stem cells preferentially 
produce cells of the myelocytic series. In addition, immature myelocytic 
elements such as myeloblasts, myelocytes and metamyelocytes are also ap-
pearing in the blood (table 2.2). In theory, these cells might also be differen-
tiated leukaemic cells. This, however, remains to be established. 
In the bone marrow, eosinophils show an increase between the time of 
inoculation and day 12 (table 2.3), which is also reflected in the blood (table 
2.2). Although an explanation is lacking, it is well-known that a transitory 
episode of eosinophilia can occur during the course of human or animal 
leukaemia or lymphoma [Hayhoe, 1960; Spry, 1972; Rizzo eta!., 1976]. 
Leukaemic promyelocytes rapidly increase in the bone marrow and in the 
blood after days 6 and 14, respectively (tables 2.2 and 2.3; figs. 2.22b and 2.19). 
After day 18, the number of promyelocytes in the bone marrow does not 
change (fig. 2.22b). At the same time, they rapidly increase in the blood 
(Td = 16.8 h; fig. 2.19). This indicates that a significant proportion of newly 
produced leukaemic promyelocytes in the bone marrow is released to the blood. 
In addition, proliferation of blood promyelocytes might also contibute to the 
small doubling time. Cell kinetic considerations will be discussed in more detail 
later. 
From fig. 2.15 it is clear that leukaemic cells taken either from the spleen, the 
blood or the bone marrow in the terminal stage of the disease produce similar 
dose-survival curves, i.e., there is no functional difference between the cells 
from the different sources. The concentration of clonogenic leukaemic cells in 
the various cell populations will therefore be the same. In most of the experi-
ments, the easily available spleen was used for leukaemia transfer. When the 
inoculated cell dose is increased by a factor 10, i.e. 3 cell doublings, the survival 
time is reduced by approximately 5 days. From these data, the average Tc 
value can be derived as being 40 h, assuming that all cells are in cycle (growth 
fraction = I) and that there is no cell loss during proliferation. This value, 
however, is much higher than the one calculated from the PLM curve (Tc = 
14 h; see Ch. 2.6.4). The discrepancy will be explained later. 
Besides the dose-survival curves, the dose-spleen weight curve (fig. 2.16) 
might also serve as a means to determine the number ofleukaemic cells present 
in a given suspension, provided that this does not exceed l 07 cells. When doses 
between 107 and 108 leukaemic cells are inoculated, no further significant 
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increase in spleen weight at day 25 is observed. Apparently, an equilibrium has 
heen reached where cell production is keeping pace with cell loss. A similar 
plateau phenomenon can be expected for the dose-survival curves (fig. 2.15): 
simple linear extrapolation towards the X-axis leads to a tumour load of !012 
cells which would he incompatible with life. However, the actual tumour load 
is much lower, as will be discussed in the context of the 51 Cr-studies. 
51Chromium has been widely used as a radioactive label in haematology 
since 1950. In contrast to other cell labels (e.g., 3H-TdR), 51Cr labels cells 
irrespective of their proliferative status. Furthermore, the isotope decays by 
both electron capture and gamma emission with 9% of its disintegrations in the 
form of320 KeV gamma rays; the physical halflife is 27.8 days. It can be used 
for hath external scanning and autoradiography [Ronai, 1969], which is not 
possible with the other label that is frequently used for studies on distribution 
kinetics, 32P-diisopropylfluorophosphate (DF32P). The 51Cr method has 
provided useful information on the lifespan and organ distribution of erythro-
cytes and platelets [Ebaugh et al., 1953; Aster and Jandl, 1964]. In addition, 
leukokinetic studies have been reported on normal granulocytes [Dresch eta!., 
1975] and lymphocytes [Torelli eta!., 1971; Scott et al., 1972] and in patients 
with acute lymphocytic leukaemia [McCall et al., 1955], acute myelocytic 
leukaemia [Boranic et a!., 1974; Rosen et a!., 1975], chronic myelocytic 
leukaemia [Duvall and Perry, 1968; Scott eta!., 1971] and chronic lymphocytic 
leukaemia [Pfisterer et al., 1967; Coco and Merritt, 1970; Spivak and Perry, 
1970; Scott eta!., 1973; Neumann eta!., 1974]. 
With our labelling procedure, autoradiography showed that more than 90% 
of the leukaemic cells were labelled. This procedure (incubation for 45 min at 
37 'C) seems to be optimal according to various authors [.\.1cCall et a!., 1955; 
McMillan and Scott, 1968]. Intracellular Cr, probably bound to cytoplasmic 
proteins [Scaife and Vittorio, 1964], is known to be reduced from a hexavalent 
to a trivalent state. The trivalent state cannot be reutilized by cells [Raj am and 
Jackson, 1958; Bunting eta!., 1963]. Moreover, no significant elution of 51Cr 
from leukocytes could be demonstrated by various authors during the first 24 h 
after labelling [McCall et al., 1955; Dresch and Najean, 1967; Duvall and 
Perry, 1968; McMillan and Scott, 1968; Lilien et a!., 1970]. Just as described 
by Hersey ( 1971), the 51Cr excretion in 24 hr collections of urine was found to 
be very low in BNML rats, i.e., between 1.5 and 3% of the injected 51 Cr per 
day. The "Cr dose used in our studies (40 [LCi/108 cells) is known to be in the 
optimal range for cell labelling [Rajam et al., 1958; Mc.\.1illan and Scott, 
1968]. 
The Na2Cr04 concentration never exceeded 0.8 [Lg/ml. This concentration is 
far below the cytotoxic dose. Various authors have reported on unimpaired 
leukocyte viability and function after labelling [McMillan and Scott, 1968; 
Spivak and Perry, 1970; Hersey 197!] as well as unaffected tumour growth 
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after injection of labelled tumour cells with concentrations below 2.5-10 [Lg/ml 
[Rajam et al., 1958; Vincent, 1962; Fisher and Fisher, 1967]. Our findings 
with the BNML are in accordance with this. Neither an increased number of 
dead cells nor a significant prolongation of the survival time was observed after 
separation, labelling and injection of BNML cells as compared with non-
treated cells. 
In summary, 51 Cr seems to be suitable as a tracer isotope for leukaemic cells 
in vivo because of its firm intracellular binding with no remarkable short-term 
elution, its low toxicity and the technical feasibility of performing external 
scanning. The major limitation is its lack oflabelling specificity. 51Cr binds to 
erythrocytes, platelets, normal leukocytes and leukaemic cells. Therefore, 
careful separation techniques are required before cell labelling is applied. 
However, autoradiographic studies showed that the affinity of 51Cr differs from 
one cell type to the other [Eyre et al., 1970]. AML cells showed by far the 
highest labelling intensity, whereas the small lymphocytes label with an 
affinity twice that of polymorphonuclear leukocytes, 15-30 times that of the 
erythrocyte and 70-100 times that of the platelet. Based on these findings and 
on the fact that we are using cell preparations containing up to 80o/0 leukaemic 
cells (see Ch. 2.6.3), it can be roughly calculated that the 51Cr radioactivity 
caused by the contamination with labelled nonleukaemic blood cells was less 
than 5% in our studies and was therefore neglected. 
The interpretation of the blood disappearance curves is schematically presented 
in fig. 2.38. The theoretical curve represents the average picture obtained in 
many experiments (see fig. 2.28 and 2.31). Essentially, 3 main components are 
recognized. Only 20% of the infused labelled cells are recovered from the 
circulating blood pool ( CBP) directly after infusion. This means that the cells 
are distributed in a pool which is - in this case - 5 times larger than the CBP. 
As has been described for normal granulocytes [Athens et al., 1961; Meuret et 
al., 1973; Dresch et al., 1975], where it was shown that this effect is not due to 
the rapid removal of damaged cells, this pool is referred to as the total blood 
pool (TBP) of leukaemic cells. It consists of the circulating blood pool (CBP) 
and the noncirculating or marginal pool ( MP). By microscopic examination, 
the marginal position of white blood cells along the walls of venules was 
demonstrated long ago [Vejlens, 1938]. It might be assumed that the infused 
leukaemic cells also exchange with a marginal pool. The same events have been 
described after reinfusion oflabelled cells in human AML [Hoelzer et al., 1972; 
Rosen et al., 1975] and in another rat myelocytic leukaemia [Sadler and 
Alexander, 1976]. This temporary margination is substantiated by the finding 
that the radioactivity in the lungs is rather high during the first few hours after 
infusion oflabelled cells (fig. 2.30). Thereafter, a rapid decline to low values is 
observed. Again, the same phenomena have been described for human AML 
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Fig. 2.38 Schematic representation of cell compartments in acute myelocytic leukaemia. 
and two other rat models for AML [Hoelzer et a!., 1973a; Sadler and Alexan-
der, 1976]. Apparently, initial trapping with subsequent release of cells occurs in 
the lungs. 
With the isotope dilution method, the total blood pool (TBP) of leukaemic 
cells can be quantified as follows: 
TBP=---··· % 51Cr-cells in CBP shortly after infusion 
CBP 
X 100 (I) 
The circulating blood pool (CBP) is calculated with the formula: 
CBP = N xVb (2), 
where N is the number of leukaemic cells per ml of blood and V b is the total 
blood volume (ml). The "% 51Cr cells in CBP" stands for the per cent of 
injected labelled cells recovered in the CBP from the total number of injected 
labelled cells shortly (i.e. 30 sec- I min) after infusion. 
The marginal pool (MP) is easily derived from: 
MP = TBP-CBP (3). 
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After the extremely rapid equilibration of cells in the TBP, leukaemic cells 
disappear from this compartment according to a multiexponential function 
(see fig. 2.38). Two main components can be distinguished. A rapid decrease 
characterized by a low value for the half-disappearance time (T' /2) is noted 
over the first 10 h after reinfusion. Thereafter, a second slower component with 
a prolonged T /2 (T' /2) is observed. 
The interpretation of the pattern of blood disappearance deserves some more 
consideration. In the experiments, leukaemic blood cells of various ages are 
labelled. If the disappearance of these cells from the blood compartment would 
only be a function of senescence, a linear decrease in radioactivity would be 
expected. However, as has been demonstrated, a multiexponential decrease is 
observed. It is therefore assumed that the cells are subject to random removal in 
addition to senescence. Another factor which might determine the pattern of 
blood disappearance could be the rapid removal of some cells damaged by the 
labelling procedure. However, as described earlier, the labelled cell suspension 
is as viable as its control, so that cell damage can be ruled out as an essential 
determinant of the blood disappearance curve. Early elution of 51Chromium 
from labelled cells with subsequent urinary excretion of the isotope could also 
contribute to a rapid decrease in blood radioactivity. As mentioned earlier, 
many authors found no significant elution during the first 24 h after labelling. 
In our experience, a low daily urinary excretion argues against significant cell 
death and 51Cr elution. Finally, studies in human AML using 3H-Cytidine 
labelled leukaemic cells have yielded similar blood disappearance curves 
[Hoelzer et a!., 1972]. This indicates that no significant artifacts were 
introduced inherent to the particular isotope involved in our studies with 
51Cr. 
The multiexponential blood disappearance curve most probably represents 
the exchange of cells between intravascular and extravascular compartments, 
i.e., multiple compartments are available for equilibration. The first rapid 
component reflects the equilibrium established between the total blood pool 
(TBP) and the extravascular - so called - rapidly exchangeable tissue pool 
(RETP). This takes about I 0 h. During this time, the various organs studied, 
such as the spleen, the liver and the femoral bone marrow, show an increase in 
radioactivity (figs. 2.29 and 2.30). The RETP should be regarded so far as a 
functional compartment without any definite anatomical localization. It may 
be assumed that this tissue pool is situated close to blood vessels. 
The size of the total rapidly exchangeable pool (TREP), i.e., the total pool 
of dilution, in which leukaemic cells are distributed within the first I 0 h after 
infusion and which comprises the CBP, the MP and the RETP, is calculated by 
extrapolating the second slow component of the disappearance curve towards 
the ordinate. From the point of intersection, i.e., the per cent of 51Cr cells in the 
CBP at equilibrium, the TREP is calculated as follows: 
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CBP TREP ~ --- x 100 % 51Cr-cells in CBP at equilibrium (4). 
From the TREP, the rapidly exchangeable tissue pool(RETP) can be derived: 
RETP ~ TREP-(CBP+MP) (5). 
With respect to the organ uptake of 51Cr-labelled cells, a rough calculation of 
the size of the MP and the RETP of an individual organ (MP0 ; RETP0) can 
be made based on the per cent of injected 51Cr-labelled cells present in the organ 
just after infusion (MP0) and at equilibrium (RETP0). The per cent at equili-
brium is obtained from extrapolation of the slow component of the organ 
uptake curve; thus: 
CBP % organ uptake of 
MP 0 ~ % "Cr-cells in CBP after inf,;;;on X "Cr-cells after infusion l6) 
and: 
CBP RETP0 ~ --- - .. % 51Cr-cells in CBP at equilibrium 
% organ uptake of 
X 51Cr-cells at equilibrium (l). 
It should be noted that the radioactivity of an organ sample is built up by 
labelled leukaemic cells in the circulating blood volume of such an organ, its 
marginal pool and the extravascularly localized cells. The first two items have 
been generally neglected, because they do not significantly change the picture. 
By subtracting the MP 0 and the RETP 0 from the total tumour cell load of a 
given organ, which can be approximated by its weight (109 cells per gram; 
table 2.4) corrected for the remaining normal tissue, the more sessile tissue 
compartment, i.e., the slowly exchangeable tissue pool (SETP 0), can be 
roughly quantified. 
The T" /2 of the second slow component of the blood disappearance curve 
indicates the duration of the blood transit time (BTT) of leukaemic cells. This 
applies only to the slowly disappearing cells. The BTT(h) is calculated as 
follows: 
BTT ~ T"/2 h 
log, 2 
(8). 
From the T" /2 and subsequent BTT values, an estimate can also be made of the 
turnover rate of leukaemic cells within the total rapidly exchangeable pool 
(TREP), i.e., 
TREP cellsjk~jh turnover rate = ..., 
BWxBTT a 
(9), 
where BW stands for body weight (kg). 
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All of the above-mentioned calculations are based on the assumption that, 
within the total rapidly exchangeable pool (TREP), leukaemic cells are 
continuously exchanging between the intra- and extravascular subcompart-
ments as well as with the more sessile tissue compartments (SETP). Functional 
evidence for this comes from the following finding. During the development of 
the leukaemia, a second wave of invasion occurs in various organs (see Ch. 2.5). 
Apparently, this is caused by leukaemic cells which, after entering the in-
travascular compartment, lodge in other extravascular organ sites and 
multiply there. Within the relatively short observation period in our experi-
ments, it can be safely assumed that there is a steady state condition with a 
constant inflow of leukaemic cells and an equal constant outflow from the 
measured compartment (TREP). 
In order to gain insight into the kinetics of blood disappearance and organ 
uptake of 51Cr-labelled leukaemic blood cells, these parameters were measured 
during 24 h after infusion on day 23 (figs. 2.28, 2.29 and 2.30). Shortly after 
infusion, the various organs, in particular the lungs, already contain a significant 
amount of radioactivity. This probably reflects the marginal pool (MP) as a 
subcompartment of the total blood pool in the organs. The initial per cent 
recovery from the CBP is 30% (fig. 2.28). The rapid initial decrease from the 
CBP (from 100 to 30 is 70%) is for the greater part recovered from the total 
initial organ uptake (±60%). It must be assumed that the rest of the radio-
activity ( ± 1 0%) will be present in organs such as the lymph nodes, the 
intestines, etc. which were not measured. Hereafter, the organs show an 
uptake pattern according to a multiexponential function with 2 main com-
ponents, i.e., a rapid component during the first 2-4 h followed by a slower one 
which ends up in a plateau. As stated earlier, the multiexponential blood 
disappearance pattern is regarded as representing exchange of cells between 
various compartments. In this experiment, an equilibrium is established be-
tween the TBP and the RETP in the various organs within 10 h after infusion. 
However, the organ uptake plateau is already reached at 2-4 h after infusion. 
This discrepancy between the organ uptake curve and the blood disappearance 
curve can be explained in the following way. The first component of the blood 
disappearance curve is the resultant of: (1) outflow of cells from the blood to 
the MP and the RETP; and (2) outflow of cells from the MP of the lungs 
where 40% of the infused cells are initially trapped (fig. 2.30), to the blood. 
This apparently results in a slower net blood disappearance as opposed to the 
rapid organ uptake oflabelled cells from the blood via the MP into the RETP. 
From this study, it can be concluded that, within a few hours after infusion, an 
equilibrium between the TBP and the total RETP has already been established. 
Thereafter, cells will either enter the more sessile tissue compartments (SETP) 
or will exchange with the blood compartment again. It is suggested that the 
number of leukaemic cells leaving an organ per unit time roughly equals the 
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number entering that same organ, because the radioactivity in the organs 
studied does not change significantly between 8 and 24 h after infusion. 
According to the formulas presented in this chapter, the following data 
were calculated: 
Leukaemic cells X I 07 
CBP 
MP 
21.5 
48.8 
-------------------- + 
TBP - 70.3 
RETP = 427.4 
--------+ 
TREP = 497.7 
circulating blood pool 
marginal pool 
total blood pool 
rapidly exchangeable tissue pool 
total rapidly exchangeable pool 
Per cent Cr-labelled cells in CBP (see fig. 2.28) 
shortly after infusion: 30.58 
- at equilibrium 4.32 
Blood transit time (BTT) 
turnover rate (TOR) 
36.0 h 
48.4 X 107 cellsjkg/h 
1160.9 X I 07 cells/kg/day. 
In a rat weighing 250 g, this means that only 2.4% of the TREP is renewed 
each hour. 
Approximations of the marginal pools and the rapidly exchangeable tissue 
pools of the organs studied are presented in table 2.8. From this table, it is clear 
Table 2.8 Quantification of organ compartments at day 23 after inoculation with 107 BNML spleen cells 
%uptake of %uptake of 
51Cr cells MP HCr cells 
after infusion X 107 at equilibrium 
liver 12.59 8.9 42.97 
spleen 0.36 0.3 7.19 
total bone marrow* 2.50 1.8 12.50 
lungs 43.29 30.4 1.91 
+ 
41.4 
calculated from blood 48.8 
disappearance (table 2.9) 
difference 7.4 
* 1 femur R> 1.2% of the total bone marrow. 
MP = marginal pool; RETP = rapidly exchangeable tissue pool. 
For further explanation: see text. 
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RETP 
X 107 
214 
36 
67 
10 
+ 
327 
that the lungs possess the largest marginal pool of all organs studied, whereas 
the largest rapidly exchangeable tissue pools are found in the liver and in the 
bone marrow. The difference of 7.4 X 107 cells between the measured and 
calculated total MP will be due to MP present in organs which have not been 
studied. 
In the next experiment, the blood disappearance and organ uptake of 51Cr-
labelled leukaemic cells were determined at various stages of the leukaemia 
(figs. 2.31 and 2.32). In tables 2.9-2.14, the various pool sizes calculated on the 
basis of either blood disappearance curves or the measured organ uptake are 
presented. The data from the previous experiment at day 23 after inoculation 
are also included. At days 0 and I 0, no pool sizes can be calculated because of 
the virtual absence of leukaemic cells in the blood. Between days 23 and the 
terminal stage (day 28; table 2.9), the TREP does not change significantly. 
However, a shift occurs in the distribution of leukaemic cells over the various 
subcompartments within the TREP. At the terminal stage, the MP equals the 
CBP, whereas the rapidly exchangeable tissue pool (RETP) has increased 
relative to the total blood pool (TBP). Apparently, there is a tendency of 
leukaemic cells to pile up in the organ compartments. However, the turnover 
rate (TOR) within the total rapidly exchangeable pool (TREP) has increased 
Table 2.9 Quantification of functional compartments at two stages of leukaemia development 
days after inoculation with 107 BNML cells 
leukaemic cells X 107 0 10 23 28 
CBP 21.5 27.0 
MP 48.8 29.2 
+ + + 
TBP 70.3 56.2 
RETP 427.4 472.2 
T + + 
TREP 497.7 528.4 
MP 
2.3 !.1 CBP 
RETP 6.1 8.4 TBP 
% 51Cr cells 
- after infusion 24.2 29.8 30.6 48.1 
- at equilibrium 7.9 8.5 4.3 5.1 
day 0 =non-leukaemic controls; CBP =circulating blood pool; MP =marginal pool; 
TBP =total blood pool; RETP =rapidly exchangeable tissue pool; TREP =total rapidly 
exchangeable pool. 
For further explanation: see text. 
89 
Table 2.10 Blood transit times and turnover rates of BNML cells at various stages of the leukaemia 
days after inoculation with 107 BNML cells 
0 10 23 28 
T'/2 (h) 1.1 1.1 1.3 0.6 
T' /2 (h) 23.9 23.2 24.9 8.2 
BTT (h) 34.4 33.5 36.0 11.9 
TOR 
- cells X I 0' /kg/h * * 48.4 159.7 
- cells x 10'/kgjday * * 1160.9 3833.4 
* not measurable. 
day 0 =non-leukaemic controls; BTT =blood transit time; TOR= turnover rate. 
For further explanation: see text. 
Table 2.11 Blood transit times ( BTT) of acute leukaemia cellls as compared with normal 
granulocytes 
BTT (h) investigator 
human 
Athens, 1969 normal granulocytes 
AML 
5.5-10.4 
32-46 Killmann et al., 1963 
Clarkson eta!., 1969, 1970 
rat 
normal granulocytes 
BNML 
6.1-11.4 
34-36 
Gerecke et al., 1973 
this study 
Table 2.12 Quantification of organ compartments at two stages after inoculation with ]0 7 BNML 
spleen cells 
%uptake of total 
days 51Cr cells organ 
after at RETP SETP load SETP 
inoculation equilibrium X IQ7 X 107 X !0' RETP 
liver 23 42.97 214 716 930 3.4 
28 46.13 244 1430 1674 5.9 
spleen 23 7.19 36 338 374 9.4 
28 4.93 26 361 387 13.9 
total bone 23 12.50 67 416 483 6.2 
marrow* 28 8.33 42 542 584 12.9 
lungs 23 1.91 10 70 80 7.0 
28 2.77 15 51 66 3.4 
* 1 femur ::::,; 1.2% of the total bone marrow. 
RETP = rapidly exchangeable tissue pool } 
SETP = slowly exchangeable tissue pool RETP+SETP =total organ load. 
For further explanation: see text. 
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more than threefold at the terminal stage as compared with day 23 (table 2.10). 
This is due mainly to the shortened T" /2 and thus to a decreased average blood 
transit time ofleukaemic cells. During the first 23 days of the disease, the BTT 
ofBNML cells is significantly prolonged as compared with normal rat granulo-
cytes [Gerecke et al., 1973]. A similar relationship between normal granulocytes 
[Athens, 1969] and AML cells [Killmann et al., 1963; Clarkson, 1969; Clarkson 
et al., 1970] has been described in man (table 2.11). In this respect, the BNML 
is highly relevant as a model for human AML. The abrupt decrease in the BTT 
of leukaemic cells in the terminal stage of the BNML leukaemia is an unex-
pected finding. It might have to do with the increased fragility of leukaemic 
cells (see Ch. 2.4.1). 
From the number of LC in the circulating blood (CBP, table 2.9) and the 
blood transit time (BTT, table 2.1 0), the influx ofleukaemic cells into the blood 
per hour can be calculated according to the formula: 
CBP LCfh 
BTT 
( 10) 
This holds only for a steady state condition. At days 23 and 28, the influx of LC 
per hour is 0.6 X 107 and 2.3 x 107, respectively. 
The individual organ pool sizes at days 23 and 28 calculated as described 
above are presented in table 2.12. Except for the lungs, it is clear that, in the 
terminal stage of the leukaemia, the magnitude of the slowly exchangeable 
tissue pool (SETP) has increased markedly relative to the rapidly exchangeable 
tissue pool (RETP). 
The added RETP, SETP and organ load of the 4 organs lead to the total 
leukaemic cell load per rat as presented in tables 2.13 (day 23) and 2.14 (day 
28; "calculated from organ uptake"). In these 2 tables, the total RETP, SETP 
and organ load are also given, calculated from the blood disappearance curves 
(table 2.9). The difference between both methods, e.g. 5.71 X 109 leukaemic 
cells for the total body load at day 23 (table 2.13) will be due to organs such as 
the lymphatic apparatus, the kidneys, the gastrointestinal tract, etc., not 
measured. Apparently, the blood disappearance curve gives the most accurate 
information on total pool sizes, however, without specification of single organs. 
In this case, the SETP is derived from the RETP by assuming the same 
quantitative relationship between both compartments as was measured from 
the organ uptakes (SETP/RETP: 4.7 on day 23 and 7.3 on day 28). 
The total body load of leukaemic cells at the terminal stage is about 4 X 1010 
cells (±40 g ofleukaemic tissue), of which about 0.5 X 1010 ( 12.5%) are present 
in the exchangeable compartment. The total tumour load calculated in this 
way is much smaller than the one obtained after simple extrapolation of the 
dose-survival curve (fig. 2.15). This discrepancy has been explained earlier. 
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Table 2.13 Comparison of pool size calculations based on blood disappearance or organ uptake at day 23 
after inoculation with I 07 B Nivf L spleen cells 
RETP SETP SETP 
X 109 X 109 RETP 
calculated from blood 4.27 20.11 4.7 
disappearance (table 2.9) 
calculated from organ 3.27 15.40 4.7 
uptake* (table 2.12) 
---
difference 1.00 4.71 
* total uptake by liver, spleen, bone marrow and lungs. 
** total body load= total organ load+TBP. 
total 
organ 
load TBP 
X 109 X 109 
24.38 0.70 
18.67 0.70 
---
5. 71 
RETP = rapidly exchangeable tissue pool ) RETP SETP 1 I d 
SETP = slowly exchangeable tissue pool + = tota organ oa · 
TBP = total blood pool (see table 2.9). 
total 
body 
load** 
X 109 
25.08 
19.37 
---
5.71 
Table 2.14 Comparison of pool size calculations based on blood disappearance or organ uptake at day 28 
after inoculation with 101 BNAfL spleen cells 
RETP SETP SETP 
X lQ9 X 109 RETP 
calculated from blood 4.72 34.41 7.3 
disappearance (table 2.9) 
calculated from organ 3.27 23.84 7.3 
uptake* (table 2.12) 
---
difference 1.45 10.57 
* total uptake by liver, spleen, bone marrow and lungs. 
** total body load= total organ load+ TBP. 
total 
organ 
load TBP 
X 109 X lQ9 
39.13 0.56 
27.11 0.56 
---
12.02 
RETP =rapidly exchangeable tissue pool ) RETP+SETP l I d 
SETP = slowly exchangeable tissue pool • = tota organ oa · 
TBP = total blood pool (see table 2.9). 
total 
body 
load** 
X 109 
39.69 
27.67 
--·-
12.02 
Figure 2.39 gives a quantitative representation of the various functional com-
partments in the terminal stage of the leukaemia. As can be seen, the majority 
of the LC is present in the slowly exchangeable tissue compartments. The liver 
has the greatest tumour load, followed by the bone marrow and the spleen. 
The arrows indicate the continuous exchange of LC between the organs and 
the blood compartments. The constants for the various flow rates will be derived 
from a computer progran1 which is being developed at present [Freriks, 
personal communication). 
The per cent of 51Cr-labelled BNML cells taken up by the organs at various 
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Fig. 2.39 Sizes of functional compartments at the terminal stage of the BN rrryelOC)Ilic leukaemia. 
Terminal stage: day 28 after inoculation with 107 BNML spleen cells. 
R(ETP) = rapidly exchangeable tissue pool. 
S(ETP) =slowly exchangeable tissue pool. 
CBP = circulating blood pool. 
MP = marginal pool. 
stages of the leukaemia deserves more attention at this point. In nonleukaemic 
rats, one femur contains 0.6% of the labelled cells at 24 h after infusion (fig. 
2.32). This figure corresponds very well with the one determined by a bioassay 
(fig. 2.23). In this experiment, about I% of injected leukaemic cells (10 5 out of 
107 ) is recovered in one femur at 24 h. As one femur represents approximately 
1.2% of the total bone marrow [Pegg, 1962; Harker, 1968), it can be concluded 
that about 50% of the infused cells lodge in the bone marrow. The remaining 
50% is fully recovered from the added percentages of the liver (42%), the 
spleen (8%) and the lungs (1.6%). The relative density of LC lodging in the 
spleen is a factor of3 greater as compared with the bone marrow: in the spleen, 
8% of the infused cells are distributed among 4x 108 cells (400 mg of tissue), 
and, in the bone marrow, 50% is distributed among 80 X 108 cells (I femur, 
representing 1.2% of the total bone marrow cellularity, contains I 08 cells; see 
fig. 2.22a), or: in the spleen I% per 0.5 X 108 cells and, in the bone marrow, 
I% per 1.6 X 108 cells. 
With respect to the spleen, there is a discrepancy between the uptake of 
infused labelled blood cells (8%) and the percentage of infused leukaemic 
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spleen cells recovered from the spleen (I%; fig. 2.27) by means of a bioassay at 
24 h after infusion. This would indicate that leukaemic blood cells enter the 
spleen more easily as compared with leukaemic spleen cells. 
Other organs in nonleukaemic rats such as lymph nodes, thymus and kidneys 
do not contain a significant amount of radioactivity after infusion of labelled 
cells. As the leukaemia progresses, the uptake by the bone marrow decreases 
markedly. At the terminal stage (days 23-28) when the entire bone marrow 
compartment has been replaced by leukaemic tissue (see Ch. 2.5.1), a very low 
uptake is observed. In fact, the leukaemic spleen also shows a decreasing uptake, 
whereas the liver and the lungs take up a few more labelled BNML cells 
towards the terminal stage. This might be explained by stating that, for organs 
which are heavily infiltrated with leukaemia, the capacity to exchange 
leukaemic cells with the blood has decreased. This argument is based on the 
assumption that, in a steady state, every cell leaving an organ is replaced by a 
cell entering it. Another point might be that, in the late stage of the leukaemia, 
more developing foci ofleukaemic tissue, e.g., in the lymph nodes, kidneys, etc., 
are exchanging with the blood compartment in competition with the organs 
measured. From fig. 2.32 it can be calculated that, at day 28, about 30% of the 
infused cells are taken up by organs other than those which were studied. 
However, if the decreased uptake of the bone marrow and the spleen would be 
simply a matter of dilution of infused cells in a larger volume, it can be cal-
culated that the femoral bone marrow and the spleen would take up 0.4% and 
6%, respectively. These figures are higher than the ones actually measured. 
Besides, the decreasing uptake per gram organ (fig. 2.33) cannot solely be 
explained by a greater random dilution in the enlarged organ, because the 
relationship between the per cent uptake per gram organ and the organ weight 
is an exponential and not a linear one (fig. 2.34). This holds in particular for 
the spleen. It may be noted that the body weight has not been used in these 
calculations, because it does not change significantly during leukaemia 
development (fig. 2.24). Together, this supports the idea that the exchange 
rates ofleukaemic cells between the bone marrow and the blood and the spleen 
and the blood are decreasing during leukaemia development. The return of 
leukaemic cells from the blood to the bone marrow has also been reported by 
Killmann eta!. (1971) and Rosen eta!. (1975) in human AML. It is quite 
possible that, after their return, the leukaemic cells can be released into the 
circulation again. This possibility is supported by Tarocco eta!. (1972), who 
found that, in acute lymphoblastic leukaemia, leukaemic cells return to the 
marrow in S-phase, divide, and then reenter the circulation. 
So far, kinetics of proliferation of BNML cells have been thoroughly in-
vestigated in the spleen. Up to day 6 after inoculation, the number of LC was 
determined by means ofbioassays (fig. 2.27). After that time, these data may be 
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Table 2.15 Cell proliferation characteristics of BNML cells in the spleen after inoculation with 107 
B N M L spleen cells 
experimental results obtained from 3 
individual animals studied at each time of 
parameters symbols observation 
days after inoculation t 4 8 14 18 23 28 
(days) 
doubling time of the T, 37 37 96 120 182 250 
leukaemic cell population (h) 
fraction of labelled LI•pleen * * 0.42 0.39 0.43 0.30 
BNML cells (see table 2.5) 
fraction of proliferating GFspleen (1.0) (1.0) 0.56 0.52 0.57 0.40 
BNML cells 
fraction of cell loss relative tpspleen (62) (62) 78 81 88 88 
to cell production (%) 
* values relevant for BNML cell proliferation not measurable. 
For further explanation: see text. 
Table 2.16 Comparison of cell kinetic parameters of normal and leukaemic fr!.Yelopoiesis in man and 
in the rat 
To T, 
(h) (h) LI GF investigators 
human 
normal 
myeloblasts 15-30 13 0.45-0.70 Cronkite, 1969 
promyelocytes 25-40 13 0.55-0.65 0.7-1.0(?) Killmann, 1972 
myelocytes 50-60 13 0.25-0.50 
AML 50-60 13-20 0.03-0.25 0.10-0.35 
rat 
normal 
myeloblasts ? ? ) 0.58 Constable and promyelocytes ? ? ? Blackett, 1972 
myelocytes 12.0 5-8 0.48 0.77 
L 5222 12.6 8.7 0.30-0.58 0.43-0.84 Harriss and Hoelzer, 1971 
BNML 14.0 10.0 0.30-0.43 0.40-0.57 this study 
T c =duration of the cell cycle; T,=duration of the DNA synthesis phase; LI =tritiated 
thymidine labelling index; GF =growth fraction; ? =unknown. 
derived from changes in splenic weight which then become detectable (fig. 
2.25). Values for the doubling time (Ta) of the leukaemic cell population are 
given in table 2.15. It is clear that the rate of accumulation ofLC is maximally 
rapid during the first 6-8 days after inoculation. The same holds for the growth 
rate in the bone marrow: up to day 6, theTa is 16.8 h (fig. 2.23). Thereafter, 
the doubling time of the promyelocyte population increases significantly (fig. 
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2.22b). In summary, during the first week after inoculation, the growth rate of 
the leukaemic cell population in the bone marrow is more rapid as compared 
with that in the spleen. Thereafter, similar values for both organs are obtained. 
The per cent labelled mitoses (PLM) curve prepared at day 18 after inocula-
tion shows 2 peaks (t = 6 hand t = 20 h; fig. 2.35). Theoretically, in between 
these 2 peaks, the curve should reach the X-axis and the peak at t = 20 h 
should be similar to the one at t = 6 h. However, this is not observed; this may 
be due to variation in cell cycle parameters within the leukaemic cell population 
andjor cells leaving the proliferative compartment during the experiment 
(enter G 0, start to differentiate, die). 
Various kinetic parameters of both human and rat normal myelopoiesis and 
acute leukaemia are compared in table 2.16. In man, AML cells differ from 
normal granulocyte precursors in terms of a prolonged average cell cycle time 
and a decreased labelling index and growth fraction. It should be noted, 
however, that the cycle times of normal myelocytes are in the same range as 
those of AML cells. Besides the BNML, data on one other model in the rat 
(the L5222 acute undifferentiated leukaemia) are compared with scanty data 
on normal rat myelopoiesis. Both the BNML and the L5222 leukaemia show a 
decreased labelling index and growth fraction and their cell cycle times are 
close to that of normal myelocytes. In this respect, rat leukaemia cells have the 
same relationship with their normal counterparts as human AML cells with 
theirs. Therefore, from a kinetic point of view, the BNML may be regarded as 
a realistic model for human AML. Although the kinetic parameters of both rat 
models are rather similar, the L5222 shows a very rapid in vivo growth, i.e., the 
survival time after inoculation with I 07 cells is 7 days. This is possibly due to a 
much lesser degree of cell loss during leukaemia growth as compared with the 
BNML. 
Using the data on the phase durations of cell cycle (table 2.6) and the LI 
Table 2.17 Method to calcdate the cell loss factor during leukaemia growth 
Td(pot) ~T"1n2 1na (15) 
where: 
a~1+GF ( 16) 
kprod 
ln 2 (17) 1 Td(pot) o:p = kprod-k xlOO% (19) 
l 1n 2 (18) J kprod T, 
T d(pot) =potential doubling time; T c =cell cycle time; oc =number of cells produced per 
division; GF =growth fraction; kprod =expected rate constant for growth; k =actual rate 
constant for growth; T d =measured doubling time; cp =cell loss factor. 
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values (table 2.5), the fraction of proliferating BNML cells (GF) can be 
calculated according to a model described by Steel (1968) in which both 
proliferating and nonproliferating cells are assumed to be present; i.e., for an 
exponentially growing cell population, 
N, GF = ---
N 
( ll) 
where N, and N stand for the number of cells in cycle and the total number of 
cells, respectively. However, because these cannot be directly measured, this 
formula is written as 
where N~ represents the number of cells in S phase. 
From 
and 
N, = LI 
N 
the growth fraction can be derived. 
( 12) 
( 13) 
( 14) 
The values thus obtained for the GF are presented in table 2.15. Because the 
LI values at days 4 and 8 could not be accurately measured, the growth fraction 
could not be calculated. However, in the early stage of the leukaemia, it seemed 
to be justified to assume a maximal GF, i.e., GF = 1.0. This decreases to 
0.5-0.6 between days 14 and 23. In the terminal stage, the GF tends to become 
still smaller. With these calculations, it is assumed that the cell cycle para-
meters determined at day 18 do not change significantly throughout the 
disease period. In fact, the cell cycle time will not be very much shorter, since 
the duration of the G,-phase (0.8 h) is already extremely short. Particularly the 
G,-phase might show considerable variation, implying that an increase in G, 
will correspond with an increase in the calculated value for the GF [Hermens, 
1973]. 
Recently, improved techniques have yielded preliminary data which suggest 
that the growth fraction in the bone marrow is even lower than in the spleen 
(Limr = 0.20~0.25 at day 16 after inoculation; Aglietta, personal communi-
cation). The LI ofleukaemic cells in the peripheral blood was 0.20. 
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From the T" values, the rate constant for growth (k) was calculated, i.e. the 
fraction of cells produced per hour (see formula 18, table 2.17). Besides these 
two parameters, which are derived from measured growth, the potential 
doubling time, T ctcvot), and the rate constant for the production of new cells, 
kv""' which describe the expected growth rate can be calculated (see formulas 
15, 16 and 17; table 2.17). In this mathematical model based on the assumption 
that only cell production plays a role, the growth fraction (GF) and hence the 
number of cells produced per division (G<) lead to TctcvotJ and kp<ad· From the 
measured and expected production rates, the cell loss factor ( 9) can be cal-
culated (see formula 19, table 2.17). In table 2.15 this factor, defined as the 
rate of cell loss relative to the rate at which cells are being added to the total 
population by mitosis, is given for the various stages of leukaemia growth. 
Concomitant with a decreasing GF, the cell loss factor increases as the leukaemia 
progresses. This can be regarded as the major factor responsible for the net 
slow growth rate of the leukaemia. 
Cell loss may be due to differentiation, migration and cell death. To what 
extent these mechanisms contribute to the observed phenomenon is difficult to 
establish. That cell death plays an important role during leukaemia growth in 
the spleen can clearly be seen in fig. 2.26. On the other hand, indications for 
loss of proliferative activity, possibly by differentiation, come from the TD50 
experiment (fig. 2.17). Clearly, in contrast with other animal leukaemia models 
such as the Shay myelocytic leukaemia and the Ll210 leukaemia, more than 
one leukaemic cell is needed to transfer the disease. The plotted points in 
fig. 2.1 7 conform to theoretical Poisson curves. 
The chance of obtaining at random an inoculum containing no "taking 
unit" for successful transplantation of the leukaemia can be calculated to be 
37% [Hewitt, 1958]. A suspension which gives 63% oftakes contains a mean of 
40 cells. This means that, of every 40 cells, only 1 is likely to induce leukaemia. 
This cell might be called a "clonogenic cell" capable of unlimited proliferation. 
However, it must be taken into account that, in this experiment, 84°/0 of the 
cells were morphologically recognizable leukaemic cells; of these, 17% were 
scored as dead cells. This would mean that, instead of 1 out of 40 cells, 1 out of 
28 cells would be a clonogenic leukaemic cell. The existence of clonogenic cells 
is furthermore supported by the observation ofleukaemic colonies in the spleens 
of nonirradiated rats 20 days after injection of leukaemic cells. 
In conclusion, the BN myelocytic leukaemia may be classified as a realistic 
model for human acute myelocytic leukaemia based on its pathophysiology 
studied so far. In addition, its response to chemotherapy is also similar to that of 
human AML. Clinically applied chemotherapy regimens for AML are far 
more effective in terms of inducing a complete remission as compared with 
treatment schedules used in acute lymphocytic leukaemia [Colly and Hagen-
beck, 1977]. 
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CHAPTER 3 
LEUKOCYTE MOBILIZING AGENTS 
3.1 Introduction 
One of the major factors determining the efficacy ofECIB treatment is the total 
number ofleukaemic cells in the circulating blood, which is determined by the 
inflow and outflow of cells per unit time. If the inflow of cells could be made to 
exceed the outflow during the whole period of treatment, leukaemic cell 
depletion by ECIB would theoretically increase. 
Certain synthetic polyanions (table 3.1) have been shown to mobilize cells 
from haemopoietic organs. In addition, they share many other biological 
properties such as inhibition of cancer metastasis formation [Suemasu and 
Table 3.1 List qf po!yanions with similar biological effects 
heparin 
heparinoids 
dextran 
pentosan 
chondroitin 
glycogen 
sucrose 
~ sulphate 
polyethylene sulphonate 
polymethacrylic acid 
polyvinyl sulphonic acid 
copolymers 
Ishikawa, 1970; Franchi eta!., 1973; Niitani eta!., 1974], a heparin-like blood 
anticoagulant activity [Ricketts, 1952; Bradfield and Born, 1974] and activa-
tion oflipoprotein lipase [Yamada et al., 1961; Boberg, 1972]. 
In normal animal species (mice, rats, dogs, goats, calfs and monkeys), the 
various polyanions induce a transient absolute lymphocytosis shortly after 
administration [Jansen et al., 1962; Sasaki, 1967; Ormai eta!., 1973; Bradfield 
and Born, 1974; Ross eta!., !975]. Some examples are given in figures 3.1, 3.2, 
and 3.3. The peak of cell mobilization (up to a threefold increase in the number 
oflymphocytes) is generally found between I and 4 h after injection. Normal 
values are again reached a few hours later. Histology and quantitative mea-
surements indicate that the spleen and the lymph nodes are the major target 
organs from which lymphocytes are mobilized [Sazaki and Suchi, 1967; Ormai 
et a!., !973]. The route along which cells reach the blood is either via the 
efferent lymphatics, including the thoracic duct, or via the "direct route"; i.e., 
from the organs directly into the circulation [Ormai and de C!ercq, 1969; 
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Fig. 3.1 Effect of polymethacrylic acid ( P MAA) on the number of lymphocytes in the peripheral blood 
ofC57BLfemale mice. 
PMAA (MW 200,000): 40 mg/kg. 
Each point represents means (±SE) of 5 mice. 
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Fig. 3.2 Effect of polymethacrylic acid ( P MAA) on the number of lymphocytes in the peripheral blood 
qfWAGJRij male rats. 
PMAA (MW 200,000): 40 mg/kg. 
Each point represents means (±SE) of 5 rats. 
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Fig. 3.3 E;jfect r.if dextran sulphate ( DS17 } on the number of lymphocytes in the peripheral blood of a 
rhesus monkey ( Macaca mulatta). 
DS, (MW 17,000): 5 mg/kg i.v. 
Ormai eta!., 1973]. Besides mobilization, leukocyte mobilizing agents (LMA) 
seem to inhibit lymphocyte recirculation to some extent; i.e., their rate of exit 
from the circulation is reduced [Bradfield and Born, 1969; Balow and Fauci, 
1976]. This is an additional factor in the elevated peripheral cell counts. At the 
end of mobilization, cells return to the spleen and the lymph nodes [Ormai et 
a!., 1973]. 
According to the morphology and biological properties of the mobilized 
lymphocytes which pour into the blood in large numbers via the thoracic duct, 
it was found that they belong to the small lymphocyte population [Ormai and 
Palkovits, 1972a]. There is also evidence that these small lymphocytes are 
immunoreactive and able to induce rejection of skin transplants in a hetero-
transplantation model in mice. Immunosuppression was induced in this model 
by rabbit-antimouse antilymphocyte globulin [van Bekkum and Ormai, 1969]. 
It has been further observed that mobilization can also be effected in rats with 
hypoplastic lymphatic organs, induced either by breeding under germ-free 
conditions, by subjecting them to neonatal thymectomy or by treating them 
with hydrocortisone injections at birth [Ormai and Palkovits, !972b]. By 
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means of the membrane fluorescence technique, it was demonstrated that both 
BandT lymphocytes are mobilized [van der Ham eta!., 1977]. 
Apart from lymphocytes, LMA cause a moderate increase in the number of 
granulocytes in the blood. However, this marginal effect may be due to the 
anaesthesia and injection procedure. In mice, an increase in haemopoietic 
stem cells (HSC) in the peripheral blood has been reported [van der Ham eta!., 
1977]. This is in contrast with our findings in the rat, where, at 2 h after injec-
tion of dextran sulphate, no significant increase or decrease in HSC was found 
in the blood and the femoral bone marrow, respectively. 
In view of a possible application of LMA in combination with ECIB, special 
attention has been paid to the mobilization ofleukaemic cells. Polymethacrylic 
acid (PMAA) induces an absolute increase in the number of leukaemic cells in 
the blood, as was shown in the mouse lymphosarcoma 2028 and in the Shay 
myelocytic leukaemia in the rat [Ormai et a!., 1970]. In this chapter, cell 
mobilization studies with the less toxic LMA Dextran Sulphate (DS) in the 
BN acute myelocytic leukaemia and in three patients with chronic lymphocytic 
leukaemia will be reported. 
3.2 Specific experimental procedures 
3.2.1 Dextran sulphates (DS) 
For experimental purposes, DS17 (MW 17,000) was used (sulphur content: 
18%; prepared by Dr. K. J. van den Berg) in a dose of 10 mgjkg i.v. 
In an initial clinical trial, DS4 (MW 4,000; sulphur content: 5%) supplied 
by the Kowa Company Ltd. (Nagoya, Japan) was injected i.v. in a dosage of 
40 mgjkg. For clinical use, the solution in saline was sterilized through a 
millipore filter. 
3.2.2 Experimental designs 
a. Experimental studies 
In a first experiment, 5 rats received DS 17 i.v. on the 20th day after inoculation 
with 107 BNML cells. Following the injection, the number of lymphocytes and 
leukaemic cells in the blood were counted at hourly intervals up to 5 h. The 
increase in the number of cells is expressed as the increase factor (IF), calculated 
as follows: 
IF = numberof cells at mobilization peak 
number of cells before injection 
In a second experiment, the effects of repeated injections ofDS17 on the number 
of blood cells were studied in 5 rats on four consecutive days (days 18, 19, 20 and 
102 
21 after inoculation with 107 BNML cells) with two injections at 3 h intervals 
per day. Each initial injection was given at 10.00 a.m. 
b. Clinical study 
As a preliminary to a possible combination of cell mobilization with clinical 
ECIB treatment, three patients with chronic lymphocytic leukaemia received 
DS4 i.v. Their haematologic parameters determined before the infusion are 
given in table 3.2. Patients 1 and 3 had enlarged spleens and lymph nodes and 
showed a significant involvement of the bone marrow, i.e., about 55 and 95o/0 
of their bone marrow cells consisted of lymphocytes respectively. Patient 2 only 
had some slightly enlarged lymph nodes and no splenomegaly. However, the 
bone marrow was involved significantly (50% lymphocytes). In none of the 
patients was hepatomegaly found. 
After the infusion of DS4 at hourly intervals, up to 5 h after injection, venous 
blood samples were taken and the number of peripheral lymphocytes was 
determined. 
Table 3.2 Haematologic parameters of three patients with chronic lymphocytic leukaemia prior to 
injection with dextran sulphate ( MW 4000) 
Hb (mmol/l) 
Ht (%) 
platelet' (X l 0" /l) 
leukocytes ( x 10~/1) 
differential counts (%) 
basophils 
eosinophils 
polymorphs 
lymphocytes 
monocytes 
Patients 
I 
c)67 yr 
BW=82kg 
8.5 
39 
122 
18.0 
10.0 
88.0 
2.0 
2 
c)66 yr 
BW= 86 kg 
8.! 
39 
129 
14.0 
2.0 
15.0 
27.0 
53.0 
3.0 
BVV =body weight; Hb = haemoglobin; Ht = haematocrit. 
3.3 Results 
3.3.1 Experimental studies 
3 
c)78 yr 
BW = 80kg 
6.9 
35 
366 
5!.0 
8.0 
8.0 
82.0 
2.0 
In fig. 3.4, changes in the number of lymphocytes and leukaemic cells after one 
injection with DS 17 are shown. The increase in the number oflymphocytes and 
leukaemic cells is at a maximum between 2-4 hand 1-3 h, respectively. At the 
peak of mobilization, the following increase factors were calculated: 
IFlymphocytes = 1.9; IF leukaemic cells = 2 .8. 
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Fig. 3.4 Effect of dextran sulphate ( DS17) on the number of {pmphocytes and leukaemic cells in the 
peripheral blood of BN rats at day 20 after inoculation with 107 BNML spleen cells. 
DS, (MW 17,000): 10 mg/kg ;.v. 
Each point represents means (±SE) of 5 rats. 
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Fig. 3.5 Effect of dextran sulphate ( DS1 7) given by repeated injections on four consecutive days during 
leukaemia growth on the number of lymphocytes and leukaemic cells in the peripheral blood of 
BN rats. 
A, B, C and D: days 18, 19, 20 and 21 after inoculation with 107 BNML spleen cells, re-
spectively. 
Each arrow represents one injection with DS17 (M',Y 17,000): 10 mg/kg i.v. 
The same rats were used throughout the experiment. 
Each point represents means (±SE) of 5 rats. 
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The values are close to normal at 5 h after injection. 
Fig. 3.5 shows the effects of repeated injections with DS17 on 4 subsequent 
days. For leukaemic cells, it is clear that, except for day 18, the second injection 
of DS causes a further increase in number. The increase factor measured at 6 h 
after the first injection is 1.8 at day 18, 3.4 at day 19, 4.5 at day 20 and 3.2 at 
day 21. Before the first injection ofDS at days 19, 20 and 21, cell counts were 
found to have decreased approximately to the original low preinjection level 
obtained at day 18. In this experiment, the increase in the number of normal 
lymphocytes is less striking. 
3.3.2 Clinical study 
In table 3.3, data on lymphocyte mobilization in patients with chronic lym-
phocytic leukaemia arc presented. The total number of lymphocytes in the 
circulating blood volume was calculated by multiplying the number of 
lymphocytes per ml by the blood volume derived from normograms. All 
three patients show cell mobilization peaking at different times after injection, 
with increase factors ranging from 1.4 to 2.2. The absolute increase calculated 
Table 3.3 Effect of dextran mlphate (DS 4 ) on the number of perijJheral blood lymphocytes in three 
patients with chronic lymphocytic leukaemia 
patients 
2 3 
cf67 year cf66 year J78 year 
BV 5330 m1 BV ~ 5500 m1 BV ~ 5040 m1 
BW = 82 kg BW = 86 kg BW ~ 80kg 
time after DS4 Tot. Ly X 10° Tot. Lyx 109 Tot. Lyx 109 
0 hr (before DS,) 84.2 40.7 211.7 
lOmin 83.1 39.6 171.4 
30 86.3 45.7 171.4 
1 hr 101.3 28.6 252.0 
2 113.5* 49.5 292.3 
3 103.4 90.8* 216.7 
4 108.7 73.2 272.2 
5 98.6 74.8 302.4* 
*IF 1.4 2.2 1.4 
*maximal absolute increase 29.3 X 10" 50.1 X 10~ 90.7x10" 
(113.5-84.2) (90.8-40. 7) (302.4-21 1.7) 
BV =blood volume; BW =body weight; Tot. Ly= total lymphocytes= Lyfmlx BV (ml); 
DS 4 =dextran sulphate (MW 4000), 40 mg/kg i.v.; 
IF . c number of lymphocytes at peak* =Increase 1actor = · 
number of lymphocytes at t = 0 
Stars indicate maximal values measured. 
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by subtracting the initial number of cells from the number at the peak of 
mobilization ranges from 30 to 90 X 109 cells. 
3. 4 Discussion 
From the foregoing, it is clear that, besides normal lymphocytes, LMA 
mobilize leukaemic cells in both various animal leukaemia models and in 
human CLL. The mobilization phenomenon is dose-dependent with the dose-
effect curve showing a plateau [Ross eta!., 1975; Ormai and Palkovits, 1975]. 
With DS1, the optimal dose was 10 mgjkg. Above this dose, no further mobili-
zation of leukaemic cells occurred, while the risk of haemorrhages due to the 
heparin-like anticoagulant activity increased [Hagenbeek et a!., 1976]. The 
clinically applied dose of DS, ( 40 mg/kg) was derived from studies in patients 
treated for pulmonary metastases [Niitani eta!., 1974]. Prior to its use in our 
CLL patients, the compound was subjected to various in vitro coagulation 
studies using human plasma. The thrombin time (TT), which is very sensitive 
to heparin-like activity in the plasma, was only slightly prolonged when DS, 
was incubated with plasma in a final concentration of I mg/ml. Moreover, DS, 
did not induce platelet aggregation in vitro. In fact, after injection of DS, in 
our patients, no changes were observed in their clinical condition. Except for a 
short-lasting prolonged cephaline time, no haematological abnormalities were 
noted. 
Although the anatomical site of origin of mobilized leukaemic cells cannot 
be identified histologically, it may be assumed that the rapidly exchangeable 
tissue pool (RETP; see Chapter 2.6.5) is the major target compartment for cell 
mobilization. From fig. 3.4, it can be calculated that, at 2 h after injection with 
DS, a net number of 29.3 X I 06 leukaemic cells per ml has been added to the 
circulating blood. With an average blood volume of 12.5 ml, the total number 
of mobilized cells is 3.7 X 108 • This number is about 10% ofthe size reported for 
the RETP at day 23 (3.27-4.27 X 109 cells; see Chapter 2.6.5, table 2.13). 
With repeated injections ofDS17 (fig. 3.5), the second injection except for day 
Table 3.4 Net increase in the number rif leukaemic cells in the circulating blood volume after repeated 
injections with dextran sulphate ( DS1 7) at four consecutive days tifter inoculation with 
101 BNML spleen cells 
days after inoculation 
3 h after the first injection with DSn 
3 h after the second injection with DS1 7 
number of leukaemic cells added to the 
circulating blood (X 10s) 
18 
1.8 
1.6 
19 
2.7 
4.6 
20 
3.6 
5.0 
21 
5.3 
6.5 
DS17 =dextran sulphate (MW 17,000), 10 mg/kg i.v. at t=O hand t=3 h (see fig. 3.5). 
The increases were calculated related to the values at t = 0 h. 
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18, significantly increases the number of leukaemic cells added to the circulat-
ing blood (table 3.4). A total net increase of6.5 X 108 cells, i.e. 15-20% of the 
RETP, was measured when mobilization was induced at day 21 after leukaemia 
inoculation. 
In the clinical study, the number ofleukacmic cells mobilized (3 X 1 010~ lQH; 
table 3.3) is between 5 and 20% of the RETP if the number of cells in the 
RETP in these patients is assumed to range from 2 X 10n to 1.5 X 1012, based on 
studies by Bremer et al. (1973a). 
Although the mechanism underlying the mobilization phenomenon is still 
unclear, studies with many copolymers indicate that the mobilizing capacity of 
a polyanion is related to the overall anionic charge or the density of charge on 
the polyanion (Ross, personal communication). The present working hypo-
thesis is that polyanions attach to the cell surface of the target cells, thereby 
changing their electronegative charge. This possibly alters the normal inter-
action between the cells and the surrounding structures (e.g. the reticulo-
endothelial system; RES), which may in turn result in an increased release to 
and possibly an impaired migration from the blood. This hypothesis is sup-
ported by the following facts. As is shown in table 3.5, in vitro incubation of cells 
from another rat leukaemia (L5222) and normal rat lymphocytes with either 
polymethacrylic acid or DS17 significantly increases their electrophoretic 
mobility towards the positive pole (Roeder and Haemmerli, personal com-
munication). The effect is dose-dependent until a plateau is reached. The same 
phenomenon has been described by Suemasu et al. (1971) for cultured 
endothelium-like cells after in vitro incubation with DS. From in vitm studies 
with 35S-labelled DS, these authors concluded that the compound interacts 
with the cell surface. For heparin also, in vivo attachment to endothelium was 
reported by Hiebert and Jaques (1976). In vivo, the electrostatic repulsion 
Table 3.5 Changes in electrophoretic mobility of L5222 rat leukaemia cells and normal rat lymphocytes 
after in vitro incubation with polyanions [Roeder and Haemmerli, 1975] 
PMAA 
concentration(%) 
0.1 
0.25 
0.5 
1.0 
0.1 
0.2 
% increase of epm over controls 
L5222 
4 
14 
28 
31 
16 
23 
lymphocytes 
7 
14 
12 
16 
15 
23 
PMAA = polymethacrylic acid (MW 200,000) ; DS1 7 =dextran sulphate (MW 17 ,000), 
Incubation: 50 min at 37 °C, concentration of cells: 107 -2X 107/ml. 
epm =electrophoretic mobility. 
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induced by the increased surface negative charge might be responsible for the 
alteration in adhesion between leukaemic cells and the RES. 
A second argument in favour of the hypothesis is derived from the observa-
tion that the lymphocytosis induced by polyanions can be abruptly abolished 
by the administration of polycations such as protamine chloride (fig. 3.6). 
Within 10 min after injection of the polycation, the number oflymphocytes has 
already decreased significantly. Apparently, the altered cell surface charge is 
neutralized. This might enhance migration of cells from the blood stream. The 
suggestion is that, in combination with mobilization from tissue stores, inhibi-
tion of recirculation at the stage of migration of cells from the peripheral blood 
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Fig. 3.6 Effect of dextran sulphate ( DS17 ) and subsequent protamine chloride on the number of lympho-
cytes in the peripheral blood of W AGf Rij male rats. 
DS, (MW 17,000): IO mg/kg i.v. 
Protamine chloride: 10 mg/kg i. v. 
Each point represents means (±SE) of 5 rats. 
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is responsible for the elevated peripheral cell counts. When mixtures of DS and 
protamine are injected, the mobilization of cells can be completely prevented 
[Sasaki, 1967]. This phenomenon is less clear in leukaemia, possibly because of 
a less specific interaction of leukaemic cells with endothelial cells at the site of 
migration. 
It has been clearly shown that the anticoagulant effect of various polyanions 
does not correlate with their ability to cause lymphocytosis [Bradfield and 
Born, 1974]. To what extent other biological properties of these compounds, 
e.g. activation of lipoprotein lipase with possible effects on endothelial struc-
tures, play an essential role in the mechanism of cell mobilization remains to be 
established. 
Finally, it should be mentioned that chronic daily administration of DS 17 
does not change the growth rate of the BNML. 
In summary, although the specific mode of action is yet unknown, LMA, 
particularly after repeated injections, add a significant number of leukaemic 
cells to the circulating blood. Their usefulness in terms of enhancing the 
efficacy of ECIB in cell depletion will be discussed in Chapter 4. 
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CHAPTER 4 
ECIB IN THE BN ACUTE MYELOCYTIC LEUKAEMIA 
4.1 Introduction 
After introducing the ECIB model which was used in the rat, including the 
cannulation procedure, the ECIB procedure, the radiation equipment and the 
dosimetry, the various effects of ECIB treatment in the BN acute myelocytic 
leukaemia will be described. Three major questions are considered: (I) is there 
a different efficacy in terms of cell depletion between one long-lasting session of 
ECIB and several repeated sessions?; (2) to what degree do leukocyte mobili-
zing agents enhance the cell depletion induced by ECIB?; and (3) does ECIB 
change the proliferation characteristics of the leukaemic cell population? 
cranial 
cauda I 
Fig. 4.1 A schematic representation of the anatomical site of aorta cannulation in the rat. 
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4.2 The ECIB model in the rat 
4.2.1 Cannulation procedure 
A schematic presentation of the cannulation of the abdominal aorta is presented 
in fig. 4.1. The cannula is inserted between both renal arteries and the aortic 
bifurcation. Only the left iliolumbar artery is cut off from its blood supply; 
however, this is without any harmful effects because of the rapid development 
of collaterals. The operation procedure is described in detail below. 
The rat is anaesthetized with ether, the abdomen is shaved and the animal is 
fixed to a cork board. The abdominal wall is opened via a midline incision 
over a length of approximately 3 em. After flexible wound retractors have been 
placed, the intestines, protected with moistened gauze, are retracted to the 
right side of the abdominal cavity to expose the aorta. The liver and the spleen 
are kept out of the operation field by compression with cotton wool rolls. With 
2 rolls, the peritoneum overlying the abdominal aorta and the adjacent 
inferior caval vein is divided (fig. 4.2). Subsequently, both vessels are dissected 
with 2 forceps. Then loose ligatures (linen thread no. 40, Ethicon, Lameris, 
Utrecht, Holland) are placed around the aorta at the 2 sites where the cannula 
is to be inserted. The appropriately curved polyethene cannula (PPlOO, 
external diameter: 1.52 mm, internal diameter 0.86 mm; Portex Ltd., Hythe, 
Kent, England) is placed in the right position after it has been exteriorized by 
piercing the dorsal musculature with a trochar (fig. 4.3). It is filled with 
physiological saline. The cannula is cut off obliquely at both ends to facilitate 
insertion into the aorta. Two bulldog clamps are placed on the abdominal 
aorta, just distal from the renal arteries and proximal to the bifurcation. After 
2 small incisions have been made in the aorta, both ends of the cannula are 
inserted and fixed by tightening the ligatures. Two additional ligatures are 
then placed at both ends before the clamps are removed (fig. 4.4). The abdo-
men is closed in two layers (linen thread no. 40, Ethicon, Lameris, Utrecht, 
Holland). 
In this way, an extracorporeal aorta by-pass is established. The blood flow 
in the cannula can be judged on the basis of the light-red colour of the arterial 
blood. A broad piece of tape (Scotch Brand Tapes, Minnesota Mining and 
Mfg. Co., St. Paul, Minnesota, U.S.A.) is wrapped around the thorax to 
prevent the rat from committing suicide by biting through its own cannula 
(fig. 4.5). The total operation takes about 15 min, with a mortality of about 
5%. The rats are caged individually. The cannula remains open for 1-2 weeks 
without the administration of anticoagulants. 
4.2.2 ECIB procedure 
To perform a session of ECIB, the rat is placed in a specially designed fixation 
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Fig. 4.2 An overview of the operation field showing the abdominal aorta and the inferior caval vein. 
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Fig. 4.3 Two loose ligatures are placed around the aorta which is dissected from the caval vein. The 
cannula is placed in the right position. 
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Fig. 4.4 Both ends if the cannula have been inserted into the aorta. Arterial blood is flowing through the 
cannula. 
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Fig. 4.5 The exteriorized part of the cannula. 
cage which makes long-lasting anaesthesia unnecessary. Then the exteriorized 
part of the cannula is closed at 2 sides with forceps and cut in the middle. The 
cannula is flushed with physiological saline containing 200 IU (2 mg) of 
heparin (Thromboliquine, Organon, Oss, Holland). A silicone tube (external 
diameter: 2.5 mm, internal diameter: 1.5 mm; SR3H, Talas, Zwolle, Holland), 
is then connected to both ends of the cannula. The tube, which is filled with 
physiologic saline, has a length of 115 em and a volume of2 ml, which is about 
1/7-1/8 of the total blood volume. It is placed as a coil in the radiation field. 
The volume which is irradiated is 1.5-1.6 ml. In this way, an extracorporeal 
blood circuit is established after removing the forceps (fig. 4.6). Twelve rats can 
be subjected to ECIB at one time. The flow rate in the loop is measured by 
determining the transit time of an air bubble introduced at the cranial end of 
the coil over a known volume part of the coil. It is regulated by a small screw 
clamp which is placed around the tube. The air surrounding the extracoporeal 
circuit is kept at a temperature of about 30 'C by a hot air blower in order to 
prevent the circulating blood from cooling. To avoid coagulation of the blood 
in the coil, 200 IU of heparin are injected every 2 h at the cranial end of the 
tube. With this method, a functioning extracorporeal blood circulation can be 
maintained for at least 24 h. 
After the completion of each ECIB session, the flow rate of the blood in the 
coil is again measured and, after a forceps is placed at the cranial part of the 
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Fig. 4.6 The extracorporeal blood circuit has been established. The tubes are placed as coils in the 
radiation field. 
cannula, the blood m the coil is pushed back into the caudal part of the 
cannula by means of air pressure from an air-filled syringe. The two parts of 
the cannula are joined with a small piece of silicone tube so that the original 
circuit is restored. The rat is then released from its fixation cage. 
4.2.3 Radiation equipment 
A conventional X-ray machine (Philips-Miiller 300) is used to irradiate the 
blood. The physical parameters of the irradiation are: 300 kV, 10 mA, HVL of 
the beam 3.0 mm Cu, distance from the focus to the bottom of the cup 14-16 
em. To avoid Bremstrahlung, the cup with the coils is placed on a lead block of 
20 by 20 em with a thickness of 5 em. The rats are placed adjacent to this block 
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Fig. 4.7b The sepaTate lead units used for efficient shielding (inner and outer cylinders, ring and 
basement blocks). 
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Fig. 4. 7c The radiation set~~p with the two lead cylinders separated. 
(fig. 4.6). Because the BN leukaemia is very radiosensitive (see Ch. 4.3), 
efficient shielding is of utmost importance; therefore, two lead cylinders were 
constructed to focus the radiation to the cup. The inner one (thickness of the 
wall: 1.6 em) is directly attached to the X-ray machine. The cup with the coils 
fits into its internal diameter ( 11 em). Between the inner conus and the lead 
block, 0.5 em is left open to give entrance to the coils. The outer cylinder 
(thickness of the wall: 0.8 em) is placed around the inner one and, with 3 legs 
(length: 3 em), rests on a lead ring (height: 1.9 em, thickness: 1.6 em), which in 
turn is placed on the lead block. In this way optimal shielding is provided 
(figs.4.7 a, b, c, d and e). 
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Fig. 4.7d The radiation set-uP in its final form. The outer lead cylinder jits around the inner one-
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1.2.4 Dosimetry 
With 300 kV, 10 rnA X-rays the dose rate to the blood measured with a Baldwin 
Ionex ionization chamber is 200 ± 20 radfmin. Radiation leaks and back 
scatter are obviously unavoidable in this construction; therefore, the radiation 
dose received at the midline of the body of the rats was carefully determined. 
The average of a number of measurements (n = 10) was 0.6±0.2 radfh. This is 
acceptable, because no significant effect on the growth rate of the leukaemia 
was noted after subjecting rats to this protracted low-dose irradiation in control 
experiments. 
With a fixed volume of the part of the coil which is irradiated ( 1.5~ 1.6 ml) 
and a fixed dose rate to the blood, the transit dose (TD) can be chosen within a 
wide range by changing the flow rate of the blood through the coil (see formula 
1, Ch. 1.3.2). The TD during a session ofECIB is taken by the average of the 
measured flow rates before and after the irradiation. Generally, the flow rate 
measured after ECIB had decreased by 10~30% as compared with the initial 
flow rate. In practice, the TD was varied between 350 and 650 rad. 
The mean total accumulated dose received by erythrocytes during one or 
more sessions ofECIB (Dx, see formula 3, Ch. 1.3.2) never exceeded 35,000 rad. 
This is far below the haemolytic dose for rat erythrocytes (100,000~200,000 
rad) as derived from data in the literature [Pellerin eta!., 1960; Pellerin and 
Remy, 1968] and from our own experiments on in vivo survival of irradiated 
51Cr-labelled erythrocytes. 
4.3 Radiosensitivity 
1.3.1 Specific experimental procedures 
In connection with the ECIB studies to be described, the D 0 for X-rays was 
determined for BNML blood cells. Leukaemic blood was irradiated in vitro at a 
concentration of 107 LCfml with varying doses: 300, 600, 900, 1200 and 1500 
rad, at a dose rate of 500 radfmin (for further physical parameters, see Ch. 
4.2.3). The various suspensions were then inoculated into different groups of 
6 rats in a dosage of 107 LC per rat. The per cent ofrats dying from leukaemia 
and the survival times were determined. As controls, 4 groups consisting of 
6 rats each received 10', 105, 104 and 103 nonirradiated leukaemic blood cells, 
respectively. From their dose-survival relationship (which was fitted by linear 
regression analysis) and the survival times of rats which received irradiated 
cells, the fraction ofLC surviving a certain radiation dose could be calculated. 
In this way, the D 0 value was derived. 
4.3.2 Results 
The dose-survival curve for nonirradiated cells is given in fig. 4.8. The mean 
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Fig. 4.8 Dose-survival time curve for BNML blood cells. 
From the survival times scored after inoculation with 107 BNML cells in vitro irradiated with 
different doses of X-rays, the corresponding number of surviving cells was derived (see dotted 
lines). Horizontal bars represent 95% confidence limits. Each point of the dose-survival time 
curve for non-irradiated BNML cells represents means of 6 rats. For further explanation: 
see text. 
survival times after injection with irradiated cells are also indicated. By 
extrapolation towards theY-axis, the corresponding numbers of viable BNML 
cells are determined. Rats which received cells irradiated with 300 and 600 rad 
and all controls died from leukaemia. However, in the 900 rad group, l of the 
6 animals (17%) survived. Furthermore, no rats receiving heavily irradiated 
BNML cells (1200, 1500 rad) developed leukaemia within the 250 days 
observation period. 
By dividing the number of surviving cells by 107, the fraction of surviving 
cells for each radiation dose is found. Based on the surviving fraction of cells 
after 300, 600 and 900 rad irradiation, the curve in fig. 4.9 could be fitted. 
From this curve, the D 0 was calculated to be 68.1 rad, the 95% confidence 
limits ranging from 58.2 to 82.2 rad. The extrapolation number (N) was 3. 7; 
this gives a Dq value of 89.0 rad, according to the formula: 
Dq = D 0 xln N. 
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4.3.3 Discussion 
BNML blood cells are characterized by a rather low D0 value in comparison 
with other experimental leukaemias. Most leukaemias studied, including the 
L5178Y, the CBA lymphocytic leukaemia, the AKR lymphoma and the P388 
leukaemia, show D 0 values ranging from 60-160 rad [Whitmore and Till, 1964; 
Broerse and van Oosterom, 1974]. 
The small shoulder of the survival curve (fig. 4.9) characterized by low 
values for D4 and N indicates that repair of sublethal damage is not a pro-
nounced phenomenon in the BNML. It indicates that the total cell kill after 
fractionated irradiation will be significantly greater than in the case of leukae-
mias showing survival curves with broader shoulders. This favours the applica-
tion ofrepeated sessions of ECIB. 
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Fig. 4.9 Survival curve for BNML blood cells after in vitro irradiation with X-rays. 
The fraction of surviving cells was calculated by dividing the number of surviving cells (see 
fig. 4.8) by 107 (the total number of injected irradiated cells). Vertical bars represent 95% 
confidence limits. 
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A dose of 900 rad results in an average survrvmg fraction of 3.6 x 10-6 
(fig. 4.9). Thus, it can be calculated that, of 107 irradiated cells, 36 cells 
survive. This number of cells induces leukaemia in 83% (5 out of6) of the rats. 
These results can be compared with those of the TD50 study. From the TD50 
curve (fig. 2.17) it would be expected that 36 cells would induce leukaemia in 
60% of the rats. If the 95% confidence limits in the TD50 experiment are taken 
into account, 83~/0 is not significantly different from 60°/0 • Thus, both experi-
ments strongly confirm each other. 
4.4 The appropriate controls for ECIB treated rats 
4.4.1 The effect of aorta cannulation on haematologic parameters 
Thirteen rats were inoculated with 107 BNML spleen cells. At day 14, eight of 
them were cannulated. Seven days later (day 21), blood samples were obtained 
from the tails of both cannulated and noncannulated rats and the absolute 
numbers of leukaemic cells, platelets, reticulocytes, erythrocytes and haema-
tocrit values were determined. 
In table 4.1, haematologic parameters derived from noncannulated leukae-
mic rats and cannulated rats are compared. Except for the number of platelets, 
all other parameters have changed significantly due to the aorta cannulation. 
Table 4.1 The effect of aorta cannulation on haematologic parameters determined 7 dq:vs after the 
operation 
(day 21 after inoculation with 107 BNML spleen cells) 
leukaemic 
cells platelets erythrocytes Ht reticulocytes 
( x 10"/m1) ( x 10'/m1) ( x 10"/m1) (%) (%,) 
non-cannulated 15.2 ± 1.3 83.4± 11.9 1109±47 44±1 44.0± 7.9 
rats (n = 5) 
cannulated rats 12.2±0.8 104.0± 11.3 710±41 38± 1 102.0± 16.4 
(n~8) 
student "t" test p <0.05 N.S. p < 0.0005 p < 0.0025 p < 0.0125 
Ht: haematocrit; N.S.: nonsignificant difference. 
Values represent means (±SE). 
In particular, the number of erythrocytes has decreased. The most likely 
explanation is that erythrocytes may have a shortened life span due to mechani-
cal damage sustained during their repeated passage through the cannula. An 
increased number of reticulocytes, indicates increased erythropoiesis to com-
pensate for the loss of erythrocytes. The number of leukaemic cells also 
decreases in the cannulated rats, most probably due to their increa<;ed fragility 
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(see Ch. 2.4.1) which makes them more vulnerable to damage during their 
passage through the cannula. 
In summary, because the cannulation per se induces distinct haematologic 
changes, non cannulated rats cannot be used as controls for the ECIB studies. 
4.4.2 Comparison between cannulated controls and rats submitted to extracorporeal 
circulation 
Two other candidate control groups for ECIB were investigated: cannulated 
controls (CC) and rats which were subjected to repeated sessions of extra-
corporeal circulation (ECC) without irradiation. The experimental protocol 
was as follows. Eleven rats were inoculated with I 07 EN '\ilL cells at day 0. 
Fourteen days later, all rats were cannulated. At days 21, 22, 23 and 24, six rats 
were subjected to ECC. Each session lasted for 5 h; the average flow rate of 
the blood in the extracorporeal circuit (F x) was 1.0 ml/min, i.e., 22 times the 
blood volume (BV) passed through the shunt per session (BV = !3.5 ml). The 
5 remaining rats received only heparin according to the schedule described in 
Ch. 4.2.2. At day 25, blood samples were obtained from the aorta and the 
various haematologic parameters were determined. The results are given in 
table 4.2. No significant differences were found for any of the parameters 
studied. Therefore, both cannulated rats and rats undergoing ECC can serve as 
optimal controls for ECIB treated rats. 
Table 4.2 The dfect of repeated extracorporeal circulation on haematologic parameters determined 
one day after the last session 
(day 25 after inoculation with 107 BNML spleen cells) 
leukaemic 
cells platelets erythrocytes Ht reticulocytes 
(X 10"/ml) (X 10"/ml) (X 10"/ml) (%) (%,) 
CC (n~5) 15.0± 1.0 58.0±4.9 339±33 13±2 178.0±33.7 
ECC (n~ 6) 16.4± 1.0 60.0±5.7 361 ±34 16±2 139.0±22.6 
student "t" test N.S. N.S. N.S. N.S. N.S. 
Ht: haematocrit; N.S.: nonsignificant difference; values represent means ±S.E. 
CC: cannulated controls; ECC: 4 x 5 h of extracorporeal circulation at days 21-24 after 
inoculation with 107 BNML spleen cells. 
For further explanation: see text. 
4.5 Comparison qf different ECI B schedules 
Three different ECIB protocols in terms of sessions per unit of time were 
investigated: I X 20 h, 2 X I 0 h and 4 X 5 h. \Vith the repeated regimens, the 
session~ were performed on consecutive days. The irradiations usually started 
between 10 and II a.m. Cannulated rats or ECC rats (which received repeated 
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injections with heparin; Ch. 4.2.2) were used as controls in all experiments. As 
a rule, cannulation was performed at day 13 or 14 after inoculation with 107 
BNML cells. 
The parameters of evaluation were: haematologic follow up before and after 
irradiation performed on blood samples obtained from the cannula; compart-
ment analysis by means of the 51Chromium method (Ch. 2.6.3; 2.6.5), which 
was started 1-2 h after completing (the last session of) ECIB; and fresh liver 
and spleen weights at the time of killing, i.e., 24-25 h after infusion of 51Cr-
labelled leukaemic cells. A list of symbols for the various physical parameters to 
be described is given in table 4.3. 
Table 4.3 .~ymbolsfor the various physical parameters used in ECIB 
parameter symbol 
body weight 
blood volume 
volume of the irradiated coil 
flow rate of the blood in the coil 
number of blood volumes passing through the coil 
dose rate 
transit dose 
mean dose to the total blood 
4.5.1 1 x20 h of ECIB 
BW (g) 
V, (ml) 
V (ml) 
F (mljmin) 
xV, 
R (md/min) 
TD (rad) 
D; (rad) 
Five rats were subjected to 1 X 20 h of ECIB which was started at day 21 after 
inoculation. In this experiment, 5 ECC rats served as controls. The physical 
parameters are shown in table 4.4. 
One hour after completing the ECIB/ECC procedure, all rats received 
4.5 X 107 51Cr-labelled BNML blood cells through the aorta cannula and the 
blood disappearance was investigated during the subsequent 25 h. At t ~ 25 h, 
the rats were killed and their organ uptake was determined. 
Changes in the number of both lymphocytes and leukaemic cells (LC) are 
plotted before and after ECIB in fig. 4.10. The number of lymphocytes has 
already decreased significantly shortly after the session. However, it takes 24 h 
more to observe a significant decrease in the number of LC as compared with 
the steadily increasing number in the ECC group. In fact, in the ECIB 
treated group, the number of LC remains at a constant level rather than 
decreasing. Table 4.5 shows the liver and spleen weights which were deter-
mined 26 h after completion of the ECIB session. No significant differences 
were noted. 
Based on calculations described in Ch. 2.6.5, changes in the size of the 
various functional compartments of LC were determined. From the blood 
disappearance curve, the total blood pool (TBP), the marginal pool (MP), the 
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Table 4.4 Pfl:.ysicalparametersoflx20h, 2x10h and 4x5h if ECIB/ECC 
-~-- l~x:2~CIB -----~ofECIB ---,-~~x5hofECIB 
session I session II 
ECIB ECC ECIB ECC ECIB ECC ECIB 
(n~5) (n~5) (n~4) (n~4) (n~4) (n~4) (n~S) 
BW (g) 2IO 220 220 210 220 2IO 260 
v, (mi) I0_5 ILO I LO 105 I LO 10.5 I3_0 
v (mi) L5 1.5 L5 L5 L5 L5 L6 
F (mijmin) 0_55 0_57 OA3 0_43 0_52 0_62 o_8o 
xV, 62-9 62-2 n5 24-6 28_4 35_4 18_5 
R (rad/min) 160 - 190 - 190 - 190 
TD (rad) 436 - 663 - 548 - 380 
D- (rad) 24,000 - I3,680 - 13,680 - 6247 
--------"M••--••••--•••- ~--------- -----
For explanation of symbols: see table 4.3; ECC: extracorporeal circulation. 
Values represent means of the indicated number of rats. In the 4 X 5 h experiment no signi-
ficant differences were found between the separate sessions; cannulated rats served as controls. 
Table 4.5 Organ weights measured 26 h after 1 X 20 h if ECIBjECC 
liver weight (g) spleen weight (g) 
ECC 
ECIB 
student "t" test 
19_8ci0-5 
m2±o_s 
Values represent means (±SE) of 5 rats. 
2-4±0_3 
2.2±0.3 
ECC: extracorporeal circulation; N.S.: nonsignificant difference. 
Table 4.6 Changes in the size of the various functional compartments after 1 X 20 h of ECI B 
(leukaemic cells x I 07 ) 
% % 
51 Cr-cells ~ 1 Cr-cells 
in CBP in CBP 
after at equi-
infusion CBP MP TBP librium RETP 
ECC 27-1 15.4 4L4 56_8 I3.1 60_8 
ECIB 32.0 11.8 24.9 36.7 14.1 46.7 
% reduction by ECIB 24 40 35 23 
Values represent means of 5 rats. 
ECC: extracorporeal circulation; CBP: circulating blood pool; MP: marginal pool; 
TREP 
117.6 
83A 
29 
TBP: total blood pool; RETP: rapidly exchangeable tissue pool; TREP: total rapidly 
exchangeable pool. 
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Table 4.7 Changes in the size of the rapidly exchangeable tissue pools ( RETP) in various organs 
after I x 20 h of ECIB 
(leukaemic cells X 1 07 ) 
liver spleen bone marrow* 
ECC 
ECIB 
% reduction by ECIB 
57.1 
37.5 
34 
3.9 
3.0 
23 
* Total bone marrow was calculated ( 1 femur= L2%). 
Values represent means of 5 rats. 
12.7 
6.6 
48 
ECC: extracorporeal circulation; RETP: rapidly exchangeable tissue pool. 
For further explanation: see text. 
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rapidly exchangeable tissue pool (RETP) and thus the total rapidly exchange-
able pool (TREP) could be quantified (table 4.6). The TBP is more effectively 
depleted (35% reduction) as compared with the RETP (23%). This is mainly 
due to a reduction in the MP to 60%1 of its original size. The entire compart-
ment of rapidly exchangeable LC (TREP) is reduced by 29%. In table 4.7, the 
values for the RETP are specified for various organs, based on 51 Cr-organ 
uptake studies. After 20 h of ECIB, the RETP of LC in the bone marrow is the 
most reduced (48%), followed by the liver, the lungs and the spleen. The 
slowly exchangeable tissue pools, calculated by means of total organ weights, 
have only been reduced by ll and 4% in the spleen and the liver, respectively 
(table 4.8). 
Table 4.8 Changes in the size of the slowly exchangeable tissue pools (SETP) in the spleen and the 
liver after 1 X 20 h of ECIB 
(leukaemic cells X 107 ) 
%reduction 
RETP SETP ofSETP by EGJB 
spleen EGG 3.9 !76.! 
EGIB 3.0 !57.0 ll 
liver EGG 57.! ll22.9 
ECJB 37.5 !082.5 4 
Values represent means of 5 rats. 
ECC: extracorporeal circulation; RETP: rapidly exchangeable tissue pool; SETP: slowly 
exchangeable tissue pool. 
4.5.2 2xiOhofECIB 
At days 20 and 21, four rats with BNML underwent 2 sessions of ECIB, each 
lasting for 10 h. Four leukaemic ECC rats were used as controls. The physical 
parameters are presented in table 4.4. After the second session, all rats were 
injected with 3 x 107 ' 1Cr labelled BNML cells for compartment analysis. 
Organ uptake was determined at 24 h after infusion. 
Fig. 4.11 shows changes in the number of peripheral lymphocytes and 
leukaemic cells. In the ECIB treated group, both cell types show a decline 
which is much more striking than in the l x 20 h experiment (fig. 4.10). 
With respect to organ weights, only the spleen weight is significantly reduced 
(table 4.9). Changes in the size of the functional compartments are given in 
tables 4.10-4.12. Both the blood compartment (TBP) and the rapidly ex-
changeable tissue compartment (RETP) are depleted to the same extent, i.e., 
to approximately 30% of their original size, by this treatment (table 4.10); this 
is about 2-3 times as much as in the l x20 h regimen (table 4.6). The RETP as 
measured in the various organs is decreased to a similar degree as the TBP and 
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Fig. 4.11 Effect of 2x 10 h of ECIBjECC on the number of leukaemic cells and lymphocytes in the 
peripheral blood. 
Each point represents means (±SE) of4 rats. 
ECC: extracorporeal circulation. 
the RETP calculated from the blood disappearance curve (table 4.11). The 
depletion of the RETP per organ is a factor of 1.5-2.5 more than after 1 X 20 h 
of ECIB (table 4.7). The SETP in the spleen is reduced by 28% (table 4.12), 
i.e., 2.5 times as much as compared with the first regimen ( 11%, table 4.8). As 
in that experiment, the SETP in the liver is again not significantly influenced 
by 2 x 10 h of ECIB (compare tables 4.8 and 4.12). 
Table 4.9 Organ weights measured 25 h ofter 2x 10 h of ECIB(ECC 
ECC 
ECIB 
student "t" test 
liver weight (g) 
17.3± 1.2 
17.8±0.3 
N.S. 
Values represent means (±SE) of4 rats. 
ECC: extracorporeal circulation; :"\I .S.: nonsignificant difference. 
spleen weight (g) 
3.7±0.5 
2.8±0.4 
p<0.05 
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Table 4.10 Changes in the size if the various functional compartments after 2x 10 h of ECIB 
(leukaemic cells X 10') 
% % 
01 CrMcells 51 CrMcells 
inCBP in CBP 
after at equi-
infusion CBP MP TBP librium RETP 
ECC 20.7 12.1 46.2 58.3 10.2 60.1 
ECIB 19.7 3.6 14.8 18.4 9.5 19.8 
% reduction by ECIB 70 68 68 67 
Values represent means of 4 rats. 
ECC: extracorporeal circulation; CBP: circulating blood pool; MP: marginal pool; 
TREP 
118.4 
38.2 
68 
TBP: total blood pool; RETP: rapidly exchangeable tissue pool; TREP: total rapidly 
exchangeable pool. 
Table 4.11 Changes in the size of the rapidly exchangeable tissue pools (RETP) in various organs 
aft" 2x 10 h of ECIB 
(leukaemic cells x I 0 7 ) 
ECC 
ECIB 
% reduction by ECIB 
liver 
57.2 
19.5 
66 
spleen 
6.4 
2.5 
61 
* Total bone marrow was calculated ( 1 femur= 1.2%). 
Values represent means of 4 rats. 
bone marrow* 
16.8 
4.8 
72 
lungs 
3.1 
0.9 
72 
ECC: extracorporeal circulation; RETP: rapidly exchangeable tissue pool. 
For further explanation: see text. 
Table 4.12 Changes in the size of the slowly exchangeable tissue pools (SETP) in the spleen and the 
liver after 2X 10 h if ECIB 
(leukaemic cells x 107 ) 
% reduction 
RETP SETP ofSETP by ECIB 
spleen ECC 6.4 303.6 
EC!B 2.5 217.5 28 
liver ECC 57.2 872.8 
ECIB 19.5 960.5 
Values represent means of 4 rats. 
ECC: extracorporeal circulation; RETP: rapidly exchangeable tissue pool; SETP: slowly 
exchangeable tissue pool. 
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4.5.3 4x5hoJECIB 
Eight rats were treated with 4 sessions of ECIB each lasting for 5 hat days 20, 
21, 22 and 23 after inoculation with leukaemia. For physical parameters, see 
table 4.4. Eight cannulated rats served as controls. In 6 ECIB rats and 6 CC 
rats, compartment analysis was performed as soon as the last session was ended; 
2.5 x I 07 51Cr-cells were infused intra-arterially. 
During this treatment regimen, the number of leukaemic cells in the blood 
initially decreases (fig. 4.12), but starts to rise again 24 hours after the second 
session of ECIB. This is in contrast with the I x 20 h regimen, where, at 24 h 
after ECIB, a slight decrease as compared with the number of LC counted 
directly after the irradiation is noted (fig. 4.10). A small decrease is also 
observed during the subsequent 24 h, after the first session of I X 10 h ofECIB; 
this continues after the second session (fig. 4.11). The increase in the 4 X 5 h 
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Fig. 4.12 Effect of 4 X 5 h of ECIB on the number of leukaemic cells in the peripheral blood. 
Each point represents means (±SE) of 8 rats. 
CC: cannulated controls. 
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Fig. 4.13 Effect of 4 X 5 h of ECIB on the number of lymphocytes in the peripheral blood. 
Each point represents means (±SE) of 8 rats. 
CC: cannulated controls. 
experiment runs approximately parallel - although at a lower level - to the 
control curve. Just as in the other two experiments, lymphocytes show a rapid 
decline in the ECIB treated group (fig. 4.13). After the second session, the 
lymphocyte count remains at a constant low level up to the end of the observa-
tion period. 
In this experiment, changes in the number of platelets, haematocrit (Ht) 
values, erythrocytes and reticulocytes were also determined. Platelets show a 
similar decrease in both the ECIB and the control group (fig. 4.14). Haem-
atocrit values also decrease (fig. 4.14) which correlates very well with de-
creasing erythrocyte counts (table 4.13). Despite the developing anaemia, 
which is mainly due to the unavoidable blood loss associated with the repeated 
ECIB procedure, reticulocytes do not change significantly during the course of 
treatment (table 4.13). Apparently, at this stage of the disease, normal 
erythropoiesis fails to keep pace with the increased demand for red cells. 
With respect to organ weights, both the liver and the spleen show a significant 
decrease after 4 sessions of ECIB (table 4.14). In table 4.15, it is shown that 
cell depletion in the RETP (by 74%) is two times as great as in the TBP 
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Each point represents means (±SE) of8 rats. 
CC: cannulated controls. 
Table 4.13 Effect of 4 X 5 h of ECIB on the number if er_ythro~ytes and reticulocytes 
reticulocytes ( %o) erythrocytes (X 10 6/ml) 
before ECIB after 4 X 5 h ECIB before ECIB after 4 x 5 h ECIB 
day 20 day 24 day 20 day 24 
cc 702±34 363±2l 45±l2 53±9 
ECIB 694±45 324±4l 54±7 50±5 
student "t" test N.S. N.S. N.S. N.S. 
Values represent means (±SE) of 8 rats. 
CC: cannulated controlsj N.S.: nonsignificant difference. 
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Table 4.14 Organ weights measured 25 h after 4 X 5 h of ECIB 
liver weight (g) spleen weight (g) 
cc 
ECIB 
student "t" test 
24.4±0.9 
21.0±0.8 
p<0.01 
Values represent means (±SE) of 6 rats. 
CC: cannulated controls. 
4.4±0.3 
3.6=0.2 
p <0.025 
Table 4.15 Changes in the size of the various functional compartments after 4 X 5 h of ECIB 
(leukaemic cells x I 0 7) 
0/ 
'" 
o• !o 
51 Cr-cells 51 Cr-cells 
in CBP inCBP 
after at equi-
infusion CBP MP TBP librium RETP 
cc 21.1 20.5 76.9 97.5 2.1 880.6 
ECIB 16.7 10.3 51.4 61.7 3.5 231.8 
% reduction by ECIB 50 33 37 74 
Values represent means of 6 rats. 
TREP 
978.1 
293.4 
70 
CC: cannulated controls; CBP: circulating blood pool; MP: marginal pool; TBP: total 
blood pool; RETP: rapidly exchangeable tissue pool; TREP: total rapidly exchangeable pool. 
Table 4.16 Changes in the size qf the rapidly exchangeable tissue pools ( RETP) in various organs 
after 4x 5 h qf ECIB 
(leukaemic cells x 1 0 7 ) 
cc 
ECIB 
% reduction by ECIB 
liver 
488.1 
148.3 
70 
spleen 
20.3 
9.4 
54 
* Total bone marrow was calculated (1 femur= 1.2%). 
Values represent means of 6 rats. 
bone marrow* 
97.8 
35.5 
64 
CC: cannulated controls; RETP: rapidly exchangeable tissue pool. 
For further explanation: see text. 
lungs 
23.7 
8.9 
62 
(reduction by 37%). The efficient size reduction of the RETP is confirmed by 
data derived from the individual organs (table 4.16): tbe RETP in all organs 
measured decreases by more than 50%. This is similar to results obtained with 
the 2 x 10 h regimen (table 4.11). However, the TBP is more drastically reduced 
after 2 x 10 h ofECIB, i.e., 68% reduction (table 4.10) a; compared with 37% 
after 4 x 5 h of irradiation. When the l X 20 h and the 4 X 5 h protocols are 
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compared, both the TBP and the RETP are depleted to a greater degree in the 
latter protocol. 
After 4x5 h ofECIB, the SETP in the spleen has decreased by 19% (table 
4.17), which is more than after l X 20 h of ECIB ( ll%; table 4.8) but less than 
after the 2 X lO h protocol (28%; table 4.12). As after the other two schedules, 
the size ofthe SETP in the liver is not reduced (table 4.17). 
Table 4.17 Changes in the size of the slowly exchangeable tissue pools ( SETP) in the spleen and the 
liver after 4 X 5 h of ECI B 
(leukaemic cells X I 07 ) 
% reduction 
RETP SETP ofSETP by ECIB 
spleen cc 20.3 359.7 
ECIB 9.4 290.6 19 
liver cc 488.1 1151.9 
ECIB 148.3 1151.7 
Values represent means of6 rats. 
CC: cannulated controls; RETP: rapidly exchangeable tissue pool; SETP: slowly exchange-
able tissue pooL 
4.6 ECIB in combination with cell mobilization 
Fifteen rats were used in this study. Five of them were subjected to two 8 h 
sessions of ECIB on days 20 and 21 after inoculation with leukaemia. The 
second group of 5 animals was treated similarly. In addition, these rats were 
given three injections with dextran sulphate (DS17 ; see Ch. 3.2.1) at lO mg/kg 
each. The injections were given through the cannula at t = -1 h, t = 3 h and 
t = 6 h, where the start of an ECIB session is designated as t = 0 h. Physical 
Table 4.18 Physical parameters of 2x 8 h of ECIB in combination with cell mobilization 
session I 
ECIB ECIB+DS, 
BW(g) 290 295 
v, (m1) 14.5 14.7 
v (m1) 1.5 1.5 
F (m1/min) 0.44 0.56 
XV; 14.6 18.2 
R (rad/min) 190 190 
TD (rad) 648 509 
D; (rad) 8550 84!8 
Values represent means of 5 rats. 
DS17 : dextran sulphate (MW 17,000). 
Cannulated rats served as nonirradiated controls. 
For explanation of symbols: see table 4.3. 
session II 
ECIB ECIB+DS, 
290 295 
14.5 14.7 
1.5 1.5 
0.45 0.54 
14.9 17.5 
190 190 
633 528 
8550 8418 
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Fig. 4.15 Effect of 2 X 8 h of ECIB in combination with cell mobilization on the number of leukaemic 
cells in the peripheral blood. 
Each point represents means ( ± SE) of 5 rats. 
CC: cannulated controls. 
DS17 : dextran sulphate (MW 17,000): 10 mg/kg i.a.; each arrow represents one injection. 
parameters are given in table 4.18. Five cannulated rats served as controls. All 
animals were heparinized during both sessions. 
As described earlier, a complete haematologic follow-up was performed, 
organ weights were determined and compartment analysis was carried out by 
infusing 2.4 X 107 51Cr-labelled leukaemic cells into all rats at l h after the 
second session was completed. 
Changes in the number of peripheral leukaemic cells are plotted in fig. 4.15. 
As LC increase steadily in the CC group, the decrease is most marked in the 
DS-treated ECIB group. In the group treated with ECIB alone, LC remain at a 
fairly constant level and finally decrease. Lymphocytes decrease significantly in 
both ECIB groups with lowest values reached in the DS-treated ECIB group 
(fig. 4.16). 
Liver and spleen weights are only significantly reduced in the DS-treated 
ECIB group both as compared with the CC group and with the group treated 
with ECIB alone (table 4.19). 
From table 4.20, it is clear that ECIB in combination with DS induces a 
more marked reduction in both the blood compartments (TBP: 68%) and the 
RETP (87%) as compared with ECIB alone (TBP: 35%; RETP: 48%). In 
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Fig. 4.16 Effect qf 2 X 8 h of ECIB in combination with cell mobilization on the number of lymphocytes 
in the peripheral blood. 
Each point represents means (±SE) of 5 rats. 
CC: cannulated controls. 
DSu: dextran sulphate (MW 17,000): 10 mgjkg i.a.; each arrow represents one injection. 
particular, the RETP is depleted. The organ uptake of infused 51 Cr-labellcd 
leukaemic cells is given in table 4.21. In all organs, except for the lungs, the 
uptake measured in the DS-treated ECIB group has significantly increased as 
compared with ECIB alone. This may be due to the fact that the capacity of the 
Table 4.19 Organ weights measured 25 h after 2 X 8 h of ECIB in combination with cell mobilization 
cc 
ECIB 
ECIB+DS, 
student "t" test 
CC-ECIB 
CC-ECIB+DS, 
ECIB-ECIB+DS, 
liver weight (g) 
18.6±1.5 
18.0±0.9 
13.8± 1.1 
N.S. 
p<0.025 
p<0.025 
Values represent means (±SE) of 5 rats. 
spleen weight (g) 
4.1±0.2 
3.7±0.1 
2.9±0.3 
x.s. 
p <0.01 
p <0.001 
CC: cannulated controls; DS17 : dextran sulphate (MW 17,000); N.S.: nonsignificant 
difference. 
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Table 4.20 Changes in the size of the various functional compartments after 2 X 8 h of ECIB in 
combination with dextran sulphate 
(leukaemic cells x 107 ) 
0/ % 
" 51 Cr-cells 51 Cr-cells 
in CBP in CBP 
after at equi-
infusion CBP MP TBP librium RETP TREP 
cc 36.6 12.3 21.4 33.7 12.8 62.6 96.3 
EC!B 37.2 8.1 13.7 21.8 15.0 32.3 54.1 
ECIB+DS, 30.1 3.3 7.6 10.8 17.3 8.0 18.8 
ryo reduction by: 
EC!B 34 36 35 48 44 
ECIB+DS, 74 65 68 87 80 
Values represent means of 5 rats. 
CC: cannulated controls; DS17 : dextran sulphate (MVV 17,000) ; CBP: circulating blood 
pool; MP: marginal pool; TBP: total blood pool; RETP: rapidly exchangeable tissue pool; 
TREP: total rapidly exchangeable pool. 
Table 4.21 Uptake of 51 Cr-labelled leukaemic cells (%) per organ measured at 20 h after irifusion 
into rats which were submitted to 2x 8 h of ECIB in combination with dextran sulphate 
liver spleen 
cc 35.6 4.0 
EC!B 32.7 4.3 
ECIB+DS, 40.1 7.7 
* Total bone marrow was calculated (1 femur= 1.2%). 
Values represent means of 5 rats. 
CC: cannulated controls; DS17 : dextran sulphate (MW 17,000). 
For further explanation: see text. 
bone marrow* lungs 
5.0 2.7 
8.3 2.4 
14.3 2.5 
Table 4.22 Changes in the size of the rapidly exchangeable tissue pools ( RETP) in various organs 
after 2x 8 h of ECIB in combination with dextran sulphate 
(leukaemic cells x 107 ) 
liver spleen 
cc 34.3 3.8 
ECIB 17.7 2.3 
ECIB,DS1 7 7.6 1.5 
% reduction by: 
ECIB 48 40 
ECIB+DS, 78 62 
* Total bone marrow was calculated ( l femur= 1.2%). 
Values represent means of 5 rats. 
bone marrow* lungs 
4.8 2.6 
4.5 1.3 
2.7 0.5 
6 50 
45 82 
CC: cannulated controls; DS1 7 : dextran sulphate (MW 17 ,000); RETP: rapidly exchangeable 
tissue pool. 
For further explanation: see text. 
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depleted RETP to take up cells from the peripheral blood has increased. These 
data also clearly demonstrate that the migration of leukaemic cells from the 
blood to the tissues is not inhibited by DS. This is in contrast with observations 
on normal lymphocytes, which show a reduced rate of exit from the circulation 
after administration of polyanions [Bradfield and Born, 1969; Balow and 
Fauci, 1976, see Ch. 3.1). 
From data on organ uptake, the size of the RETP in the various organs was 
calculated (table 4.22). ECIB in combination with DS causes an extra reduc-
tion in this compartment in all organs measured, in particular in the bone 
marrow. It should be mentioned however, that, in this experiment, 2 X 8 h of 
ECIB alone was less effective in terms of cell depletion than 2 X 10 h of ECIB 
(table 4.11). \Vhether this is due to 4 hours more irradiation in the latter 
regimen or to variations between experimental animals and the stage of the 
disease remains to be established. 
The most striking difference between ECIB and ECIB in combination with 
DS is the degree of reduction in the SETP (table 4.23). In the DS-treated 
ECIB group, the reduction in the SETP in the spleen and the liver is 3 and 
!!-fold greater, respectively, as compared with the group which only underwent 
ECIB. In contrast to all other ECIB experiments described earlier, the SETP in 
the liver is significantly decreased by 44%. The reduction of the SETP in the 
spleen (with 34%) is also the most effective one found so far. 
Table 4.23 Changes in the size of the slowl_)l exchangeable tissue pools (SETP) in the spleen and the 
liver after 2x 8 h of ECIB in combination with dextran sulphate 
(leukaemic cells X 1 0 7 ) 
% reduction 
RETP SETP of SETP by ECIB 
spleen cc 3.8 346.2 
ECIB 2.3 307.7 ll 
ECIB+DS17 1.5 228.5 34 
liver cc 34.3 1025.7 
ECIB 17.7 982.3 4 
ECIB+DS, 7.6 572.4 44 
Values represent means of 5 rats. 
CC: cannulated controls; DS, 7 : dextran sulphate (MW 17 ,000); RETP: rapidly exchangeable 
tissue pool; SETP: slowly exchangeable tissue pool. 
4.7 The effect of ECIB on the proliferation of leukaemic cells 
At day 22 after leukaemia transfer, 4 rats were treated with ECIB. After 6 hand 
13 h of irradiation, respectively, ECIB was completed in two groups of two 
rats (see table 4.24 for physical parameters). Thereafter, they received 1 1-'Ci 
tritiated thymidine ("H-TdR) per gram body weight through the cannula 
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Table 4.24 Physical parameters of6 h -13 h of ECIB 
BW (g) 
V, (m1) 
V (m1) 
F (mljmin) 
X Vo 
R (radjmin) 
TD (rad) 
D; (rad) 
Values represent means of 2 rats. 
Cannulated rats served as controls. 
6 h of ECIB 
260 
13.0 
1.6 
0.89 
24.6 
195 
351 
7,693 
For explanation of symbols: see table 4.3. 
13 h of ECIB 
260 
13.0 
1.6 
0.90 
54.0 
195 
347 
16,668 
Table 4.25 3H- TdR labelling indices of leukaemic cells in the spleen after 6 h -13 h of ECIB 
student "t" test 
cc 
after 6 h of ECIB 
after 13 h of ECIB 
CC-6 h of ECIB 
CC-13 h of ECIB 
6 h of ECIB-13 h of ECIB 
LI 
0.32±0.02 
0.29±0.01 
0.25±0.01 
N.S. 
p <0.05 
p<0.05 
CC: cannulated controls; LI: tritiated thymidine (3 H-TdR) labelling index; N.S.: non-
significant difference. 
(specific activity 2 Cijmmol; The Radiochemical Centre, Amersham, England). 
The rats were killed thirty minutes later and impression slides of the spleen 
were made for determining the labelling index (LI) of leukaemic cells by 
means of direct autoradiography according to the procedures described in 
Chapter 2.6.4. In this experiment, 3 cannulated rats served as controls. Two 
impression slides from each rat were counted (500 cells per slide). 
The results are given in table 4.25. During the first 6 h of ECIB, the LI tends 
to decrease, although it is not significantly different from the nonirradiated 
control group (CC). However, after 13 h of irradiation, a significantly lower LI 
is found both as compared with the CC group and with the group which 
received 6 h of continuous irradiation. 
4.8 Discussion 
The ECIB model described offers the unique possibility to apply repeated 
sessions of ECIB. Moreover, the exteriorized aorta by-pass can also be used for 
continuous flow leukapheresis, intra-arterial infusions, cross circulation studies, 
140 
regular sampling of arterial blood, etc. The mortality due to the cannulation 
procedure is low (approximately 5%), the main cause offailure being damage 
to the inferior vena cava. During extracorporeal circulation sometimes, 
clotting occurs in the shunt despite heparinization. These clots can be easily 
removed, thereby restoring the circulation. 
With respect to the radiation dose, transit doses ranging from 350 to 650 
rad have been used, because of the different blood flow rates and radiation 
dose rates in the various experiments. If a cell suspension should be irradiated 
with these doses, the fraction of surviving cells would range from 2 X 1 o-z to 
2.6 x 10-• (see fig. 4.9, Chapter 4.3). However, during a session of ECIB, the 
majority of peripheral leukaemic cells (LC) passes the irradiator more than one 
time, thereby receiving twice or more times the transit dose. Given the pro-
longed blood transit time of LC (table 2.11) and their rather slow exchange rate 
with the tissue compartments, the difference in terms of cell depletion between 
ECIB regimens applied with different transit doses will be insignificant. 
By comparing the three ECIB treatment schedules as described in Chapter 
4.5 it can be concluded that repeated sessions (2 X 10 h; 4 X 5 h) are far more 
effective in terms of cell depletion than one long-lasting continuous irradiation 
( 1 x 20 h). No complete or even partial remissions were obtained, as judged by 
blood and bone marrow cytology. However, the objectives of these experiments 
were to study the quantitative relationships among the various functional com-
partments and changes induced by the selective depletion of one of these 
(CBP). 
Comparing the reduction in the blood compartments (CBP+MP) with that 
of the rapidly exchangeable tissue pool (RETP) leads to striking discrepancies 
between the three treatment regimens. In table 4.26, it is shown that, after 
1 x 20 h of ECIB, the decrease in the TBP is greater relative to the decrease in 
the RETP. The reverse, however, holds for the 4 X 5 h regimen, whereas the 
2 x 10 h schedule reduces both compartments to a similar degree. This might 
be explained by assuming different patterns of mobilization of LC from the 
RETP. Repeated short-lasting sessions apparently result in a more marked 
traffic of cells to the blood as is seen in fig. 4.12 ( 4 X 5 h of ECIB). After the 
second session ofECIB, the number ofLC in the blood starts to increase despite 
Table 4.26 The size reduction of the total blood pool relative to that of the rapidly exchangeable tissue 
pool after three d{tferent ECIB treatment Tel;imens 
%reduction % reduction ~~~5!~<:!!~~ of __ !_~~ 
ECIB ofTBP ofRETP % reduction of RETP 
l X 20 h 35 23 1.5 table 4.6 
2 X 10 h 68 67 l.O table 4.10 
4x5h 37 74 0.5 table 4.15 
TBP: total blood pool; RETP: rapidly exchangeable tissue pool. 
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two more treatment sessions. Apparently, cell depletion in the peripheral blood 
induces a certain degree of mobilization of cells from the tissues. In the 4 x 5 h 
treatment schedule, the number of cells mobilized exceeds the number of cells 
killed by irradiation. Individual organ studies indicate that the mobilized cells 
come from the RETP, which is significantly depleted (table 4.16). The 
induction of a significant degree of mobilization apparently takes some days 
(fig. 4.12). In general, it might be stated that the entrance rate ofLC into the 
blood increases with diminishing numbers of peripheral LC. In the 2 x 10 h 
treatment regimen, besides a significant reduction of the RETP (tables 4.10 and 
4.11) which is similar to the 4 X 5 h regimen, the TBP and :VIP are depleted to 
a greater extent (a factor of 2) than after the 4 x 5 h protocol (compare tables 
4.10 and 4.15). This might be due to the fact that, in these longer lasting 
sessions, cell depletion keeps pace with cell mobilization (fig. 4.11). Thus, the 
2 X 10 h regimen has been an optimal choice for balanced size reduction in all 
exchangeable compartments. Although some mobilization occurs during the 
20 h irradiation session (fig. 4.10), this schedule - in which about as much 
depletion of the TBP is observed as in the 4 X 5 h schedule (compare tables 4.6 
and 4.15) - has remarkably less influence on the sizes of the rapidly ex-
changeable tissue compartments (tables 4.6 and 4.7). 
In all three experiments, a completely different picture is obtained for normal 
lymphocytes. Cell kill by irradiation clearly exceeds cell mobilization, as 
indicated by the significant decrease in the number oflymphocytes in the blood 
(figs. 4.1 0, 4.11 and 4.13). That mobilization occurs is demonstrated by slightly 
rising peripheral cell counts between two sessions of ECIB (figs. 4.11 and 4.13). 
The slowly exchangeable tissue compartments of LC (SETP) only decrease 
to a small degree (tables 4.8, 4.12 and 4.17). In fact, only the SETP of the 
spleen shows a significant depletion especially after repeated sessions of ECIB. 
It is clear from these tables that the RETP of a given organ is rather small as 
compared with the SETP (see also table 2.12 and fig. 2.39). This explains why 
ECIB reduces the total tumour load only to a small degree. 
These data support the hypothesis of the presence of various functional com-
partments in acute leukaemia (see fig. 2.38), each having its own exchange rate 
parameters with the adjacent compartment. The data obtained thus far will be 
further analyzed by a computer program for compartment analysis which is 
presently being developed (Freriks, personal communication). With the re-
cently acquired knowledge on the presence of at least two populations of LC 
in the BNML, i.e. clonogenic-(LCFUs) versus nonclonogenic cells, the question 
remains as to whether or not there is a preferential mobilization and sub-
sequent killing of one of these cell types. 
When ECIB is combined with dextran sulphate, the induction of extra 
mobilization followed by killing results in a significantly greater reduction in 
all functional compartments studied as compared with ECIB alone. From 
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table 4.20, it can be calculated that the extra reduction factor, which is similar 
for all compartments, is in the order of 1.9. Essentially the same factor is 
calculated for the RETP of the various individual organs (table 4.22). However, 
in case of the bone marrow, ECIB in combination with DS causes a 7 .5-fold 
extra decrease as compared with ECIB alone. It should be mentioned that the 
measured reduction in the size of the RETP is the resultant of (I) cell mobiliza-
tion from this compartment to the blood compartments, and (2) influx of cells 
mobilized from the SETP (table 4.23). In summary, there is an increased rate 
of exchange of LC from the tissue compartments into the direction of the 
peripheral blood. The increased influx in the latter compartment apparently 
does not exceed the capacity ofthe irradiation regimen used to kill these cells. 
This is indicated by the decreasing number ofLC in the blood measured before 
and after ECIB (fig. 4.15). Essentially the same pattern is observed for normal 
lymphocytes (fig. 4.16). The major adjuvant effect ofDS seems to be a signifi-
cant mobilization effect on the SETP, which is only slightly influenced by 
ECIB alone (table 4.23). 
From the follow-up of a few small groups of rats which were not sacrificed 
for 51Cr-determinations after ECIB, it was concluded that the different ECIB 
regimens did not significantly change the survival time of the leukaemic rats. 
Both the ECIB treated rats and their controls die between days 26 and 29 after 
Table 4.27 Reduction f!f the total number of leukaemic cells after 2x 8 h of ECIB in combination with 
dextran sulphate 
leukaemic cells (X 108 ) 
cc ECIB+DS17 
TBP 3.4 1.1 
liver RETP 3.4 0.8 SETP 102.6 57.2 
RETP 0.4 0.2 
spleen SETP 34.6 22.9 
bone marrow 50.0 * 27.5 ** 
lungs 7.8 l.7 
rest 50.0 30.0 
---+ + 
total tumour load 2.5x1010 1.4 X lQlO 
TBP (total blood pool): see table 4.20. 
Pool sizes in liver and spleen: see table 4.23. 
The total tumour load in the bone marrow was calculated from 1 femur= 1.2%. 
* CC: 1 femur contains 6.0 X 107 leukaemic cells (see fig. 2.22b); 
** ECIB+DS17 : 1 femur contains 3.3 X 107 leukaemic cells (±45% reduction, table 4.22). 
The total tumour load in the lungs was derived from measured leukaemic lung weights 
corrected for the normal lung weight. 
The "rest" was derived from table 2.13; ECIB+DS17 : 40% reduction. 
CC: cannulated controls; RETP: rapidly exchangeable tissue pool; SETP: slowly exchange-
able tissue pool; DS17 : dextran sulphate (MW 17 ,000). 
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inoculation. After treatment, two factors determine the length of the remaining 
life span: ( l) the total tumour load which is left; and (2) the growth rate of the 
remaining leukaemic cells. With respect to the reduction in the tumour load, 
table 4.27 represents the most effective regimen used, i.e., ECIB in combination 
with dextran sulphate. The total tumour load was roughly quantified by 
adding the various compartments. As can be seen, the total reduction is about 
50%. This means that I doubling of the leukaemic cell population is required 
to reach the initial tumour mass again. From the data on cell proliferation in 
the spleen in nontreated leukaemic rats, it is derived that, after ECIB, the 
remaining total tumour load at day 21 is similar to that between days 14 and 18 
in nontreated leukaemic rats (see table 2.15; Ch. 2.6). In other words, at day 
16, l doubling ofthe leukaemic cell population takes about 4.5 days (96-120 h). 
Thus, from this calculation, a prolongation of the life span of ECIB treated rats 
by 4.5 days as compared with the controls would be expected. However, as 
stated earlier, this is not observed. In theory, this discrepancy might be due to 
an increased proliferation rate after ECIB with shortened cell cycle parameters 
and/or an increased growth fraction (GF). If it is assumed that the cell cycle 
parameters remain unchanged, then the GF will be reduced, as concluded 
from the observation that the tritiated thymidine LI measured in the spleen 
tends to decrease under the influence of ECIB treatment (table 4.25); i.e., the 
proliferation rate will certainly not have increased. The decreasing LI in the 
spleen might also be due to a return of significant numbers of nonlabelled 
irradiated LC to the spleen or a preferential mobilization of cycling cells from 
the tissues during ECIB. The decrease in the LI is in contrast with observations 
of other authors applying ECIB treatment to human acute leukaemia (see Ch. 
!.4. 7c; tables !.4 and !.5). However, they also reported on patients in whom no 
changes in the proliferation parameters were noted. It should be kept in mind 
that, with the available data, it cannot be ruled out that cell proliferation (i.e. 
the LI and the GF) increases at a later stage after ECIB has been completed. 
This hypothesis is not supported by preliminary data on the effectiveness of 
chemotherapy witb cycle active cytostatic drugs (cytosine arabinoside) at 
various time intervals after ECIB. This treatment further reduces the tumour 
load in a pure additive way without any signs of synergism. 
The most likely explanation for the discrepancy between the expected and 
the measured survival time of ECIB treated rats is a combination of two 
factors. Firstly, the repeated ECIB procedure might adversely affect the general 
condition of the leukaemic rat. Secondly, a prolongation of the life span by 
only 4-5 days may not have been distinguished from control rats because of a 
large spread in the survival times of the treated and non treated animals. 
In summary, ECIB significantly reduces the total tumour burden, in partic-
ular in combination with cell mobilization. The maximal reduction is 50% with 
different degrees of cell depletion in the various functional cell compartments. 
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This indicates the presence of a regulatory mechanism, at least in this rat 
model for acute myelocytic leukaemia, which controls the distribution of 
leukaemic cells over the various compartments. On the other hand, ECIB 
treatment, with its technical limitations, used either alone or in combination 
with chemotherapy, certainly cannot compete with other treatment modalities 
in acute myelocytic leukaemia, such as chemotherapy (2-7 log cell kill) or 
daily low-dose whole body irradiation (2-3 log cell kill), which have been 
shown to significantly prolong the survival time of leukaemic rats [Hagenbeek 
et al., to be published]. Obviously, ECIB treatment should be regarded as 
palliative rather than curative. 
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CHAPTER 5 
GENERAL DISCUSSION 
As most of the specific data have been discussed in detail in the previous 
chapters, only general ideas emerging from these studies will be presented in 
this chapter. 
5.1 The suitability of the rat leukaemia model as a model for human acute 
myelocytic leukaemia; implications for future (clinical) research 
Animal models for human diseases generally serve the purpose of making the 
disease accessible to experimentation, which is often impossible in patients. 
The objectives of model research in leukaemia are: to extend the knowledge on 
the pathogenesis, to develop new methods of investigation and therapy and 
finally to extrapolate the information to humans for the purpose of devising 
more efficient treatment regimens for human leukaemia. 
The first prerequisite is to establish leukaemia models which are more 
relevant to human leukaemia. Many leukaemia models, both of "spontaneous" 
origin and induced by chemicals, radiation or tumour viruses have been 
investigated during the past decades. Although some of them have yielded very 
useful information (e.g., the Ll210 transplantable mouse leukaemia for the 
screening of potential antileukaemia drugs), only few show a reasonable 
resemblance to human leukaemia in terms of growth characteristics. 
It is likely that one leukaemia model in an inbred strain of animals stands for 
one leukaemic patient, because of the large variety of growth patterns among 
individual patients. However, this does not necessarily limit the usefulness of 
basic studies, as they are meant to discover fundamental characteristics of 
leukaemia growth applicable to man. 
As described in Chapter 2, two of the most important features which make 
the EN myelocytic leukaemia relevant to human AML are its slow growth and 
the severe suppression of normal haemopoiesis during leukaemia development. 
In addition, many other characteristics, such as the cytological and cytochem-
ical characterization, the type of coagulation defects, cell surface properties and 
the response patterns to various treatment modalities, are reminiscent ofhuman 
acute promyelocytic leukaemia. This was concluded at a recent workshop 
during which many aspects of the BNML were analysed in detail [Hagenbeek 
and van Bekkum, 1977]. 
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A. Kinetics of proliferation 
Although the kinetics of proliferation in the BNML cannot be directly com-
pared with human acute leukaemia, an identical relationship was found 
between proliferation parameters of normal and leukaemic haemopoiesis in the 
rat and normal and leukaemic haemopoiesis in human AML (see table 2.16). 
However, if the time from diagnosis to death is related to the total life span of 
the species, a different picture is obtained. In the BNML, the period between 
the time of diagnosis and death (10-15 days) is l.l-1.7% of the median normal 
rat life span (30 months;]. Burek, personal communication). In untreated 
human AML, the median survival time is 2-3 months (Killmann, personal 
communication), i.e., about 0.3% of human life span (70 years). Untreated 
human chronic myelocytic leukaemia (CML) gives a median survival of 
2 years, which is about 3% of human life span. Thus, in this respect, the BNML 
should be classified as an intermediate form between acute and chronic leukae-
mia, assuming that this direct interspecies comparison is allowable and valid. 
However, another method to compare the BNML with human AML might be 
to relate the time from diagnosis to death to the cell cycle time. In the BNML, 
10-15 days take 17-26 cell cycle times (Tc = 14 h; table 2.16); in human 
AML, 24-43 cell cycle times (Tc = 50-60 h; table 2.16) are equal to 2-3 
months. Thus, from this intercomparison where the growth fraction is assumed 
to be similar in both leukaemias, the progression of the disease in the BN rat 
is about equally acute as in human AML. Also, because of the immaturity of 
the BNML cells ("hiatus leukaemicus,.) and their failure to produce colonies 
in vitro, it is concluded that the BNML model is much closer to human AML 
than to CML. 
In contrast to spontaneous rodent leukaemias, which might serve as models 
for studying the pre-diagnosis stage of human leukaemia, each passage of a 
transplantable leukaemia such as the BNML should be compared with each of 
a succession of remissions and relapses in a single patient [van Bekkum and 
Hagenbeek, 1977]. 
B. Kinetics of distribution 
The studies on the distribution of leukaemic cells after injection (Chapter 2) 
have yielded important information, particularly with respect to the question 
as to at which point can one interfere with the progression of the disease. After 
infusion of leukaemic cells, a pattern of initial trapping was observed. This 
presumably takes place in the capillary beds in various parts of the body, but 
particularly in the lungs. The cells are subsequently released and this is followed 
by a secondary pattern of homing in organs such as the bone marrow, the 
spleen and the liver where they start to proliferate. Questions that remain are: 
What is the mode of interaction between leukaemic cells and the reticuloendo-
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thelial system in the process of trapping and secondary homing?; 'What is the 
significance of specific characteristics of the tumour cell surface in relation to 
this process?; Are there means to prevent trapping or perhaps induce trapping 
followed by immediate tumour cell destruction? 
Studies on distribution kinetics confirmed the hypothesis concerning the 
presence of various functional cell compartments in leukaemia, i.e., rapidly 
versus slowly exchangeable compartments. On determining the sizes of these 
pools, it appeared that the further the leukaemia progresses, the greater the 
fraction of cells present in the slowly exchangeable tissue pools, or, the lower 
the exchange rates of!cukaemic cells between the tissues and the blood. This is 
of particular interest with respect to the efficacy of specific treatment modalities 
such as ECIB and leukapheresis, which require a certain degree of exchange to 
yield a significant therapeutic benefit (see Chapter 5.2). 
C. The fate of the normal haemopoietic stem cell 
The suppression of normal haemopoiesis at the level of the haemopoietic stem 
cell (HSC) is another interesting feature of the BNML which reminds one of 
human AML. In human AML, a significant decrease in the number of CFUc 
in the bone marrow has been reported [Moore, 1974; van Bekkum, 1976a]. In 
the BNML, apart from an absolute numerical decrease (see table 2.7), are-
distribution of HSC seems to take place, i.e., the number of HSC decreases in 
the bone marrow but increases in the blood and in the spleen as the leukaemia 
progresses (see fig. 2.37). ·whether extramedullary haemopoiesis is due to 
lodging of circulating HSC or to stimulation of resting HSC by a feed back 
mechanism or to a combination of these two should be further analysed. 
Other specific questions to be answered are: does the proliferative status of the 
HSC change during leukaemia development, and: is there again a redistribution 
of HSC after remission induction chemotherapy? Obviously, it would be very 
useful to investigate similar phenomena in human acute leukaemia. However, 
this will be a difficult task with the presently available methods. Regular CFU c 
determinations in the bone marrow and the blood might be possible, but, one is 
faced with technical and ethical problems as regards the extramedullary sites. 
In particular, it would be important to answer the question as to whether or not 
there is an increase in the number of CFU c in the blood and for other organs 
at a certain stage during remission or relapse. These studies might certainly 
have implications for clinical leukaemia treatment, e.g., harvesting HSC from 
the peripheral blood for autologous bone marrow transplantation at the time of 
the virtual absence of HSC in the bone marrow. 
D. Subpopulations of leukaemic cells 
A final essential point deals with the leukaemic cell population per se. There 
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appeared to be at least two populations ofleukaemic cells: clonogenic (LCFUs) 
and nonclonogenic cells. Further experiments are needed to determine their 
functional and quantitative relationship. In this respect, an important question 
is what are the conditions for in vitro culturing of leukaemic cells so that they 
give rise to colonies. Although some authors claim to have achieved in vitro 
colony formation by AML cells after stimulation with phytohaemagglutinin 
[Dicke et a!., 1976b], this was not reproducible with BNML cells. In vitro 
culturing of leukaemic cells would also make it possible to test drug sensitivity, 
to detect residual leukaemic cells after treatment and to study factors which 
might influence proliferation and even maturation. 
5.2 Recommendations for application of ECI B in the future 
In the BNML model, the different regimens of ECIB studied did not result in a 
significant prolongation of the life span of the rats. When the exchange rate of 
leukaemic cells between the tissues and the blood was increased by means of 
leukocyte mobilizing agents (Chapter 3), ECIB (2 x 8 h) reduced the total 
tumour load by about 50% (Chapter 4). In this case, the calculated survival 
time would increase by 4.5 days, i.e., 0.5% of the total life span of a normal rat 
(30 months) would be added. If the same calculation is applied to man, a 
similar ECIB regimen would result in a prolongation of the life span by about 
4 months. If more sessions of ECIB were applied, this figure might even become 
greater. In this respect, ECIB might be of therapeutic value, particularly in 
cases of drug resistance or toxicity. This has been shown in four patients with 
chronic lymphocytic leukaemia who received repeated sessions of ECIB. Their 
total tumour load as measured by the 51Cr-method was reduced by 3-6 x I 012 
cells [Hagenbeek et a!., to be published]. Although no complete remissions 
were achieved, the progression of the leukaemia could be significantly retarded. 
With 4-6 series of ECIB sessions per year, a satisfying general condition and a 
good quality of life could be maintained in these patients who were resistant to 
chemotherapy. Thus, in selected cases ofleukaemia, ECIB is certainly beneficial 
from a therapeutic point of view. 
From the experimental studies on the quantitative changes in the various 
functional cell compartments induced by ECIB, it appeared that the traffic of 
leukaemic cells is subject to a regulatory mechanism. The more the peripheral 
compartment is depleted, the more cells are mobilized from the rapidly and 
slowly exchangeable tissue compartments. \Vhether this mobilization phe-
nomenon is induced by degradation products from irradiated leukaemic cells 
remains to be established. In this respect, it should be worthwhile to perform 
similar studies with leukapheresis by which cells are removed instead of being 
destroyed. 
The 51Cr-method has provided rough quantitative information on the degree 
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of tumour cell depletion in response to ECIB in both the rat and man. In the 
rat, a rather precise insight into the changes in the rapidly exchangeable and 
more sessile tissue compartments could be obtained by the principle of isotope 
dilution in combination with organ weight measurements. For obvious 
reasons, one is faced with serious problems with respect to evaluating the 
reduction in the total tumour load in response to therapy in man. A combination 
of isotope dilution methods, methods of in vitro culturing of clonogenic leukaemic 
cells and measurements of specific biochemical markers (e.g., muramidase) 
might lead to achieving this goal. 
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SUMMARY 
In 1962, extracorporeal irradiation of the blood (ECIB) was introduced as a 
possible therapeutic measure in the treatment of leukaemia, particularly in 
patients who are unresponsive to chemotherapy [Lajtha et a!., 1962]. The 
rationale for this treatment modality is that leukaemic cells are far more 
radiosensitive than other types of blood cells. 
Besides its theoretical therapeutical usefulness, it was thought that the ECIB 
technique might make a significant contribution to the study of the kinetics of 
proliferation and distribution of leukaemic cells, as is pointed out in Chapter 1. 
In this chapter, an historical review on the development of ECIB is also 
presented and the various techniques and parameters in general use are 
described. In addition, recent developments in experimental and clinical 
ECIB are reviewed. It appears from the literature that, particularly in chronic 
lymphocytic leukaemia, the tumour cell load can be significantly reduced by 
ECIB, whereas, in chronic myelocytic leukaemia and in the acute leukaemias, 
varied results are obtained. In some patients, a partial remission is achieved at 
best; in others, the growth rate of the leukaemia increases in response to ECIB. 
Because of the lack of comprehensive clinical and experimental studies, it 
seemed justified to study the effects of ECIB in leukaemia from both a kinetic 
and a therapeutic point of view. 
The general experimental procedures and the experimental model are 
described in detail in Chapter 2. A chemically induced leukaemia in the Brown 
Norway inbred rat strain was used. This leukaemia gives a reproducible 
growth pattern upon cell transfer. It is classified as an acute promyelocytic 
leukaemia, with a high degree of similarity to human acute myelocytic leukae-
mia (AML). Firstly, in contrast to most other animal leukaemia models, it 
has a rather slow growth rate. After inoculation with 107 leukaemic cells, the 
rats survive 28 ± 2 days. The responsible factors in the death of the animal are 
bleeding, infections in the lungs and impaired functions of vital organs which 
are infiltrated with leukaemic cells. The cellular kinetics of proliferation 
essentially show deviations which are identical with those seen in human AML. 
With a cell cycle time of 14.0 h, the decreasing growth fraction (to 0.40) and the 
increasing cell loss (to 88%) during the development of the disease fully 
explain the net slow growth. 
A second feature of analogy with the human disease is the severe suppression 
of normal haemopoiesis during tl1e development of leukaemia. By means of 
methods to assay normal haemopoietic stem cells (HSC), it was found that 
these stem cells decrease in the bone marrow and increase in the blood and 
extramedullary sites such as, e.g., the spleen. Replacement by leukaemic cells, 
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possibly in combination with a decreasing proliferation rate of HSC, are the 
major factors responsible for the significantly decreased normal haemopoiesis. 
Studies on the histological pattern of spread and the kinetics of distribution 
of injected 51Chromium-labelled leukaemic cells are also reported in Chapter 2. 
After inoculation, the majority of cells lodges in the bone marrow, the spleen 
and the liver, where they start to proliferate. During the development of the 
disease, most organs become heavily infiltrated with leukaemia. It was con-
cluded from the isotope studies that two functional compartments can be 
distinguished in acute leukaemia, i.e., a rapidly exchangeable pool of cells 
(including the circulating blood pool, the marginal noncirculating blood pool 
and the rapidly exchangeable tissue pool; RETP) and a slowly exchangeable 
tissue pool (SETP). The sizes of these various compartments were roughly 
quantified at various stages of the disease by calculations based on the principle 
of isotope dilution and organ weight measurements. It was found that, as the 
leukaemia progresses, the size of the SETP increases significantly relative to the 
size of the RETP. Simultaneously, the exchange rates of leukaemic cells 
between the organs and the blood decrease. The blood transit time ofleukaemic 
cells was also significantly prolonged, as is the case in human AML. 
Finally, evidence was provided for the presence of at least two subpopula-
tions of leukaemic cells: clonogenic and nonclonogenic cells. 
With the purpose of increasing the leukaemic cell depletion by ECIB, 
leukocyte mobilizing agents were introduced (Chapter 3). Within a few hours 
after injection, these synthetic polyanions induce a marked increase in the 
number of peripheral lymphocytes and leukaemic cells, as has been demon-
strated in various animal species, in animal leukaemia models and in three 
patients with chronic lymphocytic leukaemia. The phenomenon is no longer 
evident within a few hours after the peak value has been reached. Although the 
mechanism underlying this mobilization of cells from the organs is still unclear, 
studies are reported which indicate that the polyanions attach to the surface of 
these cells and alter their interaction with the reticuloendothelial system by 
changing their electronegative charge. This would then result in an increased 
release to and possibly an impaired migration from the blood. 
In Chapter 4, the ECIB model in the rat is described in terms of the cannula-
tion technique, the ECIB procedure, the radiation equipment and dosimetry. 
The D 0 for X-rays ofleukaemic cells in the blood was 68.1 rad. 
After the appropriate controls were selected, ECIB studies in the BN acute 
myelocytic leukaemia were performed to answer the following questions: 
(I) Is there a different efficacy in terms of cell depletion between one long-
lasting session of ECIB and several repeated sessions? It was found that 
repeated sessions of ECIB (2 X 10 h; 4 X 5 h) are far more effective in 
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terms of cell depletion than one long-lasting session (I X 20 h). "Chromium 
studies indicated that the sizes of the blood compartments and of the 
rapidly exchangeable tissue pool are markedly reduced (maximally by 
about 70%). The more sessile organ compartments are only slightly 
influenced. 
(2) To what degree do leukocyte mobilizing agents enhance the cell depletion 
induced by ECIB? Besides a depletion of the rapidly exchangeable com-
partments, ECIB (2 X 8 h) in combination with cell mobilization by 
dextran sulphate induces a significant depletion in the slowly exchange-
able tissue pool as measured in the various organs. The reduction in the 
total tumour load was about 50%. 
(3) Does ECIB change the proliferation characteristics of the leukaemic cell 
population? Tritiated thymidine studies performed during a prolonged 
session of ECIB suggested that this treatment does not change the pro-
liferation rate of the leukaemia. 
In summary, ECIB significantly reduced the tumour burden, particularly in 
combination with cell mobilization, causing different degrees of cell depletion 
in the various functional cell compartments. This suggests the presence of a 
regulatory mechanism (at least in this rat model for acute myelocytic leukae-
mia) which controls the distribution of leukaemic cells over the various com-
partments. From a therapeutic point of view, ECIB treatment should be 
regarded as palliative rather than curative. The method certainly cannot 
compete with chemotherapy, which more effectively reduces the total tumour 
load. 
The suitability of the BN rat leukaemia model as a model for human acute 
myelocytic leukaemia is discussed in Chapter 5. Based on studies described in 
this thesis, implications for future clinical research are indicated. Each passage 
of this transplantable rat leukaemia should be compared with each of a 
succession of remissions and relapses in a single patient. 
From the data on experimental ECIB treatment, extrapolations are made 
towards the clinical treatment ofleukaemia. It is concluded that ECIB in man 
can certainly be of therapeutic value, especially in cases of drug resistance or 
toxicity. 
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SAMENVATTINGfSUMMARY IN DUTCH 
In 1962 werd extracorporale bestraling van het bloed (ECBB) als een mogelijke 
behandelwijze van leukaemic geintroduceerd, in het bijzonder voor patienten 
die niet reageren op chemotherapie [Lajtha eta!., 1962]. De rationale bij deze 
behandelingsmethode ligt in het feit dat leukaemiecellen vee! meer stralings-
gevoelig zijn dan andere soorten cellen in het bloed. 
Afgezien van de therapeutische bruikbaarheid van ECBB, zou deze methode 
een significante bijdrage kunnen leveren aan kinetiek studies betreffende de 
proliferatie en distributie van leukaemiecellen, zoals in Hoofdstuk l uiteenge-
zet wordt. In dit hoofdstuk wordt tevens een historisch overzicht gegeven van 
de ontwikkeling van de ECBB methode, terwijl ook de verschillende technieken 
en parameters, die erbij worden gebruikt, worden beschreven. Daarnaast 
wordt een samenvatting gegeven van recente ontwikkelingen op het gebied van 
experimentele en klinische toepassingen van ECBB. Uit de literatuur blijkt dat 
ECBB, met name bij chronische lymphatische leukaemic, het totaal aantal 
tumorcellen aanzienlijk vermindert. In chronische myeloide leukaemic en in de 
acute leukaemieen worden zeer wisselende resultaten verkregen. In sommige 
patienten wordt een partiele remissie bereikt, in anderen wordt een toename 
van de groeisnelheid van de leukaemic in het beenmerg gemeld ten gevolge van 
ECBB. Vanwege het gebrek aan systematisch klinisch en experimenteel onder-
zoek leek het gerechtvaardigd om, zowel vanuit het oogpunt van kinetisch 
leukaemie-onderzoek als vanuit een therapeutisch standpunt bezien, de 
effecten van ECBB in leukaemic te bestuderen. 
In Hoofdstuk 2 worden de algemeen gebruikte experimentele procedures 
alsmede het experimentele model beschreven. Er werd gebruik gemaakt van 
een chemisch ge'induceerde leukaemie in de ingeteelde Brown Norway ratten-
stam. Deze leukaemie vertoont een reproduceerbaar groeipatroon na elke 
transplantatie van leukaemiecellen. De leukaemie is geclassificeerd als een acute 
promyelocyten leukaemic, die op vele punten een sterke gelijkenis vertoont met 
acute myeloide leukaemic (AML) in de mens. In de eerste plaats groeit deze 
leukaemie, in tegenstelling tot de meeste andere transplanteerbare leukaemieen 
in proefdieren tamelijk langzaam. Na het inspuiten van 107 leukaemiecellen 
overleven de ratten 28 ± 2 dagen. De belangrijkste doodsoorzaken zijn 
bloedingen, longontsteking en verslechterde funkties van vitale organen, die 
met leukaemiecellen zijn geinfiltreerd. De proliferatiekinetiek vertoont dezelfde 
afwijkingen van normaal als in humane AML. Hoewel de eel cyclus tijd vrij 
kort is (14.0 uur), kan de !age groeisnelheid volledig worden verklaard uit het 
afnemen van de groeifraktie (tot 0.40) en toenemend celverlies (tot 88%) ge-
durende de ontwikkeling van de ziekte. 
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Een tweede overeenkomst met humane AML is de sterke onderdrukking van 
de normale haemopoiese gedurende de ontwikkeling van de leukaemic. Met 
behulp van methoden om normale haemopoietische stamcellen (HSC) te 
detecteren, werd een afname van deze stamcellen in het beenmerg geconsta-
teerd en een toename in het bloed en in extramedullaire organen zoals de milt. 
Complete vervanging door leukaemiecellen, mogelijk in combinatie met een 
verminderde groeisnelheid van HSC, zijn de belangrijkste factoren op grand 
waarvan de sterk verminderde haemopoiese verklaard wordt. 
In Hoofdstuk 2 worden oak onderzoekingen beschreven betreffende het 
histologisch groeipatroon en de distributiekinetiek van ingespoten 51Chroom-
gelabelde leukaemiecellen. Na inspuiting nestelen de meeste cellen zich in het 
beenmerg, de milt en de lever, waar ze beginnen te prolifereren. In de loop van 
de ontwikkeling van de ziekte worden de meeste organen massaal gelnfiltreerd 
met leukaemiecellen. Uit de isotoop-studies werd geconcludeerd, dat er in 
acute leukaemic twee functionele celcompartimenten onderscheiden kunnen 
worden, te weten: een snel uitwisselbaar compartiment (bestaande uit het 
circulerende bloed-, het marginale niet-circulerende bloed- en een snel uit-
wisselbaar weefselcompartiment) en een langzaam uitwisselbaar weefselcom-
partiment. De grootten van deze verschillende compartimenten konden bij be-
nadering worden bepaald in verschillende stadia van de ziekte door mid del van 
berekeningen gebaseerd op het principe van isotoop verdunning en orgaan ge-
wichten. Het langzaam uitwisselbare weefselcompartiment bleek in verhouding 
tot de snel uitwisselbare compartimenten, het sterkst in grootte toe te nemen 
naarmate het ziekteproces voortschreed. Tegelijkertijd neemt de uitwisselings-
snelheid van leukaemiecellen tussen de organen en het bloed af. Evenals in 
humane AML werd ook een verlengde verblijfsduur van leukaemiecellen in het 
bloed gevonden. 
Tenslotte werden er aanwijzingen gevonden voor het bestaan van ten-
minste twee subpopulaties leukaemiecellen: clonogene- en niet-clonogene 
cell en. 
Met het doe! om de leukaemiecel depletie door ECBB te vergroten werden 
studies betreffende leukocyten mobilizerende stoffen geintroduceerd (Hoofd-
stuk 3). Binnen een paar uur na injectie veroorzaken deze synthetische 
polyanionen een sterke toename in het aantal perifere lymphocyten en 
leukaemiecellen, zoals werd aangetoond in verschillende soorten normale 
proefdieren, in diermodellen voor leukaemie en in drie patienten met chro-
nische lymphatische leukaemic. Dit verschijnsel verdwijnt weer binnen een 
paar uur nadat de piekwaarde is bereikt. Hoewel het mechanisme dat aan deze 
mobilizatie van cellen uit organen ten grondslag ligt nog niet geheel is opge-
helderd, worden er onderzoekingen beschreven, die erop wijzen dat de polyan-
ionen zich hechten a an het oppervlak van deze cell en en hun interactie met het 
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reticulo-endotheliale systeem beinvloeden door verandering van de elektrone-
gatieve lading van het celoppervlak. Dit zou dan kunnen resulteren in een toe-
name van de afgifte van cellen aan het bloed, mogelijk in combinatie met een 
belemmerde migratie uit de bloedstroom naar de weefsels. 
In Hoofdstuk 4 wordt het ECBB model in de rat beschreven met betrekking 
tot de cannulatietechniek, de ECBB procedure, de bestralingsopstelling en de 
dosimetric. De D 0 voor Rbntgenstralen van leukaemiecellen in het bloed was 
68.1 rad. 
N adat de geschikte con troles waren gekozen, werden er ECBB studies ver-
richt in de BN acute myeloide leukaemic met het doe! om de volgende vragen 
te beantwoorden: 
( 1) Bestaat er een verschil in de graad van celdepletie geinduceerd door een 
langdurige ECBB sessie en door enkele herhaalde sessies? Onderzoekingen 
wezen uit dat herhaalde ECBB sessies (2 X 10 uur; 4 x 5 uur) in dit opzicht 
vee! effectiever zijn dan een langdurige sessie (1 x20 uur). Uit 51 Chroom 
studies bleken de bloedcompartimenten en het snel uitwisselbare weefsel-
compartiment sterk gereduceerd te worden (met maximaal 70%). Het 
langzaam uitwisselbare weefselcompartiment wordt slechts in geringe 
mate belnvloed. 
(2) In welke mate verhogen leukocyten mobilizerende stoffen de door ECBB 
veroorzaakte celdepletie? Behalve een afname in de grootte van de snel 
uitwisselbare compartimenten, induceert ECBB, in combinatie met cel-
mobilizatie door dextraansulphaat, in de verschillende organen een duide-
lijke depletie in de langzaam uitwisselbare compartimenten. Het totale 
aantal tumorcellen werd met ongeveer 50% gereduceerd. 
(3) Belnvloedt ECBB de proliferatiekarakteristieken van de leukaemiecel 
populatie? Tritium thymidine studies, uitgevoerd gedurende een lang-
durige ECBB sessie, gaven aan dat deze behandeling de groeisnelheid van 
deze leukaemic niet duidelijk verandert. 
Samenvattend kan worden gesteld dat ECBB de tumorcelpopulatie aanzienlijk 
reduceert, in het bijzonder als de methode met celmobilizatie wordt gecom-
bineerd. De verschillende functionele celcompartimenten worden in verschil-
lende mate gedepleteerd. Dit wijst op het bestaan van een regulatiemechanisme 
(ten minste in dit rattenmodel voor acute myeloide leukaemic) met betrekking 
tot de verdeling van leukaemiecellen over de diverse compartimenten. Vanuit 
een therapeutisch standpunt bekeken is ECBB veeleer een palliatieve dan een 
curatieve behandelingsmethode. Voor wat betreft de reductic van het aantal 
tumorcellen heeft chemotherapie een vee] drastischer effect . 
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In Hoofdstuk 5 wordt de relevantie van het BN rattenleukaemie model als 
model voor de humane acute myeloide leukaemic besproken. Op grond van 
studies in dit proefschrift beschreven, worden implicaties voor klinisch leukae-
mie-onderzoek aangegeven. Vanaf het moment dat leukaemiecellen worden 
ingespoten kan deze transplanteerbare rattenleukaemie worden vergeleken met 
een remissie gevolgd door een relapse in een individuele patient. 
Gegevens verkregen uit de experimentele ECBB behandeling worden ge-
extrapoleerd naar de klinische behandeling van leukaemic. Concluderend, kan 
klinisch toegepaste ECBB behandeling zeker van therapeutisch belang zijn, met 
name in gevallen waar resistentie, toxiciteit of contraindicaties ten aanzien van 
chemotherapie bestaat. 
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